Polypeptides self-assembling into nanoparticles

Engineered polypeptides self-assemble into nanoparticles to encapsulate and deliver oligonucleotides efficiently, addressing delivery challenges by ensuring safe and controlled release, thereby improving gene expression modulation.

JP2024164003AInactive Publication Date: 2024-11-26ETH ZURICH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024115450
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-08-07
Filing Date
2024-07-19
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing oligonucleotide delivery systems face challenges such as suboptimal pharmacokinetic properties, susceptibility to nucleases, rapid degradation, urinary excretion, and undesired immune responses, making them inefficient and unsafe for intracellular delivery.

Method used

Development of engineered non-natural polypeptides that self-assemble into nanoparticles capable of encapsulating negatively charged macromolecules like oligonucleotides, facilitating efficient cellular uptake and controlled cargo release, while being safe and biodegradable.

Benefits of technology

The polypeptides effectively deliver therapeutic oligonucleotides into cells, minimizing degradation and immune responses, and allow for conditional release of cargo, thus enhancing gene expression modulation with high yield and safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024164003000011
    Figure 2024164003000011
  • Figure 2024164003000012
    Figure 2024164003000012
  • Figure 2024164003000013
    Figure 2024164003000013
Patent Text Reader

Abstract

To provide designed and non-naturally occurring novel polypeptides that are not only capable of self-assembling into nanoparticles, but the nanoparticles are furthermore capable of encapsulating negatively charged macro molecules such as oligonucleotides with high binding affinity and delivering the macromolecules in vitro as well as in vivo.SOLUTION: The present invention discloses a polypeptide comprising a specific sequence, a nucleic acid sequence encoding the polypeptide, a nanoparticle comprising at least one polypeptide of the invention, a complex comprising the nanoparticle and one or more cargo molecules, and a method for transfecting a cell with the complex.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the field of polypeptides that self-assemble into nanoparticles.In particular, the present invention relates to a polypeptide comprising the amino acid sequence I (SEQ ID NO:1), a nucleic acid sequence encoding said polypeptide, a nanoparticle comprising at least one polypeptide of the present invention, a complex comprising said nanoparticle and one or more negatively charged cargo molecules, and a method for transfecting cells with said complex.

[0002] Related Technology Oligonucleotides (ONs) are a branch of molecular medicine with many potential clinical applications, but their suboptimal pharmacokinetic properties have substantially hindered drug development (Whitehead, KA et al., Nat. Rev. Drug Discov. 2009, 8, 129-138). In particular, intracellular delivery of ONs remains a significant obstacle, as ONs are rather large, highly charged entities and do not enter cells by diffusion (Lundin, KE et al., Oligonucleotide Therapies: The Past and the Present. Hum. Gene Ther. 2015, 26, 475-485). Further concerns for in vivo applications include susceptibility to nucleases present in biological serum, resulting in rapid degradation, as well as urinary excretion and undesirable off-target effects, as well as activation of intracellular and extracellular immune responses.

[0003] To overcome these shortcomings, the use of oligonucleotide delivery systems such as virus-like particles (VLPs) derived from bacteriophage P22 (Qazi, S. et al., Mol. Pharm. 2016, 13, 1191-1196) or Q virus-like particle (VLP) functional nanoparticles has been proposed (Fang, PY et al., Nucleic Acids Res. 2017, 45, 3519). However, the creation of virus-like particles carrying the desired therapeutic cargo is complex, costly, and still fraught with safety concerns.

[0004] Although a wide range of materials have been proposed as oligonucleotide delivery vectors, simple, effective, safe, and non-toxic delivery solutions remain to be sought (Whitehead, KA et al., Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 2009, 8, 129-138). Recently, the development of computer-designed proteins that can self-assemble into highly ordered and symmetric cage-like nanostructures has been described (King, NP et al., Science, 2012, 336, 1171-1174, US 9,630,994(B2)). Furthermore, the design of such self-assembling protein nanocages has recently been described for envelope protein nanocages (EPNs) that direct their own release from human cells into vesicles. One of the engineered symmetric self-assembling scaffolds that supports EPN formation when fused to an N-terminal p6Gag peptide and a C-terminal PH domain was named O3-33 (King, et al., 2012, op. cit.; J. Votteler, et al., Nature, 2016, 540, 292-295). Summary of the Invention

[0005] The present invention provides a designed non-natural novel polypeptide that can not only self-assemble into nanoparticles, but also encapsulate negatively charged macromolecules such as oligonucleotides with high binding affinity, and deliver the macromolecules in vitro and in vivo.Furthermore, it has been found that the preferred nanoparticles of the present invention can be efficiently taken up by mammalian cells, release their cargo, and induce, for example, RNA interference and knockdown gene expression.Therefore, the designed non-natural novel polypeptide is designed to produce nanoparticles that enable cargo delivery, particularly nucleic acid delivery, while minimizing or avoiding the undesirable properties of prior art delivery vehicles.

[0006] Importantly, the nanoparticles of the present invention are easily made and purified in high yield, allowing any macromolecule, particularly any oligonucleotide, to be packaged in the nanoparticles in vitro. Moreover, the nanoparticles of the present invention therefore provide a useful general platform for delivering a wide variety of such cargos into cells, such as therapeutic ONs for regulating gene expression in a variety of different applications, such as genetic interference. Their utility therefore encompasses biotechnological and therapeutic applications. Furthermore, the nanoparticles of the present invention are typically of uniform size, are particularly safe in vivo, are well tolerated, and are typically biodegradable. In addition, designed non-natural novel polypeptides can typically and preferably be easily made by recombinant expression, which is scalable and economical, allowing both genetic and post-translational (chemical) modifications. By adjusting the properties of the nanoparticles of the present invention, the nanoparticles can furthermore not only enter cells, but also conditionally release cargos in the cytoplasm, for example, to control gene expression as described.

[0007] Thus, the non-natural novel polypeptides developed by the inventors self-assemble into nanoparticles, which are capable of encapsulating and delivering cargo, preferably negatively charged macromolecules such as ONs.

[0008] Thus, in a first aspect, the present invention provides a polypeptide comprising an amino acid sequence I consisting of: MX 13 QAIGILELX1SIAAGMELGDAMLKSAX 14 VX 15 LLVSKTISX2GKFLLMLGGDIX8AIX9X 12 AIX 10 TGTX 11 QAGX3LLVDSLVLAX 16 IHPSVLPAIX 17 GX 18 NX 19 VX 20 X7X 21 QAVGIVETX4SVAACISAADX22 AVX 23 GSX 24 VTLVRVHMAX5GIGGKCYMVVAGDVSDVALAVTVASSSAGAYGX6LVYASLIPX 25 PHX 26 AMWX 27 QMVX 28 GX 29 E (SEQ ID NO: 1) X1 to X6 are independently positively charged amino acids, provided that at least three of X1 to X6 are independently positively charged amino acids. 29 are, independently of each other, amino acids, and optionally, X1 to X2 of SEQ ID NO: 1 29 Up to five amino acids at positions other than those indicated may be replaced by any amino acid.

[0009] In a further aspect, the present invention provides a nucleic acid sequence encoding a polypeptide of the present invention.

[0010] In a further aspect, the present invention provides nanoparticles comprising at least one polypeptide of the present invention.

[0011] In a further embodiment, the present invention provides a complex comprising a nanoparticle of the present invention and one or more cargo molecules, wherein said one or more cargo molecules are encapsulated in said nanoparticle.

[0012] In a further aspect, the present invention provides a method for transfecting a cell comprising the step of contacting said cell with a complex of the present invention.

[0013] In a further aspect, the present invention provides a method for producing a nanoparticle of the invention comprising the step of self-assembling a polypeptide of the invention into said nanoparticle.

[0014] In a further embodiment, the present invention provides a method for producing a complex of the present invention, comprising the step of mixing a nanoparticle of the present invention with one or more negatively charged macromolecules.

[0015] In a further aspect, the present invention relates to the use of the complex of the invention for transfecting a cell. [Brief description of the drawings]

[0016] [Figure 1] (a) Surface model of the OP cage from the four-fold and two-fold symmetry axes, with one trimer shown as a ribbon. Model constructed from X-ray diffraction data. (b) Side view of one trimer, with arginine insertion positions shown as filled spheres. (c) Luminal surface of the trimer, with arginine positions shown as filled spheres. (d) Negative stain transmission electron micrograph (TEM) of an OP. [Diagram 2] (a) Electrophoretic mobility shift assay of OP and Atto488-labeled ssDNA visualized by Atto488 fluorescence. (b) Absorbance spectrum of SEC-purified OP:nucleic acid complex. (C) Plot of [OP] vs. Kobs value obtained from fluorescence quenching of Atto488-ssDNA cargo upon addition of OP to determine k. (d) Plot of fluorescence recovery of Atto488-ssDNA released from OP cage induced by addition of unlabeled competitor DNA. [Diagram 3] (a) Cellular uptake of Atto488-DNA with and without OP as determined by flow cytometry (n=3). (b) Confocal fluorescence microscopy of HeLa cells treated with Atto488-DNA or OP:Atto488-DNA (Atto488-ssDNA cargo with OP). Hoechst refers to nuclear stain. (c) Flow cytometry analysis of cellular uptake across different cell lines. Median fluorescence intensity of seven different cell types after 18 h treatment with 200 nM Atto488-DNA or OP:Atto488-DNA. Median fluorescence intensity was obtained from 10,000 cells. MCF-7-breast cancer, HepG2-liver cancer, A431-skin cancer, HT-29-colon cancer, CHO-K1-hamster ovary (non-cancerous), Vero-African green monkey kidney (non-cancerous). [Figure 4](a) GFP knockdown determined by flow cytometry (n=4). OP:scrambled refers to scrambled siRNA that does not target GFP mRNA or any other endogenous sequence, and No His6 refers to siRNA packaged into OP cages without a His6 tag. (b) Native AGE analysis of tRNA-induced release of dsDNA cargo from OPs over time, visualized by Atto488 fluorescence. (c) Flow cytometry analysis of cellular uptake across different cell lines. Median fluorescence intensity of seven different cell types after 18 h treatment with 200 nM of Atto488-DNA or OP:Atto488-DNA. Median fluorescence intensity was obtained from 10,000 cells. [Diagram 5] Electrostatic potential surfaces. Coulomb surface comparison of the trimeric subunits from the crystal structures of O3-33 and OP, showing both the inner and outer faces. [Figure 6] SDS-PAGE. Both proteins from crude cell lysates and products isolated from Ni-NTA are shown. The lower mobility of OPs is due to additional positively charged amino acids, not differences in molecular weight. After size-exclusion chromatography, a faint band above the OPs is removed. Gel visualized with Coomassie blue. Typical yield of OP protein after Ni-NTA is 100 mg / L E. coli culture. [Figure 7]SEC of O3-33 and OP. Size-exclusion chromatography of O3-33 and OP, a positively charged caged nanoparticle of the present invention. Both the crude mixture and analytical traces of the purified assembly from Ni-NTA chromatography are shown. The dotted line corresponds to absorbance at 260 nm (nucleic acid) and the solid line corresponds to absorbance at 280 nm (protein). Based on TEM analysis, the peak at 12-14 mL for OP(Ni-NTA) contains fully organized caged dimers, trimers, and higher order aggregates rather than alternative quaternary assemblies. The peak at 22 mL for OP(Ni-NTA) contains nucleic acid fragments that were loaded during protein expression in E. coli and easily removed by SEC. The major peak at 16 mL represents the elution fraction of the protein that was collected and further characterized. SEC of OP is representative, with OTR101-OTR503 showing comparable elution volumes of approximately 16 mL. [Figure 8]DLS and AGE of O3-33 and OP. (a) Dynamic light scattering (DLS) of the original (O3-33) and the positively charged (OP) cage variant. (b) Native agarose gel electrophoresis (AGE) (3%); lane 1: O3-33, lane 2: OP, stained with Coomassie blue. Considering the SEC, DLS, TEM, and X-ray diffraction data, the reduced mobility of OP compared to O3-33 is due to increased positive charge, not a change in size. (c) 3% AGE of the OP variant. Proteins stained with Coomassie blue. The difference in mobility is due to overall charge, not a change in size. The smearing is due to high protein loading, not cage disassembly. Lane 1: O3-33. Lane 2: OTR101. Lane 3: OTR201. Lane 4: OTR202. Lane 5: OTR203. Lane 6: OTR301. Lane 7: OTR302. Lane 8: OTR401. Lane 9: OTR402. Lane 10: OTR501. Lane 11: OTR502. Lane 12: OTR503. Lane 13: OP. All proteins have comparable electrophoretic mobility and the particles have been shown by both SEC and TEM to be the same size, with minor deviations occurring as the number of positively charged arginine residues increases. Taken together, these characterization approaches support the hypothesis that the structure of all mutants is the same as OP. [Figure 9] Transmission electron microscopy (TEM) images. Scale bars for OP and O3-33 are 100 nm and for OTR501 are 200 nm. Negatively stained transmission electron microscopy images were obtained for OP and OTR101-OTR503. SECs shown here are representative of OP and all mutants OTR101-OTR503. These images suggest a uniform distribution of mutant capsids and a morphology consistent with OP. [Figure 10]EMSA of O3-33 and OP with ssDNA. Electrophoretic mobility shift assay of Atto488-labeled ssDNA with increasing equivalents of OP or O3-33. Lanes 1-7: Atto488-ssDNA+OP, lane 8: Atto488-ssDNA, lanes 9-15: Atto488-ssDNA+O3-33. Gel visualized by Atto488 fluorescence. [Figure 11] EMSA of OPs with dsDNA and dsRNA. Electrophoretic mobility shifts of (a) dsDNA and (b) dsRNA with increasing molar equivalents of OP cages, both 21 bp in length. The faint band of free nucleic acid at 0.5 equivalents of OP is due to non-equilibrium conditions during electrophoresis and represents a small fraction of the total nucleic acid. Since there are 144 arginine residues per capsid, charge neutrality is achieved when only 144 nucleotides are encapsulated, which corresponds to 3.6 duplexes (21 bp) per capsid. The maximum loading capacity of two duplexes observed here can be rationalized in terms of RNA-RNA charge repulsion, physical constraints imposed by the spherical container, and the requirement for accessible arginine residues to contribute to favorable binding interactions. Nucleic acids stained with GelRed. [Figure 12] SEC of nucleic acid encapsulation. Size-exclusion chromatography of empty OP cages compared to OPs after incubation with 5 equivalents per cage of either ssDNA, dsDNA, or dsRNA (all 21 nt in length). The dotted line corresponds to absorbance at 260 nm (nucleic acid) and the solid line corresponds to absorbance at 280 nm (protein). No nucleic acid-mediated aggregation is observed. All complexes show the same retention volume as the empty OP cage, but with an increased A260 / A280 ratio, indicating internalization of the oligonucleotide. [Figure 13]Kinetic measurements. Representative data set for determining the 1:1 encapsulation kinetics of ssDNA within the OP cage. As evident from the band intensities seen in the EMSA (Figure 10), encapsulation of Atto488-ssDNA by OPs results in quenching of the fluorophore utilized for the time-resolved binding assay presented herein. The Atto488 fluorophore was excited at 488 nm and emission was measured at 515 nm. In each experiment (a-e), the concentration of Atto488-ssDNA was 10 nM and the concentration of OP added at t=0 is indicated on the plot. (f) Comparison of single exponential fits (shown in a-e) of these five concentration points without normalization. [Figure 14] Nuclease assays. (a) Native agarose gel showing free nucleic acids (R=dsRNA, ssD=ssDNA and dsD=dsDNA) treated with the indicated nucleases (Bzase=Benzonase) and (b) the same nucleic acids prepackaged in OP cages (also treated with the indicated nucleases). Lane M contains 300 nt ssRNA for reference. Samples were incubated with nucleases for 18 h at 37 °C in PBS. In the case of Benzonase for DNA samples and for DNaseI for single-stranded DNA, digestion is somewhat incomplete (a, upper gel lanes 8, 11, and 12). Nevertheless, comparing encapsulated and fully digested samples it becomes clearly evident that OPs are able to protect the cargo from the large nucleases Benzonase and DNaseI, while the small RNaseA can enter the cage and digest the RNA cargo. [Figure 15] Cytotoxicity of OPs and Lipofectamine 2000 at various concentrations in HeLa cells after (a) 24 h and (b) 48 h of incubation. Controls: PBS or 1% TritonX-100 detergent (n=3). [Figure 16]Qualitative assessment of GFP knockdown by fluorescence microscopy. Knockdown of GFP expression in HeLa cells, shown in terms of relative GFP content from live cell fluorescence microscopy. The trends seen here are in good agreement with the quantitative flow cytometry analysis (Figure 4a). Sample names are indicated above each panel pair, with bright field on the left and GFP fluorescence on the right (LED excitation at 470 nm, emission filter 535 / 50 nm). The siRNA concentration for each sample was 100 nM, and images were obtained 46 hours after addition of siRNA samples. Scale bar is 100 μm. [Figure 17] Reaction kinetics at higher DNA to OP ratios. With increasing Atto488-DNA to OP ratios, two effects are observed that are consistent with the loading of two molecules of ssDNA per OP cage. First, an increase in quenching is observed, which is evident from the endpoints in (a)–(c). This is most likely due to self-quenching of the fluorophore, which has a high effective concentration within the small cavity of the OP. The second effect is a transition from single to double exponential decay, revealing two distinct binding events. For (b) and (c), the single exponential fit is shown as a solid line and the double exponential fit is shown as a dashed line. [Figure 18] Characterization of OPs without His6 tag. (a) SDS-PAGE comparison of OP (lane 1) and without OP-His6 (lane 2). (b) SEC without OP-His6 shows similar retention volume as OP (16 mL). (c) Negative stain TEM without OP-His6 appears consistent with OP. (d) Native AGE with lane 1: OP and lane 2: OP-His. Gel visualized with Coomassie blue for protein. (e) Native AGE showing siRNA encapsulation at 1:1 molar ratio in OP (lane 2) and without OP-His6 (lane 3). Lane 1 is a control for free siRNA. Visualized with GelRed for nucleic acid. (f) SEC without OP-His6 after incubation with 5 equivalents of siRNA shows the same retention volume as the empty cage (16 mL), but the A260 / A280 ratio is increased, indicating internalization of oligonucleotides. The peak at 19-21 mL corresponds to excess RNA. [Figure 19] Encapsulation of tRNA. Native agarose gel analysis showing complete binding of tRNA in the presence of 1.2 equivalents of OP cage. Lane 1 - tRNA, lane 2 - tRNA+OP. Stained with GelRed. [Figure 20] EMSA of oligonucleotides with O3-33. (a) The same native agarose gel stained with GelRed for nucleic acids and (b) Coomassie blue for proteins. Arrows: complexes (nanoparticles and ssDNA). Unlabeled ssDNA, dsDNA, and dsRNA were analyzed after incubation with 2 equivalents of O3-33. There is no interaction between the protein cage and the oligonucleotide. [Figure 21] Loading of different DNA sequences. (a) The same native agarose gel (3% native AGE) stained with GelRed for DNA and (b) Coomassie blue for proteins. Down arrow: ssDNA, up arrow: complex (nanoparticles with ssDNA, dsDNA, dsRNA). Each sample has a 2:1 ratio of ssDNA to capsid, oligonucleotides range from 18 to 26 nt and contain random sequences (provided in Table 2 below). Lane 1 - 18nt ssDNA1, lane 2 - 26nt ssDNA, lane 3 - OP, lane 4-12 - OP + 2 equivalents of various ssDNA. [Figure 22] Serum stability. The same native agarose gel stained with (a) GelRed for RNA and (b) Coomassie blue for proteins. Down arrow: dsRNA, up arrow: complex (nanoparticles and dsRNA), middle arrow: BSA. There is no obvious interaction of the dsRNA-loaded OP cage with serum proteins and no displacement or degradation of the RNA cargo. Lane 1 - dsRNA, lane 2 - OP:dsRNA, lane 3-7 - OP:dsRNA after incubation in 10% FBS for 0.5, 1, 2, 4, and 7 h at 37 °C, lane 8 - 10% FBS only. [Diagram 23]Small angle X-ray scattering. (a) One-dimensional scattering curves for OP, OP:dsDNA, and OP:dsRNA. Experimental data are shown as dots, and the fits used to create the distance distributions are shown as grey lines. (b) Pair distance distribution functions for OP, OP:dsDNA, and OP:dsRNA calculated from the above data using AUTOGNOM2-3. The dashed lines correspond to the particle sizes obtained from DLS experiments (Figure 8a), where the tailing in distance of more than 14 nm is due to transient intermolecular interactions between each protein cage. Upon complexation with oligonucleotides, there is no change in the external diameter of the protein cages, and the density transitions from hollow sphere-like particles to packed spheres. Both phenomena are consistent with the internalization of the oligonucleotides within the cavities of the OPs. [Figure 24] Circular dichroism spectra of O3-33 and OP. The solid lines are the average values ​​and the error bars indicate the standard deviation from triplicate measurements of each protein. [Diagram 25] Overview of the preparation and use of the nanoparticles and complexes of the invention. [Figure 26] ssDNA loading into nanoparticles (NPs) investigated by electrophoretic mobility shift assay (EMSA). (a) 2% native gel visualized by Atto488-absorbance with UV transillumination. Lane 1: O3-33. Lane 2: OTR101. Lane 3: OTR201. Lane 4: OTR202. Lane 5: OTR203. Lane 6: OTR301. Lane 7: OTR302. Lane 8: OTR401. Lane 9: OTR402. Lane 10: OTR501. Lane 11: OTR502. Lane 12: OTR503. Lane 13: OP. Lane 14: Atto488-ssDNA. The broad band results from impurities in the DNA batch. (b) Proteins were visualized with Coomassie blue. [Figure 27]Fluorescence quenching upon ssDNA encapsulation. (a) Fluorescence decay of all mutants at 50 nM protein concentration in 10 nM Atto-488 ssDNA, showing that the decay rate depends on the number and position of arginines. (b) Zoomed-in view of the slow mutants in (a), where it is clearly visible that O3-33, OTR101, OTR201, OTR202, and OTR203 are not bound to ssDNA. [Figure 28] In vitro study of dsDNA loading into nanoparticles (NPs). (a) Native AGE visualized by Atto-488 absorbance of hpDNA. (b) The same gel after staining with Coomassie blue for protein visualization. Lane 1: hpDNA. Lane 2: OTR301. Lane 3: OTR302. Lane 4: OTR401. Lane 5: OTR402. Lane 6: OTR501. Lane 7: OTR502. Lane 8: OTR503. Lane 9: OP. [Figure 29] GFP knockdown measured by flow cytometry (n=3). [Diagram 30] Immunogenicity of OP cages in mice measured by ELISA. OP-specific IgG1 (a), IgG2a (b), and IgG2b (c) antibody titers were measured in the serum of BALB / c mice immunized with OP, as indicated by the arrows. Each point is the average IgG titer of four mice. [Diagram 31] Time course of immunogenicity of OP cages in mice as measured by ELISA. OP-specific IgG1 (a), IgG2a (b), and IgG2b (c) antibody titers were measured in sera from BALB / c mice immunized with OP, as indicated by the arrows. Each point is the average IgG titer of four mice. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0017] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0018] Throughout this specification and the claims which follow, unless the context indicates otherwise, the word "comprise" or "include", as well as variations such as "comprises / includes" and "comprising / including", should be understood to imply the inclusion of an element, stated integer, step, or group thereof, but not the exclusion of any other element, stated integer, step, or group thereof.

[0019] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0020] When used in connection with a numerical value, the term "about" or "approximately" is meant to encompass a range of numerical values ​​having a lower limit of 0-10% less than the indicated numerical value and an upper limit of 0-10% more than the indicated numerical value. The term "about" or "approximately" preferably means ±10%, more preferably ±5%, even more preferably ±3% or most preferably ±0%, each referring to a given numerical value. In embodiments of the present invention, "about" may be omitted. All ranges of values ​​disclosed herein refer to and include any and all values ​​within the range, including the values ​​defining the range.

[0021] In a first aspect, the present invention relates to a polypeptide comprising an amino acid sequence I consisting of: MX 13 QAIGILELX1SIAAGMELGDAMLKSAX 14 VX 15 LLVSKTISX2GKFLLMLGGDIX8AIX9X 12 AIX 10 TGTX 11 QAGX3LLVDSLVLAX 16 IHPSVLPAIX 17 GX 18 NX 19 VX 20X7X 21 QAVGIVETX4SVAACISAADX 22 AVX 23 GSX 24 VTLVRVHMAX5GIGGKCYMVVAGDVSDVALAVTVASSSAGAYGX6LVYASLIPX 25 PHX 26 AMWX 27 QMVX 28 GX 29 E (SEQ ID NO: 1) X1 to X6 are independently positively charged amino acids, provided that at least three of X1 to X6 are independently positively charged amino acids. 29 are, independently of each other, amino acids, and optionally, X1 to X2 of SEQ ID NO: 1 29 Up to five amino acids at positions other than those indicated may be replaced by any amino acid.

[0022] In a preferred embodiment, the polypeptide comprises an amino acid sequence consisting of SEQ ID NO: 1, and is selected from the group consisting of X1 to X6, with the proviso that at least three of X1 to X6 are independently positively charged amino acids. 29 are, independently of each other, amino acids.

[0023] The term "polypeptide" as used herein refers to any peptide-linked polymer of amino acids, regardless of size, length, secondary and tertiary structure, number of subunits, or post-translational modification. Thus, the term "polypeptide" should be understood to encompass the terms "peptide", "protein", "amino acid chain", and "amino acid sequence". A polypeptide according to the present invention is an open linear peptide chain or a cyclic peptide, and alternatively or additionally, the peptide of the present invention may include at least one chemical modification, such as lipidation, glycosylation, and phosphorylation. As understood herein, peptides, particularly peptides of the present invention, may be isolated or, preferably, produced by chemical synthesis, RNA translation, and / or recombinant processes.

[0024] The term "amino acid" as used herein refers to an organic compound that contains the functional groups amine (-NH2) and carboxylic acid (-COOH) and their zwitterions, typically and preferably with a side chain specific to each amino acid. The term "amino acid" typically and preferably includes naturally occurring amino acids, such as proteinogenic amino acids (produced by RNA translation), non-proteinogenic amino acids (produced by other metabolic mechanisms, e.g., post-translational modifications), standard or canonical amino acids (directly encoded by codons in the genetic code), and non-standard or non-canonical amino acids (not directly encoded by the genetic code). Naturally occurring amino acids include non-eukaryotic and eukaryotic amino acids. The term "amino acid" as used herein also includes chemically synthesized non-natural amino acids. Furthermore, the term encompasses amino acids such as alpha-(α-), beta-(β-), gamma-(γ-) and delta-(δ-), as well as mixtures thereof in any ratio, and, where applicable, any isomer of an amino acid, i.e., its D- and L-stereoisomers (alternatively referred to as (R) and (S) nomenclature), as well as mixtures thereof in any ratio, preferably in a 1:1 racemic ratio. The amino acids of the present invention are typically and preferably in the L-configuration. The terms "D-stereoisomer", "L-stereoisomer", "D-amino acid" or "L-amino acid" refer to the chiral alpha carbon of an amino acid. Amino acids can include modified and / or conjugated compounds, as well as residues used in peptide synthesis, such as Boc, Fmoc, or both.

[0025] "X n ~X m " and "X n~m " are used interchangeably herein to denote the position of a particular amino acid in SEQ ID NO:1.

[0026] Optionally, X in SEQ ID NO:1 1~29Up to five amino acids at positions other than those indicated by can be replaced with any amino acid. The terms "amino acid replacement" or "replaced by any amino acid" used interchangeably herein refer to replacement by deletion of one amino acid, or replacement (addition) of a single amino acid with one or more amino acids, more preferably one, two or three amino acids. Most preferably, the term "amino acid replacement" refers to deletion of a single amino acid, or replacement of a single amino acid with one, two or three amino acids. In a preferred embodiment, the amino acid replacement is a substitution. In another preferred embodiment, the amino acid replacement is a conservative amino acid replacement.

[0027] The term "conservative substitution" refers to an amino acid substitution that replaces a given amino acid with a different amino acid that has similar biochemical properties.Conservative substitution includes and preferably refers to isosteric substitution and substitution that maintains the charged, polar, aromatic, aliphatic or hydrophobic nature of amino acid.Conservative substitution refers to substitution that maintains the ability of the polypeptide of the present invention to self-assemble into nanoparticles, preferably the caged nanoparticles of the present invention.

[0028] As used herein, the term "positively charged" includes and preferably refers to molecules that have positively charged groups. More preferably, the positively charged molecules have positively charged groups at neutral or physiological pH.

[0029] In a preferred embodiment of the present invention, optionally, X of SEQ ID NO: 1 1~29 Up to four amino acids, more preferably up to three amino acids, even more preferably up to two amino acids, and most preferably one amino acid at positions other than those indicated are replaced with any amino acid.

[0030] In a preferred embodiment, the polypeptide has a length of about 500 amino acids or less, preferably about 400 amino acids or less, more preferably 300 amino acids or less, even more preferably 250 amino acids or less, even more preferably 200 amino acids or less, even more preferably 188-230 amino acids, and most preferably 192 amino acids.

[0031] In another preferred embodiment, the polypeptide is an isolated polypeptide.

[0032] In another preferred embodiment, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1. In another preferred embodiment, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1, optionally with X of SEQ ID NO: 1. 1~29 Up to five amino acids at positions other than those indicated may be replaced by any amino acid.

[0033] In another preferred embodiment, the at least three positively charged amino acids of X1 to X6 are, independently of one another, arginine or conservative substitutions of arginine. In another preferred embodiment, the at least three positively charged amino acids of X1 to X6 are, independently of one another, selected from the group consisting of arginine, 5-methyl-arginine, c-gamma-hydroxyarginine, 2-amino-4-guanidinobutyric acid, 2-amino-3-guanidinopropionic acid, canavanine, homoarginine, lysine, diaminobutyric acid, 2,3-diaminopropanoic acid, (2s)-2,8-diaminooctanoic acid, ornithine, thialysine, and histidine.

[0034] In another preferred embodiment, the at least three positively charged amino acids of X1 to X6 are independently selected from the group consisting of arginine, 5-methyl-arginine, c-gamma-hydroxyarginine, 2-amino-4-guanidinobutyric acid, 2-amino-3-guanidinopropionic acid, canavanine, homoarginine, lysine, diaminobutyric acid, 2,3-diaminopropanoic acid, (2s)-2,8-diaminooctanoic acid, ornithine, and thialysine.

[0035] In another more preferred embodiment, the at least three positively charged amino acids among X1 to X6 are independently histidine, arginine, or lysine. In another more preferred embodiment, the at least three positively charged amino acids among X1 to X6 are independently arginine or lysine. In another more preferred embodiment, the at least three positively charged amino acids among X1 to X6 are independently arginine. In another more preferred embodiment, the at least three positively charged amino acids among X1 to X6 are independently arginine. In one embodiment, the positively charged amino acids X1 to X6 are each arginine. In one embodiment, the positively charged amino acids X1 to X6 are each lysine.

[0036] In a preferred embodiment, the polypeptide of the present invention comprises a histidine tag (His tag) consisting of three or more consecutive histidines, wherein the His tag is attached to the C-terminus or N-terminus, preferably the C-terminus of amino acid sequence I, and in sequence I, at least three positively charged amino acids among X1 to X6 are independently arginine or lysine. In a preferred embodiment, the polypeptide of the present invention comprises a histidine tag (His tag) consisting of three or more consecutive histidines, wherein the His tag is attached to the C-terminus or N-terminus, preferably the C-terminus of amino acid sequence I, and in sequence I, at least three positively charged amino acids among X1 to X6 are arginine. In a preferred embodiment, the polypeptide of the present invention comprises a histidine tag (His tag) consisting of three or more consecutive histidines, wherein the His tag is attached to the C-terminus or N-terminus, preferably the C-terminus of amino acid sequence I, and in sequence I, at least three positively charged amino acids among X1 to X6 are lysine.

[0037] In a preferred embodiment, the polypeptide of the present invention comprises a histidine tag (His tag) consisting of 3 to 9 consecutive histidines, wherein the His tag is attached to the C-terminus or N-terminus, preferably the C-terminus of the amino acid sequence I, and at least three positively charged amino acids among the X1 to X6 are independently arginine or lysine. In a preferred embodiment, the polypeptide of the present invention comprises a histidine tag (His tag) consisting of 3 to 9 consecutive histidines, wherein the His tag is attached to the C-terminus or N-terminus, preferably the C-terminus of the amino acid sequence I, and at least three positively charged amino acids among the X1 to X6 are arginine. In a preferred embodiment, the polypeptide of the present invention comprises a histidine tag (His tag) consisting of 3 to 9 consecutive histidines, wherein the His tag is attached to the C-terminus or N-terminus, preferably the C-terminus of the amino acid sequence I, and at least three positively charged amino acids among the X1 to X6 are lysine.

[0038] X7 is a cysteine, a conservative substitution thereof, or a positively charged amino acid.

[0039] In a preferred embodiment, the conservative substitution for cysteine ​​is selected from the group consisting of methionine, homocysteine, selenocysteine, serine, hydroxynorvaline, 2-amino-5-hydroxypentanoic acid, allo-threonine, 3,3-dihydroxy-alanine, 4-hydroxy-L-isoleucine, (2s,3r)-2-amino-3-hydroxy-4-methylpentanoic acid, beta-hydroxyleucine, homoserine, 3-hydroxy-l-valine, 4,5-dihydroxy-isoleucine, 6-hydroxy-l-norleucine, s-(2-hydroxyethyl)-l-cysteine, phosphoserine, 4-hydroxy-l-threonine, threonine, and phosphothreonine. In a preferred embodiment, the conservative substitution of cysteine ​​is selected from the group consisting of homocysteine, selenocysteine, serine, hydroxynorvaline, 2-amino-5-hydroxypentanoic acid, allo-threonine, 3,3-dihydroxy-alanine, 4-hydroxy-L-isoleucine, (2s,3r)-2-amino-3-hydroxy-4-methylpentanoic acid, beta-hydroxyleucine, homoserine, 3-hydroxy-l-valine, 4,5-dihydroxy-isoleucine, 6-hydroxy-l-norleucine, s-(2-hydroxyethyl)-l-cysteine, phosphoserine, 4-hydroxy-l-threonine, threonine, and phosphothreonine.More preferably, the conservative substitution of cysteine ​​is selected from the group consisting of homocysteine, selenocysteine, and serine.Even more preferably, the conservative substitution of cysteine ​​is homocysteine ​​or selenocysteine.

[0040] In another preferred embodiment, X7 is selected from the group consisting of homocysteine, selenocysteine, cysteine, arginine, 5-methyl-arginine, c-gamma-hydroxyarginine, 2-amino-4-guanidinobutyric acid, 2-amino-3-guanidinopropionic acid, canavanine, homoarginine, lysine, diaminobutyric acid, 2,3-diaminopropanoic acid, (2s)-2,8-diaminooctanoic acid, ornithine and thialysine.

[0041] In another preferred embodiment, X7 is selected from the group consisting of homocysteine, selenocysteine, serine, hydroxynorvaline, 2-amino-5-hydroxypentanoic acid, allo-threonine, 3,3-dihydroxy-alanine, 4-hydroxy-L-isoleucine, (2s,3r)-2-amino-3-hydroxy-4-methylpentanoic acid, beta-hydroxyleucine, homoserine, 3-hydroxy-l-valine, 4,5-dihydroxy-isoleucine, 6-hydroxy-l-norleucine, s- Selected from the group consisting of (2-hydroxyethyl)-l-cysteine, phosphoserine, 4-hydroxy-l-threonine, threonine and phosphothreonine, arginine, 5-methyl-arginine, c-gamma-hydroxyarginine, 2-amino-4-guanidinobutyric acid, 2-amino-3-guanidinopropionic acid, canavanine, homoarginine, lysine, diaminobutyric acid, 2,3-diaminopropanoic acid, (2s)-2,8-diaminooctanoic acid, ornithine and thialysine.In another preferred embodiment, said X7 is selected from arginine, lysine, serine, homocysteine ​​or cysteine.In another more preferred embodiment, said X7 is selected from arginine, lysine, homocysteine ​​or cysteine.

[0042] When X7 is a cysteine ​​or a conservative substitution of cysteine, it can be used to add a positively charged group to the polypeptides of the invention via disulfide formation (eg, cysteamine, 1-(3-mercaptopropyl)guanidine, etc.).

[0043] In one embodiment, the at least three of X1 to X6 are, independently of one another, lysine or arginine, and X7 is selected from arginine, lysine, serine, homocysteine, or cysteine.

[0044] In the amino acid sequence I consisting of SEQ ID NO: 1, at least three of the amino acids X1 to X6 are positively charged amino acids independently of one another. In a preferred embodiment, at least four, more preferably at least five, and even more preferably six of the amino acids X1 to X6, i.e., each, independently of one another, are positively charged amino acids.

[0045] In a preferred embodiment, at least four, preferably at least five, more preferably six of the amino acids X1 to X6, i.e. each independently of one another, are positively charged amino acids, the positively charged amino acid being arginine or lysine. In a preferred embodiment, at least four, preferably at least five, more preferably each independently of one another, are positively charged amino acids, the positively charged amino acid being arginine. In a preferred embodiment, at least four, preferably at least five, more preferably six of the amino acids X1 to X6, independently of one another, are positively charged amino acids, the positively charged amino acid being lysine.

[0046] In a preferred embodiment, at least three of the positively charged amino acids X1 to X6 are X1 to X3, independently of one another. In another preferred embodiment, at least three of the positively charged amino acids X1 to X6 are X1, X2, and X4, independently of one another. In another preferred embodiment, at least three of the positively charged amino acids X1 to X6 are X1, X2, and X5, independently of one another. In another preferred embodiment, at least three of the positively charged amino acids X1 to X6 are X1, X2, and X6, independently of one another.

[0047] In another preferred embodiment, at least three of the positively charged amino acids X1 to X6, which are independent of one another, are X2, X3, and X4. In another preferred embodiment, at least three of the positively charged amino acids X1 to X6, which are independent of one another, are X2, X3, and X5. In another preferred embodiment, at least three of the positively charged amino acids X1 to X6, which are independent of one another, are X2, X3, and X6.

[0048] In another preferred embodiment, at least three of the positively charged amino acids X1 to X6, independently of one another, are X3, X4, and X5. In another preferred embodiment, at least three of the positively charged amino acids X1 to X6, independently of one another, are X3, X4, and X6. In another preferred embodiment, at least three of the positively charged amino acids X1 to X6, independently of one another, are X3, X4, and X1.

[0049] In another preferred embodiment, at least three of the positively charged amino acids X1 to X6, which are independent of one another, are X4, X5, and X6. In another preferred embodiment, at least three of the positively charged amino acids X1 to X6, which are independent of one another, are X4, X5, and X1. In another preferred embodiment, at least three of the positively charged amino acids X1 to X6, which are independent of one another, are X4, X5, and X2.

[0050] In another preferred embodiment, at least three of the positively charged amino acids X1 to X6, independently of one another, are X5, X6, and X1. In another preferred embodiment, at least three of the positively charged amino acids X1 to X6, independently of one another, are X5, X6, and X2. In another preferred embodiment, at least three of the positively charged amino acids X1 to X6, independently of one another, are X5, X6, and X3.

[0051] In another preferred embodiment, at least three of the X1 to X6 which are positively charged amino acids, independently of one another, are X1, X3, and X5. In another preferred embodiment, at least three of the X1 to X6 which are positively charged amino acids, independently of one another, are X1, X3, and X6. In another preferred embodiment, at least three of the X1 to X6 which are positively charged amino acids, independently of one another, are X2, X4, and X6. In another preferred embodiment, at least three of the X1 to X6 which are positively charged amino acids, independently of one another, are X1, X4, and X6.

[0052] In another preferred embodiment, at least three of the X1 to X6 which are positively charged amino acids are X1, X2, X3, and X4. In another preferred embodiment, at least three of the X1 to X6 which are positively charged amino acids are X1, X2, X3, and X5. In another preferred embodiment, at least three of the X1 to X6 which are positively charged amino acids are X1, X2, X3, and X6. In another preferred embodiment, at least three of the X1 to X6 which are positively charged amino acids are X2, X3, X4, and X5. In another preferred embodiment, at least three of the X1 to X6 which are positively charged amino acids are X2, X3, X4, and X6. In another preferred embodiment, at least three of the X1 to X6 which are positively charged amino acids are X3 to X6. In another preferred embodiment, at least three of the X1 to X6 which are positively charged amino acids are X2, X4, X5, and X6. In another preferred embodiment, at least three of the X1 to X6 which are positively charged amino acids are X1, X4, X5, and X6. In another preferred embodiment, at least three of the X1 to X6 which are positively charged amino acids are X1, X3, X5, and X6. In another preferred embodiment, at least three of the X1 to X6 which are positively charged amino acids are X1, X3, X4, and X6. In another preferred embodiment, at least three of the X1 to X6 which are positively charged amino acids are X2, X3, X4, and X6.

[0053] In another preferred embodiment, at least three of X1 to X6, which are positively charged amino acids, are independently selected from X 1~5 In another preferred embodiment, at least three of the X1 to X6 which are positively charged amino acids are independently 1~4In another preferred embodiment, at least three of the X1 to X6, which are positively charged amino acids, are independently selected from X 1~3 , X5 and X6. In another preferred embodiment, at least three of the X1 to X6 which are positively charged amino acids independently of one another are X1, X2, and X4 to X6. In another preferred embodiment, at least three of the X1 to X6 which are positively charged amino acids independently of one another are X1 and X 3~6 In another preferred embodiment, the positively charged amino acids are independent of each other. 6の At least three of them are X2~X6.

[0054] In another preferred embodiment, at least three of X1 to X6 which are independently positively charged amino acids are X1 to X6 which are independently positively charged amino acids.

[0055] More preferably, at least three of the X1 to X6 which are positively charged amino acids are selected from X1 to X6, or X4 to X6, or X1, X2 and X5, or X1, X2, X4 and X5, or X1, X3, X4 and X6, or X1 and X4 to X6, or X1 to X3 and X 6、 More preferably, at least three of the X1 to X6 which are positively charged amino acids are, independently of one another, X1 to X6, or X4 to X6, or X1, X2 and X5, or X1, X2, X4 and X5, or X1, X3, X4 and X6, or X1 and X4 to X6, or X1 to X3 and X 6、 Or X1 to X5.

[0056] In a preferred embodiment, X4 to X6 are each independently lysine or arginine. In another preferred embodiment, X1, X2, and X4 are each independently lysine or arginine. In another preferred embodiment, X1, X2, X4, and X5 are each independently lysine or arginine. In another preferred embodiment, X1, X3, X4, and X6 are each independently lysine or arginine. In another preferred embodiment, X1, and X3 to X6 are each independently lysine or arginine. In another preferred embodiment, X 1~3 , X5 and X6 are each independently lysine or arginine. 1~5 are each independently lysine or arginine. In another preferred embodiment, X1 to X6 are each independently lysine or arginine.

[0057] In a preferred embodiment, the polypeptide of the present invention comprises a histidine tag (His tag) consisting of 3 to 9 consecutive histidines, wherein the His tag is bound to the C-terminus or N-terminus, preferably the C-terminus of amino acid sequence I, and each of X1 to X6 is independently arginine or lysine. In a preferred embodiment, the polypeptide of the present invention comprises a histidine tag (His tag) consisting of 3 to 9 consecutive histidines, wherein the His tag is bound to the C-terminus or N-terminus, preferably the C-terminus of amino acid sequence I, and each of X1 to X6 is arginine. In a preferred embodiment, the polypeptide of the present invention comprises a histidine tag (His tag) consisting of 3 to 9 consecutive histidines, wherein the His tag is bound to the C-terminus or N-terminus, preferably the C-terminus of amino acid sequence I, and each of X1 to X6 is lysine.

[0058] In another preferred embodiment, X1 to X6 are each independently lysine or arginine, and X7 is selected from arginine, lysine, or cysteine.

[0059] The present inventors have12 It has been found that the amino acids at positions X8 to X9 determine the pore size of the nanoparticles formed through self-assembly by the polypeptide of the present invention. 12 Larger amino acids at these positions decreased the pore size, whereas smaller amino acids at these positions increased the pore size of the nanoparticles.

[0060] Therefore, in a preferred embodiment, the X8 to X9 of the polypeptide of the present invention are selected so that the cargo can be loaded onto the nanoparticles comprising the polypeptide without degradation. 12 In another preferred embodiment, the amino acids at positions X8 to X of the polypeptide of the invention are selected so that cargo can be loaded onto and released from the nanoparticles comprising the polypeptide without degradation. 12 In another preferred embodiment, the amino acids at positions X8 to X9 of the polypeptide of the present invention are selected so that cargo can be loaded onto nanoparticles comprising the polypeptide in vitro and released from the nanoparticles in vivo without degradation. 12 In another preferred embodiment, the amino acids at positions X8 to X9 of the polypeptide of the present invention are selected so that a cargo can be loaded extracellularly onto a nanoparticle comprising the polypeptide and released from the nanoparticle intracellularly, preferably into the cytoplasm of the cell, without degradation. 12 Preferably, the cargo is a negatively charged macromolecule, more preferably an RNA, even more preferably an RNA selected from the group consisting of antisense oligonucleotides (ASO), small interfering RNA (siRNA), small hairpin RNA (shRNA), microRNA (miRNA) and anti-miRNA, most preferably an siRNA.

[0061] In another preferred embodiment, the amino acids at positions X8 to X12 of the polypeptide of the present invention are selected so that the nanoparticles comprising at least one polypeptide of the present invention contain pores having a size of 3 to 4 nm, and the cargo can be loaded onto the nanoparticles comprising the polypeptide without being decomposed. In another preferred embodiment, the amino acids at positions X8 to X12 of the polypeptide of the present invention are selected so that the nanoparticles comprising at least one polypeptide of the present invention contain pores having a size of 3 to 4 nm, and the cargo can be loaded onto the nanoparticles comprising the polypeptide without being decomposed and released from the nanoparticles. In another preferred embodiment, the amino acids at positions X8 to X12 of the polypeptide of the present invention are selected so that the nanoparticles comprising at least one polypeptide of the present invention contain pores having a size of 3 to 4 nm, and the cargo can be loaded onto the nanoparticles comprising the polypeptide in vitro without being decomposed and released from the nanoparticles in vivo. In another preferred embodiment, the amino acids at positions X8 to X12 of the polypeptide of the present invention are selected such that the nanoparticles comprising at least one polypeptide of the present invention contain pores having a size of 3 to 4 nm, and the cargo can be loaded extracellularly onto the nanoparticles comprising the polypeptide without degradation and released from the nanoparticles intracellularly, preferably into the cytoplasm of the cell. Preferably, the cargo is a negatively charged macromolecule, more preferably an RNA, even more preferably an RNA selected from the group consisting of antisense oligonucleotides (ASO), small interfering RNA (siRNA), small hairpin RNA (shRNA), microRNA (miRNA) and anti-miRNA, most preferably an siRNA.

[0062] In a preferred embodiment, each of X8, X9, X10, X11 and X12 is independently selected from glycine, alanine, leucine, valine, tert-leucine, homoleucine, isoleucine, alloisoleucine, 2-aminobutyric acid, diethylalanine, norleucine, norvaline, glutamine, asparagine, beta-hydroxyasparagine, 3-methyl-1-glutamine, (2s,4s)-2,5-diamino-4-hydroxyasparagine, 5-amino-1-propanediol ... 5-Oxopentanoic acid, n-methyl-asparagine, glutamate, aspartate, 2s,4r-4-methylglutamate, (3s)-3-methyl-l-glutamic acid, (3r)-3-methyl-l-glutamic acid, 5-o-methyl-glutamic acid, 4-hydroxy-glutamic acid, 6-carboxylysine, beta-hydroxyaspartic acid, 2-amino-propanedioic acid, 3,3-dimethylaspartic acid , 2-aminoadipic acid, 3-methyl-aspartic acid, serine, homoserine, threonine, 4-hydroxy-l-threonine, 6-hydroxy-l-norleucine, 4,5-dihydroxy-isoleucine, 3-hydroxy-l-valine, hydroxynorvaline, 2-amino-5-hydroxypentanoic acid, allo-threonine, 3,3-dihydroxy-alanine, 4-hydroxy-L-isoleucine, (2s,3r)-2-amino-3-hydroxy-4-methylpentanoic acid, beta-hydroxyleucine, and allo-threonine, and the amino acids at positions X8 to X12 of the polypeptide of the invention are selected such that nanoparticles comprising at least one polypeptide of the invention contain pores having a size of 3 to 4 nm and cargo can be loaded onto and released from the nanoparticles without degradation.In a preferred embodiment, each of X8, X9, X10, X11 and X12 is independently selected from glycine, alanine, leucine, valine, tert-leucine, homoleucine, isoleucine, alloisoleucine, 2-aminobutyric acid, diethylalanine, norleucine, norvaline, glutamine, asparagine, beta-hydroxyasparagine, 3-methyl-l-glutamine, (2s,4s)-2,5-diamino-4-hydroxy-5-oxo-1,4-trimethyl ... sopentanoic acid, n-methyl-asparagine, glutamate, aspartate, 2s,4r-4-methylglutamate, (3s)-3-methyl-l-glutamic acid, (3r)-3-methyl-l-glutamic acid, 5-o-methyl-glutamic acid, 4-hydroxy-glutamic acid, 6-carboxylysine, beta-hydroxyaspartic acid, 2-amino-propanedioic acid, 3,3-dimethylaspartic acid, 2-aminoadipic acid, 3-methyl and the amino acids at positions X8 to X12 of the polypeptide of the present invention are independently selected from the group consisting of l-aspartic acid, serine, homoserine, threonine, 4-hydroxy-l-threonine, 6-hydroxy-l-norleucine, 4,5-dihydroxy-isoleucine, 3-hydroxy-l-valine, hydroxynorvaline, 2-amino-5-hydroxypentanoic acid, allo-threonine, 3,3-dihydroxy-alanine, 4-hydroxy-l-isoleucine, (2s,3r)-2-amino-3-hydroxy-4-methylpentanoic acid, beta-hydroxyleucine, and allo-threonine, and the amino acids at positions X8 to X12 of the polypeptide of the present invention are selected such that the nanoparticles comprising at least one polypeptide of the present invention contain pores having a size of 3 to 4 nm, and cargo can be loaded extracellularly onto the nanoparticles comprising the polypeptide without degradation and released from the nanoparticles intracellularly, more preferably into the cytoplasm of the cell.In a further preferred embodiment, each of X8, X9, X10, X11 and X12 is independently selected from the group consisting of glycine, alanine, leucine, valine, glutamate, aspartate, glutamine, asparagine, serine, threonine and homoserine, and the amino acids at positions X8 to X12 of the polypeptide of the present invention are selected such that nanoparticles comprising at least one polypeptide of the present invention contain pores having a size of 3 to 4 nm and cargo can be loaded onto and released from the nanoparticles comprising the polypeptide without degradation. In a further preferred embodiment, each of X8, X9, X10, X11 and X12 is independently selected from the group consisting of glycine, alanine, leucine, valine, glutamate, aspartate, glutamine, asparagine, serine, threonine and homoserine, and the amino acids at positions X8 to X12 of the polypeptide of the present invention are selected such that nanoparticles comprising at least one polypeptide of the present invention comprise pores having a size of 3 to 4 nm, and cargo can be loaded extracellularly onto the nanoparticles comprising the polypeptide without degradation, and released from the nanoparticles intracellularly, more preferably into the cytoplasm of the cell. In a further preferred embodiment, each of X8, X9, X10, X11 and X12 is independently selected from the group consisting of serine, glycine, glutamine and glutamate, and the amino acids at positions X8 to X12 of the polypeptide of the present invention are selected so that the nanoparticles comprising at least one polypeptide of the present invention contain pores having a size of 3 to 4 nm, and the cargo can be loaded onto the nanoparticles comprising the polypeptide without being decomposed and released from the nanoparticles. In a further preferred embodiment, each of X8, X9, X10, X11 and X12 is independently selected from the group consisting of serine, glycine, glutamine and glutamate, and the amino acids at positions X8 to X12 of the polypeptide of the present invention are selected so that the nanoparticles comprising at least one polypeptide of the present invention contain pores having a size of 3 to 4 nm, and the cargo can be loaded onto the nanoparticles comprising the polypeptide outside the cell without being decomposed and released from the nanoparticles into the cell, more preferably into the cytoplasm of the cell.Preferably, the cargo is a negatively charged macromolecule, more preferably an RNA, even more preferably an RNA selected from the group consisting of antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), small hairpin RNAs (shRNAs), microRNAs (miRNAs) and anti-miRNAs, most preferably siRNAs.

[0063] In a preferred embodiment, X1 to X6 are each independently lysine or arginine, X7 is selected from arginine, lysine, or cysteine, and each of X8, X9, X10, X11, and X12 is independently glycine, alanine, leucine, valine, tert-leucine, homoleucine, isoleucine, alloisoleucine, 2-aminobutyric acid, diethylalanine, norleucine, norvaline, glutamine, asparagine, beta-hydroxylase, hydroxypropyl ester ... l-methylasparagine, 3-methyl-l-glutamine, (2s,4s)-2,5-diamino-4-hydroxy-5-oxopentanoic acid, n-methyl-asparagine, glutamate, aspartate, 2s,4r-4-methylglutamate, (3s)-3-methyl-l-glutamic acid, (3r)-3-methyl-l-glutamic acid, 5-o-methyl-glutamic acid, 4-hydroxy-glutamic acid, 6-carboxylysine, beta-hydroxyasparagine and the amino acids at positions X8 to X12 of the polypeptide of the invention are selected such that nanoparticles comprising at least one polypeptide of the invention contain pores having a size of 3 to 4 nm and cargo can be loaded onto and released from the nanoparticles without degradation.In a preferred embodiment, X1 to X6 are each independently lysine or arginine, X7 is selected from arginine, lysine, or cysteine, and each of X8, X9, X10, X11, and X12 is independently glycine, alanine, leucine, valine, tert-leucine, homoleucine, isoleucine, alloisoleucine, 2-aminobutyric acid, diethylalanine, norleucine, norvaline, glutamine, asparagine, beta-hydroxyasparagine. , 3-Methyl-l-glutamine, (2s,4s)-2,5-diamino-4-hydroxy-5-oxopentanoic acid, n-methyl-asparagine, glutamate, aspartate, 2s,4r-4-methylglutamate, (3s)-3-methyl-l-glutamic acid, (3r)-3-methyl-l-glutamic acid, 5-o-methyl-glutamic acid, 4-hydroxy-glutamic acid, 6-carboxylysine, beta-hydroxyaspartic acid, 2-amino-propanedioic acid, 3, The amino acids at positions X8 to X12 of the polypeptide of the invention are independently selected from the group consisting of 3-dimethylaspartic acid, 2-aminoadipic acid, 3-methyl-aspartic acid, serine, homoserine, threonine, 4-hydroxy-l-threonine, 6-hydroxy-l-norleucine, 4,5-dihydroxy-isoleucine, 3-hydroxy-l-valine, hydroxynorvaline, 2-amino-5-hydroxypentanoic acid, allo-threonine, 3,3-dihydroxy-alanine, 4-hydroxy-L-isoleucine, (2s,3r)-2-amino-3-hydroxy-4-methylpentanoic acid, beta-hydroxyleucine, and allo-threonine, and are selected such that nanoparticles comprising at least one polypeptide of the invention comprise pores having a size of 3 to 4 nm, and cargo can be loaded extracellularly onto the nanoparticles comprising the polypeptide without degradation, and released from the nanoparticles intracellularly, more preferably into the cytoplasm of the cell.In a further preferred embodiment, X1 to X6 are, independently of one another, lysine or arginine, X7 is selected from arginine, lysine, or cysteine, and each of X8, X9, X10, X11, and X12 is independently selected from the group consisting of glycine, alanine, leucine, valine, glutamate, aspartate, glutamine, asparagine, serine, threonine, and homoserine, and the amino acids at positions X8 to X12 of the polypeptide of the present invention are selected such that nanoparticles comprising at least one polypeptide of the present invention comprise pores having a size of 3 to 4 nm, and cargo can be loaded onto and released from the nanoparticles comprising the polypeptide without degradation. In a further preferred embodiment, X1 to X6 are, independently of each other, lysine or arginine, X7 is selected from arginine, lysine or cysteine, and each of X8, X9, X10, X11 and X12 is independently selected from the group consisting of glycine, alanine, leucine, valine, glutamate, aspartate, glutamine, asparagine, serine, threonine and homoserine, and the amino acids at positions X8 to X12 of the polypeptide of the present invention are selected such that nanoparticles comprising at least one polypeptide of the present invention comprise pores having a size of 3 to 4 nm, and cargo can be loaded extracellularly onto the nanoparticles comprising the polypeptide without degradation, and released from the nanoparticles intracellularly, more preferably into the cytoplasm of the cell. In a further preferred embodiment, X1 to X6 are, independently of one another, lysine or arginine, X7 is selected from arginine, lysine, or cysteine, and each of X8, X9, X10, X11 and X12 is independently selected from the group consisting of serine, glycine, glutamine, and glutamate, and the amino acids at positions X8 to X12 of the polypeptide of the present invention are selected such that nanoparticles comprising at least one polypeptide of the present invention comprise pores having a size of 3 to 4 nm, and cargo can be loaded onto and released from the nanoparticles comprising the polypeptide without degradation.In a further preferred embodiment, X1 to X6 are each independently lysine or arginine, X7 is selected from arginine, lysine, or cysteine, and each of X8, X9, X10, X11, and X12 is independently selected from the group consisting of serine, glycine, glutamine, and glutamate, and the amino acids at positions X8 to X12 of the polypeptide of the present invention are selected so that nanoparticles comprising at least one polypeptide of the present invention contain pores having a size of 3 to 4 nm, and cargo can be loaded extracellularly onto the nanoparticles comprising the polypeptide without degradation, and released from the nanoparticles intracellularly, more preferably into the cytoplasm of the cell. Preferably, the cargo is a negatively charged polymer, more preferably an RNA, even more preferably an RNA selected from the group consisting of antisense oligonucleotides (ASO), small interfering RNA (siRNA), small hairpin RNA (shRNA), microRNA (miRNA) and anti-miRNA, most preferably an siRNA.

[0064] In a preferred embodiment, X1 to X6 are each independently lysine or arginine, X7 is selected from arginine, lysine, or cysteine, and each of X8, X9, X10, X11, and X12 is independently glycine, alanine, leucine, valine, tert-leucine, homoleucine, isoleucine, alloisoleucine, 2-aminobutyric acid, diethylalanine, norleucine, norvaline, glutamine, asparagine, beta-hyalin, ...glycine, alanine, leucine, valine, tert-le hydroxyasparagine, 3-methyl-l-glutamine, (2s,4s)-2,5-diamino-4-hydroxy-5-oxopentanoic acid, n-methyl-asparagine, glutamate, aspartate, 2s,4r-4-methylglutamate, (3s)-3-methyl-l-glutamic acid, (3r)-3-methyl-l-glutamic acid, 5-o-methyl-glutamic acid, 4-hydroxy-glutamic acid, 6-carboxylysine, beta-hydroxyasparagine The amino acids at positions X8 to X12 of the polypeptide of the present invention are independently selected from the group consisting of oleic acid, 2-amino-propanedioic acid, 3,3-dimethylaspartic acid, 2-aminoadipic acid, 3-methyl-aspartic acid, serine, homoserine, threonine, 4-hydroxy-l-threonine, 6-hydroxy-l-norleucine, 4,5-dihydroxy-isoleucine, 3-hydroxy-l-valine, hydroxynorvaline, 2-amino-5-hydroxypentanoic acid, allo-threonine, 3,3-dihydroxy-alanine, 4-hydroxy-L-isoleucine, (2s,3r)-2-amino-3-hydroxy-4-methylpentanoic acid, beta-hydroxyleucine, and allo-threonine, and the amino acids at positions X8 to X12 of the polypeptide of the present invention are selected such that a nanoparticle comprising six of the polypeptides comprises six pores having a size of 3 to 4 nm, and a cargo can be loaded onto and released from the nanoparticles without degradation.In a preferred embodiment, X1 to X6 are each independently lysine or arginine, X7 is selected from arginine, lysine, or cysteine, and each of X8, X9, X10, X11, and X12 is independently glycine, alanine, leucine, valine, tert-leucine, homoleucine, isoleucine, alloisoleucine, 2-aminobutyric acid, diethylalanine, norleucine, norvaline, glutamine, asparagine, beta-hydroxyasparagine, or the like. , 3-methyl-l-glutamine, (2s,4s)-2,5-diamino-4-hydroxy-5-oxopentanoic acid, n-methyl-asparagine, glutamate, aspartate, 2s,4r-4-methylglutamate, (3s)-3-methyl-l-glutamic acid, (3r)-3-methyl-l-glutamic acid, 5-o-methyl-glutamic acid, 4-hydroxy-glutamic acid, 6-carboxylysine, beta-hydroxyaspartic acid, 2-amino-propanedioic acid, The amino acids at positions X8 to X12 of the polypeptide of the present invention are independently selected from the group consisting of 3,3-dimethylaspartic acid, 2-aminoadipic acid, 3-methyl-aspartic acid, serine, homoserine, threonine, 4-hydroxy-1-threonine, 6-hydroxy-l-norleucine, 4,5-dihydroxy-isoleucine, 3-hydroxy-l-valine, hydroxynorvaline, 2-amino-5-hydroxypentanoic acid, allo-threonine, 3,3-dihydroxy-alanine, 4-hydroxy-L-isoleucine, (2s,3r)-2-amino-3-hydroxy-4-methylpentanoic acid, beta-hydroxyleucine, and allo-threonine, and are selected such that a nanoparticle comprising six of the polypeptides comprises six pores having a size of 3 to 4 nm, and a cargo can be loaded extracellularly onto the nanoparticle comprising the polypeptide without degradation and released from the nanoparticle into a cell, more preferably into the cytoplasm of a cell.In a further preferred embodiment, X1 to X6 are, independently of one another, lysine or arginine, X7 is selected from arginine, lysine, or cysteine, and each of X8, X9, X10, X11, and X12 is independently selected from the group consisting of glycine, alanine, leucine, valine, glutamate, aspartate, glutamine, asparagine, serine, threonine, and homoserine, and the amino acids at positions X8 to X12 of the polypeptide of the present invention are selected such that a nanoparticle comprising six of the polypeptides comprises six pores having a size of 3 to 4 nm, and a cargo can be loaded onto and released from the nanoparticle comprising the polypeptide without degradation. In a further preferred embodiment, X1 to X6 are, independently of one another, lysine or arginine, X7 is selected from arginine, lysine, or cysteine, and each of X8, X9, X10, X11, and X12 is independently selected from the group consisting of glycine, alanine, leucine, valine, glutamate, aspartate, glutamine, asparagine, serine, threonine, and homoserine, and the amino acids at positions X8 to X12 of the polypeptide of the present invention are selected such that nanoparticles comprising six of the polypeptides comprise pores having a size of 3 to 4 nm, and cargo can be loaded extracellularly onto the nanoparticles comprising the polypeptides without degradation, and released from the nanoparticles intracellularly, more preferably into the cytoplasm of the cells. In a further preferred embodiment, X1 to X6 are, independently of one another, lysine or arginine, X7 is selected from arginine, lysine, or cysteine, and each of X8, X9, X10, X11, and X12 is independently selected from the group consisting of serine, glycine, glutamine, and glutamate, and the amino acids at positions X8 to X12 of the polypeptide of the present invention are selected such that a nanoparticle comprising six of the polypeptides comprises six pores having a size of 3 to 4 nm, and a cargo can be loaded onto and released from the nanoparticle comprising the polypeptide without degradation.In a further preferred embodiment, X1 to X6 are each independently lysine or arginine, X7 is selected from arginine, lysine, or cysteine, and each of X8, X9, X10, X11, and X12 is independently selected from the group consisting of serine, glycine, glutamine, and glutamate, and the amino acids at positions X8 to X12 of the polypeptide of the present invention are selected so that a nanoparticle containing six of the polypeptides contains six pores having a size of 3 to 4 nm, and a cargo can be loaded extracellularly on the nanoparticle containing the polypeptide without degradation and released from the nanoparticle into the cell, more preferably into the cytoplasm of the cell. Preferably, the cargo is a negatively charged polymer, more preferably an RNA, even more preferably an RNA selected from the group consisting of antisense oligonucleotides (ASO), small interfering RNA (siRNA), small hairpin RNA (shRNA), microRNA (miRNA) and anti-miRNA, most preferably an siRNA.

[0065] In a further preferred embodiment, X1 to X6 are, independently of one another, lysine or arginine, X7 is selected from arginine, lysine, or cysteine, and each of X8, X9, X10, X11, and X12 is independently selected from the group consisting of glycine, alanine, leucine, valine, glutamate, aspartate, glutamine, asparagine, serine, threonine, and homoserine, and the nanoparticles comprising at least one polypeptide of the invention comprise pores having a size of 3 to 4 nm, the pore size being selected such that cargo can be loaded onto and released from the nanoparticles comprising the polypeptide without degradation. In a further preferred embodiment, X1 to X6 are, independently of one another, lysine or arginine, X7 is selected from arginine, lysine, or cysteine, and each of X8, X9, X10, X11, and X12 is independently selected from the group consisting of glycine, alanine, leucine, valine, glutamate, aspartate, glutamine, asparagine, serine, threonine, and homoserine, and the nanoparticles comprising at least one polypeptide of the invention comprise pores having a size of 3 to 4 nm, the pore size being selected such that a cargo can be loaded extracellularly onto the polypeptide-containing nanoparticles without degradation and released from the nanoparticles intracellularly, more preferably into the cytoplasm of a cell. In a further preferred embodiment, X1 to X6 are, independently of one another, lysine or arginine, X7 is selected from arginine, lysine, or cysteine, and each of X8, X9, X10, X11 and X12 is independently selected from the group consisting of serine, glycine, glutamine, and glutamate, and the pore size is selected such that the nanoparticles comprising at least one polypeptide of the invention comprise pores having a size of 3 to 4 nm, and cargo can be loaded onto and released from the nanoparticles comprising the polypeptide without degradation.In a further preferred embodiment, X1 to X6 are each independently lysine or arginine, X7 is selected from arginine, lysine, or cysteine, and each of X8, X9, X10, X11, and X12 is independently selected from the group consisting of serine, glycine, glutamine, and glutamate, and the pore size is selected such that the nanoparticles comprising at least one polypeptide of the present invention comprise pores having a size of 3 to 4 nm, and a cargo can be loaded extracellularly onto the nanoparticles comprising the polypeptide without degradation and released from the nanoparticles intracellularly, more preferably into the cytoplasm of the cell. Preferably, the cargo is a negatively charged macromolecule, more preferably an RNA, even more preferably an RNA selected from the group consisting of antisense oligonucleotides (ASO), small interfering RNA (siRNA), small hairpin RNA (shRNA), microRNA (miRNA) and anti-miRNA, most preferably an siRNA.

[0066] In a preferred embodiment, each of X8, X9, X10, X11 and X12 is independently selected from glycine, alanine, leucine, valine, tert-leucine, homoleucine, isoleucine, alloisoleucine, 2-aminobutyric acid, diethylalanine, norleucine, norvaline, glutamine, asparagine, beta-hydroxyasparagine, 3-methyl-l-glutamine, (2s,4s)-2,5-diamino-4-hydroxy-5-oxopentanoic acid, n-methyl-asparagine, glutamate, aspartate, 2s,4r-4-methylglutamate, (3s)-3-methyl-l-glutamic acid, (3r)-3-methyl-l-glutamic acid, 5-o-methyl-glutamic acid, 4-hydroxy-glutamic acid, 6-carboxylysine, beta-hydroxyaspartic acid, 2-amino-propanoic acid, 5 ... The nanoparticles comprising six of the polypeptides independently selected from the group consisting of propanedioic acid, 3,3-dimethylaspartic acid, 2-aminoadipic acid, 3-methyl-aspartic acid, serine, homoserine, threonine, 4-hydroxy-l-threonine, 6-hydroxy-l-norleucine, 4,5-dihydroxy-isoleucine, 3-hydroxy-l-valine, hydroxynorvaline, 2-amino-5-hydroxypentanoic acid, allo-threonine, 3,3-dihydroxy-alanine, 4-hydroxy-l-isoleucine, (2s,3r)-2-amino-3-hydroxy-4-methylpentanoic acid, beta-hydroxyleucine, and allo-threonine, comprise six pores having a size of 3-4 nm, and cargo can be loaded onto and released from the nanoparticles without degradation.In a preferred embodiment, each of X8, X9, X10, X11 and X12 is independently selected from glycine, alanine, leucine, valine, tert-leucine, homoleucine, isoleucine, alloisoleucine, 2-aminobutyric acid, diethylalanine, norleucine, norvaline, glutamine, asparagine, beta-hydroxyasparagine, 3-methyl-l-glutamine, (2s,4s)-2,5-diamino-4-hydroxy-5-oxopentanoic acid, n-methyl-asparagine, glutamate, aspartate, 2s,4r-4-methylglutamate, (3s)-3-methyl-l-glutamic acid, (3r)-3-methyl-l-glutamic acid, 5-o-methyl-glutamic acid, 4-hydroxy-glutamic acid, 6-carboxylysine, beta-hydroxyaspartic acid, 2-amino-propanedioic acid, 3,3-dimethylamino- The nanoparticles comprising six of said polypeptides independently selected from the group consisting of: aspartic acid, 2-aminoadipic acid, 3-methyl-aspartic acid, serine, homoserine, threonine, 4-hydroxy-1-threonine, 6-hydroxy-l-norleucine, 4,5-dihydroxy-isoleucine, 3-hydroxy-l-valine, hydroxynorvaline, 2-amino-5-hydroxypentanoic acid, allo-threonine, 3,3-dihydroxy-alanine, 4-hydroxy-l-isoleucine, (2s,3r)-2-amino-3-hydroxy-4-methylpentanoic acid, beta-hydroxyleucine, and allo-threonine, comprise six pores having a size of 3-4 nm, and cargo can be loaded extracellularly onto the nanoparticles and released from the nanoparticles intracellularly, more preferably into the cytoplasm of the cell, in both cases without degradation. In a further preferred embodiment, each of X8, X9, X10, X11 and X12 is independently selected from the group consisting of glycine, alanine, leucine, valine, glutamate, aspartate, glutamine, asparagine, serine, threonine and homoserine, and the nanoparticles comprising six of the polypeptides of the present invention comprise six pores having a size of 3-4 nm, and cargo can be loaded onto and released from the nanoparticles without degradation.In a further preferred embodiment, each of X8, X9, X10, X11 and X12 is independently selected from the group consisting of serine, glycine, glutamine and glutamate, and the nanoparticles containing six polypeptides of the present invention contain six pores with a pore size of 3-4 nm, and cargo can be loaded extracellularly into the nanoparticles and released from the nanoparticles into the cells, more preferably into the cytoplasm of the cells, in both cases without degradation. In a further preferred embodiment, each of X8, X9, X10, X11 and X12 is independently selected from the group consisting of serine, glycine, glutamine and glutamate, and the nanoparticles containing six polypeptides of the present invention contain six pores with a pore size of 3-4 nm, and cargo can be loaded extracellularly into the nanoparticles and released from the nanoparticles into the cells, more preferably into the cytoplasm of the cells, in both cases without degradation. Preferably, the cargo is a negatively charged macromolecule, more preferably an RNA, even more preferably an RNA selected from the group consisting of antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), small hairpin RNAs (shRNAs), microRNAs (miRNAs) and anti-miRNAs, most preferably siRNAs.

[0067] In a further preferred embodiment, the polypeptide of the present invention comprises a histidine tag (His tag) consisting of three or more consecutive histidines, wherein the His tag is attached to the C-terminus or N-terminus of the polypeptide, X1 to X6 are each independently lysine or arginine, X7 is selected from arginine, lysine, or cysteine, and each of X8, X9, X10, X11, and X12 is independently glycine, alanine, leucine, valine, tert-leucine, homoleucine, Isoleucine, Alloisoleucine 2-Aminobutyric Acid, Diethylalanine, Norleucine, Norvaline, Glutamine, Asparagine, Beta-Hydroxyasparagine, 3-Methyl-l-glutamine, (2s,4s)-2,5-Diamino-4-Hydroxy-5-Oxopentanoic Acid, N-Methyl-asparagine, Glutamate, Aspartate, 2s,4r-4-Methylglutamate, (3s)-3-Methyl-l-glutamic acid, (3r)-3-Methyl-l-glutamic acid, 5-o-Methyl-glutamic acid, 4 -Hydroxy-glutamic acid, 6-carboxylysine, beta-hydroxyaspartic acid, 2-amino-propanedioic acid, 3,3-dimethylaspartic acid, 2-aminoadipic acid, 3-methyl-aspartic acid, serine, homoserine, threonine, 4-hydroxy-l-threonine, 6-hydroxy-l-norleucine, 4,5-dihydroxy-isoleucine, 3-hydroxy-l-valine, hydroxynorvaline, 2-amino-5-hydroxypentanoic acid, allo-threonine, 3,3-dihydroxy -alanine, 4-hydroxy-L-isoleucine, (2s,3r)-2-amino-3-hydroxy-4-methylpentanoic acid, beta-hydroxyleucine, and allo-threonine, and the amino acids at positions X8 to X12 of the polypeptide of the present invention are selected such that a nanoparticle comprising six polypeptides of the present invention contains six pores having a pore size of 3 to 4 nm, and a cargo can be loaded onto and released from the nanoparticle comprising the polypeptide without degradation.In a further preferred embodiment, the polypeptide of the present invention comprises a histidine tag (His tag) consisting of three or more consecutive histidines, wherein the His tag is attached to the C-terminus or N-terminus of the polypeptide, X1 to X6 are each independently lysine or arginine, X7 is selected from arginine, lysine, or cysteine, and each of X8, X9, X10, X11, and X12 is independently glycine, alanine, leucine, valine, tert-leucine, homoleucine, isoleucine, , Alloisoleucine 2-aminobutyric acid, Diethylalanine, Norleucine, Norvaline, Glutamine, Asparagine, Beta-Hydroxyasparagine, 3-Methyl-l-glutamine, (2s,4s)-2,5-Diamino-4-hydroxy-5-oxopentanoic acid, N-Methyl-asparagine, Glutamate, Aspartate, 2s,4r-4-Methylglutamate, (3s)-3-Methyl-l-glutamic acid, (3r)-3-Methyl-l-glutamic acid, 5-o-Methyl-glutamic acid, 4-Hydroxy-glutamine Acid, 6-carboxylysine, beta-hydroxyaspartic acid, 2-amino-propanedioic acid, 3,3-dimethylaspartic acid, 2-aminoadipic acid, 3-methyl-aspartic acid, serine, homoserine, threonine, 4-hydroxy-l-threonine, 6-hydroxy-l-norleucine, 4,5-dihydroxy-isoleucine, 3-hydroxy-l-valine, hydroxynorvaline, 2-amino-5-hydroxypentanoic acid, allo-threonine, 3,3-dihydroxy-alanine, 4-hydroxy-l-isoleucine, The amino acids at positions X8 to X12 of the polypeptide of the present invention are independently selected from the group consisting of soleucine, (2s,3r)-2-amino-3-hydroxy-4-methylpentanoic acid, beta-hydroxyleucine, and allo-threonine, and are selected such that a nanoparticle comprising six of the polypeptide of the present invention comprises six pores having a pore size of 3 to 4 nm, and a cargo can be loaded extracellularly onto the nanoparticle comprising the polypeptide without degradation, and released from the nanoparticle into the cell, more preferably into the cytoplasm of the cell.In a further preferred embodiment, the polypeptide of the present invention comprises a histidine tag (His tag) consisting of three or more consecutive histidines, wherein the His tag is attached to the C-terminus or N-terminus of the polypeptide, X1 to X6 are, independently of each other, lysine or arginine, X7 is selected from arginine, lysine, or cysteine, and each of X8, X9, X10, X11 and X12 is independently selected from the group consisting of glycine, alanine, leucine, valine, glutamate, aspartate, glutamine, asparagine, serine, threonine, and homoserine, and the amino acids at positions X8 to X12 of the polypeptide of the present invention are selected such that a nanoparticle comprising six polypeptides of the present invention comprises six pores having a pore size of 3 to 4 nm, and a cargo can be loaded onto and released from the nanoparticle comprising the polypeptide without degradation. In a further preferred embodiment, the polypeptide of the present invention comprises a histidine tag (His tag) consisting of three or more consecutive histidines, wherein the His tag is attached to the C-terminus or N-terminus of the polypeptide, X1 to X6 are, independently of each other, lysine or arginine, X7 is selected from arginine, lysine, or cysteine, and each of X8, X9, X10, X11 and X12 is independently selected from the group consisting of glycine, alanine, leucine, valine, glutamate, aspartate, glutamine, asparagine, serine, threonine, and homoserine, and the amino acids at positions X8 to X12 of the polypeptide of the present invention are selected such that a nanoparticle comprising six polypeptides of the present invention comprises six pores having a pore size of 3 to 4 nm, and a cargo can be loaded extracellularly onto the nanoparticle comprising the polypeptide without degradation and released from the nanoparticle into a cell, more preferably into the cytoplasm of a cell.In a further preferred embodiment, the polypeptide of the present invention comprises a histidine tag (His tag) consisting of three or more consecutive histidines, wherein the His tag is attached to the C-terminus or N-terminus of the polypeptide, X1 to X6 are, independently of each other, lysine or arginine, X7 is selected from arginine, lysine, or cysteine, and each of X8, X9, X10, X11, and X12 is independently selected from the group consisting of serine, glycine, glutamine, and glutamate, and the amino acids at positions X8 to X12 of the polypeptide of the present invention are selected such that nanoparticles comprising six of the polypeptides of the present invention comprise six pores having a pore size of 3 to 4 nm, and cargo can be loaded onto and released from the nanoparticles comprising the polypeptide without degradation. wherein the polypeptide of the present invention comprises a histidine tag (His tag) consisting of three or more consecutive histidines, wherein the His tag is attached to the C-terminus or N-terminus of the polypeptide, X1 to X6 are, independently of one another, lysine or arginine, X7 is selected from arginine, lysine, or cysteine, and each of X8, X9, X10, X11, and X12 is independently selected from the group consisting of serine, glycine, glutamine, and glutamate, and the amino acids at positions X8 to X12 of the polypeptide of the present invention are selected such that nanoparticles comprising six of the polypeptides of the present invention comprise six pores having a pore size of 3 to 4 nm, and a cargo can be loaded extracellularly onto the nanoparticles comprising the polypeptide without degradation, and released from the nanoparticles intracellularly, more preferably into the cytoplasm of a cell. Preferably, the cargo is a negatively charged polymer, more preferably an RNA, even more preferably an RNA selected from the group consisting of an antisense oligonucleotide (ASO), a small interfering RNA (siRNA), a small hairpin RNA (shRNA), a microRNA (miRNA) and an anti-miRNA, most preferably an siRNA. More preferably, the three or more consecutive histidines are 3 to 9 his tags.

[0068] In a preferred embodiment, said X8 is glycine or its conservative substitution.Preferably, said conservative substitution of glycine is selected from the group consisting of alanine, leucine, valine, tert-leucine, homoleucine, isoleucine, alloisoleucine 2-aminobutyric acid, diethylalanine, norleucine and norvaline.More preferably, said conservative substitution of glycine is selected from the group consisting of alanine, leucine, valine, tert-leucine, homoleucine, isoleucine, alloisoleucine 2-aminobutyric acid, diethylalanine, norleucine and norvaline.In a further preferred embodiment, said X8 is selected from the group consisting of glycine, alanine, leucine and valine.In a preferred embodiment, said X8 is glycine.

[0069] In another preferred embodiment, the X and X 12 are, independently of each other, glutamine or a conservative substitution thereof. Preferably, the conservative substitution for glutamine is selected from the group consisting of asparagine, beta-hydroxyasparagine, 3-methyl-l-glutamine, (2s,4s)-2,5-diamino-4-hydroxy-5-oxopentanoic acid, and n-methylasparagine. In another preferred embodiment, the X and X 12 are, independently of each other, glutamine or asparagine.

[0070] In another preferred embodiment, the X and X 12 In another preferred embodiment, X and X are both glutamine. 12 In another preferred embodiment, X or X are both asparagine. 12 In another preferred embodiment, X is glutamine. In another preferred embodiment, X is glutamine. 12 is glutamine.

[0071] In another preferred embodiment, the X 10is glutamate or a conservative substitution thereof. Preferably, the conservative substitution of glutamate is selected from the group consisting of glutamate, aspartate, 2s,4r-4-methylglutamate, (3s)-3-methyl-l-glutamic acid, (3r)-3-methyl-l-glutamic acid, 5-o-methyl-glutamic acid, 4-hydroxy-glutamic acid, 6-carboxylysine, beta-hydroxyaspartic acid, 2-amino-propanedioic acid, 3,3-dimethylaspartic acid, 2-aminoadipic acid and 3-methylaspartic acid. In a further preferred embodiment, the X 10 is glutamate or aspartate. 10 is glutamate.

[0072] In another preferred embodiment, the X 11is selected from the group consisting of serine or a conservative substitution thereof.Preferably, the conservative substitution of serine is selected from the group consisting of cysteine, methionine, homocysteine, selenocysteine, hydroxynorvaline, 2-amino-5-hydroxypentanoic acid, allo-threonine, 3,3-dihydroxy-alanine, 4-hydroxy-L-isoleucine, (2s,3r)-2-amino-3-hydroxy-4-methylpentanoic acid, beta-hydroxyleucine, homoserine, 3-hydroxy-l-valine, 4,5-dihydroxy-isoleucine, 6-hydroxy-l-norleucine, s-(2-hydroxyethyl)-l-cysteine, phosphoserine, 4-hydroxy-l-threonine, threonine, and phosphothreonine. More preferably, the conservative substitution for serine is selected from the group consisting of cysteine, homocysteine, selenocysteine, hydroxynorvaline, 2-amino-5-hydroxypentanoic acid, allo-threonine, 3,3-dihydroxy-alanine, 4-hydroxy-L-isoleucine, (2s,3r)-2-amino-3-hydroxy-4-methylpentanoic acid, beta-hydroxyleucine, homoserine, 3-hydroxy-l-valine, 4,5-dihydroxy-isoleucine, 6-hydroxy-l-norleucine, s-(2-hydroxyethyl)-l-cysteine, phosphoserine, 4-hydroxy-l-threonine, threonine, and phosphothreonine. Even more preferably, said conservative substitution for serine is selected from the group consisting of hydroxynorvaline, 2-amino-5-hydroxypentanoic acid, allo-threonine, 3,3-dihydroxy-alanine, 4-hydroxy-L-isoleucine, (2s,3r)-2-amino-3-hydroxy-4-methylpentanoic acid, beta-hydroxyleucine, homoserine, 3-hydroxy-l-valine, 4,5-dihydroxy-isoleucine, 6-hydroxy-l-norleucine, s-(2-hydroxyethyl)-l-cysteine, phosphoserine, 4-hydroxy-l-threonine, threonine, and phosphothreonine.Even more preferably, said conservative substitution for serine is selected from the group consisting of homoserine, threonine, 4-hydroxy-l-threonine, 6-hydroxy-l-norleucine, 4,5-dihydroxy-isoleucine, 3-hydroxy-l-valine, hydroxynorvaline, 2-amino-5-hydroxypentanoic acid, allothreonine, 3,3-dihydroxy-alanine, 4-hydroxy-L-isoleucine, (2s,3r)-2-amino-3-hydroxy-4-methylpentanoic acid, beta-hydroxyleucine, and allo-threonine.

[0073] In a further preferred embodiment, the X 11 is selected from the group consisting of serine, homoserine, and threonine. 11 is serine.

[0074] In a preferred embodiment, X8 is selected from the group consisting of glycine, alanine, leucine, valine, tert-leucine, homoleucine, isoleucine, alloisoleucine 2-aminobutyric acid, diethylalanine, norleucine, and norvaline; X9 and X 12 are independently selected from the group consisting of glutamine, asparagine, beta-hydroxyasparagine, 3-methyl-l-glutamine, (2S,4S)-2,5-diamino-4-hydroxy-5-oxopentanoic acid, and n-methyl-asparagine; X 10 is selected from the group consisting of glutamate, aspartate, 2s,4r-4-methylglutamate, (3s)-3-methyl-l-glutamic acid, (3r)-3-methyl-l-glutamic acid, 5-o-methyl-glutamic acid, 4-hydroxy-glutamic acid, 6-carboxylysine, beta-hydroxyaspartic acid, 2-amino-propanedioic acid, 3,3-dimethylaspartic acid, 2-aminoadipic acid and 3-methylaspartic acid; and X 11is selected from the group consisting of serine, homoserine, threonine, 4-hydroxy-l-threonine, 6-hydroxy-l-norleucine, 4,5-dihydroxy-isoleucine, 3-hydroxy-l-valine, hydroxynorvaline, 2-amino-5-hydroxypentanoic acid, allothreonine, 3,3-dihydroxy-alanine, 4-hydroxy-L-isoleucine, (2s,3r)-2-amino-3-hydroxy-4-methylpentanoic acid, beta-hydroxyleucine, and allothreonine.

[0075] In a further preferred embodiment, X8 is selected from the group consisting of glycine, alanine, leucine, and valine, and X9 and X 12 are, independently of each other, glutamine or asparagine, and X 10 is glutamate or aspartate, and X 11 is selected from the group consisting of serine, threonine, and homoserine.

[0076] In a further preferred embodiment, X8 is glycine, and X9 and X 12 is glutamine, and X 10 is glutamate and X 11 is serine.

[0077] In a preferred embodiment, X8, X9, X 10 , X 11 and X 12each of which is independently selected from glycine, alanine, leucine, valine, tert-leucine, homoleucine, isoleucine, alloisoleucine, 2-aminobutyric acid, diethylalanine, norleucine, norvaline, glutamine, asparagine, beta-hydroxyasparagine, 3-methyl-l-glutamine, (2s,4s)-2,5-diamino-4-hydroxy-5-oxopentanoic acid, n-methyl-asparagine, glutamate, aspartate, 2s,4r-4-methylglutamate, (3s)-3-methyl-l-glutamic acid, (3r)-3-methyl-l-glutamic acid, 5-o-methyl-glutamic acid, 4-hydroxy-glutamic acid, 6-carboxylysine, Independently selected from the group consisting of beta-hydroxyaspartic acid, 2-amino-propanedioic acid, 3,3-dimethylaspartic acid, 2-aminoadipic acid, 3-methyl-aspartic acid, serine, homoserine, threonine, 4-hydroxy-l-threonine, 6-hydroxy-l-norleucine, 4,5-dihydroxy-isoleucine, 3-hydroxy-l-valine, hydroxynorvaline, 2-amino-5-hydroxypentanoic acid, allo-threonine, 3,3-dihydroxy-alanine, 4-hydroxy-L-isoleucine, (2s,3r)-2-amino-3-hydroxy-4-methylpentanoic acid, beta-hydroxyleucine, and allo-threonine.

[0078] In a further preferred embodiment, X8, X9, X 10 , X 11 and X 12 Each of is independently selected from the group consisting of glycine, alanine, leucine, valine, glutamate, aspartate, glutamine, asparagine, serine, threonine, and homoserine.

[0079] In a further preferred embodiment, X8, X9, X 10 , X 11 and X 12 Each of is independently selected from the group consisting of serine, glycine, glutamine, and glutamate.

[0080] In another preferred embodiment, X 1~6 at least three of X are, independently of each other, lysine or arginine; X7 is selected from arginine, lysine or cysteine; X8 is selected from the group consisting of glycine, alanine, leucine, and valine; and X9 and X 12 are, independently of each other, glutamine or asparagine, and X 10 is glutamate or aspartate, and X 11 is selected from the group consisting of serine, threonine, and homoserine. 1~6 X is lysine or arginine, X7 is selected from arginine, lysine or cysteine, X8 is selected from the group consisting of glycine, alanine, leucine, and valine, X9 and X 12 are, independently of each other, glutamine or asparagine, and X 10 is glutamate or aspartate, and X 11 is selected from the group consisting of serine, threonine, and homoserine.

[0081] Preferably, In a further preferred embodiment, the polypeptide of the present invention comprises a histidine tag (His tag) consisting of three or more consecutive histidines, wherein the His tag is attached to the C-terminus or N-terminus, preferably the C-terminus, of amino acid sequence I, and in sequence I, X 1~6 is lysine or arginine, X7 is selected from arginine, lysine, or cysteine, and X8, X9, X 10 , X 11 and X 12each of which is independently selected from glycine, alanine, leucine, valine, tert-leucine, homoleucine, isoleucine, alloisoleucine, 2-aminobutyric acid, diethylalanine, norleucine, norvaline, glutamine, asparagine, beta-hydroxyasparagine, 3-methyl-l-glutamine, (2s,4s)-2,5-diamino-4-hydroxy-5-oxopentanoic acid, n-methyl-asparagine, glutamate, aspartate, 2s,4r-4-methylglutamate, (3s)-3-methyl-l-glutamic acid, (3r)-3-methyl-l-glutamic acid, 5-o-methyl-glutamic acid, 4-hydroxy-glutamic acid, 6-carboxylysine, In a further preferred embodiment, the polypeptide of the present invention comprises a histidine tag (His tag) consisting of 3 to 9 consecutive histidines, wherein the His tag is attached to the C-terminus or N-terminus, preferably the C-terminus, of the amino acid sequence I, and wherein in the sequence I, X is selected from the group consisting of beta-hydroxyaspartic acid, 2-amino-propanedioic acid, 3,3-dimethylaspartic acid, 2-aminoadipic acid, 3-methyl-aspartic acid, serine, homoserine, threonine, 4-hydroxy-l-threonine, 6-hydroxy-l-norleucine, 4,5-dihydroxy-isoleucine, 3-hydroxy-l-valine, hydroxynorvaline, 2-amino-5-hydroxypentanoic acid, allo-threonine, 3,3-dihydroxy-alanine, 4-hydroxy-L-isoleucine, (2s,3r)-2-amino-3-hydroxy-4-methylpentanoic acid, beta-hydroxyleucine, and allo-threonine. 1~6 is lysine or arginine, X7 is selected from arginine, lysine, or cysteine, and X8, X9, X 10 , X 11 and X 12each of which is independently selected from glycine, alanine, leucine, valine, tert-leucine, homoleucine, isoleucine, alloisoleucine, 2-aminobutyric acid, diethylalanine, norleucine, norvaline, glutamine, asparagine, beta-hydroxyasparagine, 3-methyl-l-glutamine, (2s,4s)-2,5-diamino-4-hydroxy-5-oxopentanoic acid, n-methyl-asparagine, glutamate, aspartate, 2s,4r-4-methylglutamate, (3s)-3-methyl-l-glutamic acid, (3r)-3-methyl-l-glutamic acid, 5-o-methyl-glutamic acid, 4-hydroxy-glutamic acid, 6-carboxylysine, Independently selected from the group consisting of beta-hydroxyaspartic acid, 2-amino-propanedioic acid, 3,3-dimethylaspartic acid, 2-aminoadipic acid, 3-methyl-aspartic acid, serine, homoserine, threonine, 4-hydroxy-l-threonine, 6-hydroxy-l-norleucine, 4,5-dihydroxy-isoleucine, 3-hydroxy-l-valine, hydroxynorvaline, 2-amino-5-hydroxypentanoic acid, allo-threonine, 3,3-dihydroxy-alanine, 4-hydroxy-L-isoleucine, (2s,3r)-2-amino-3-hydroxy-4-methylpentanoic acid, beta-hydroxyleucine, and allo-threonine.

[0082] In another preferred embodiment, the polypeptide of the present invention comprises a histidine tag (His tag) consisting of three or more consecutive histidines, wherein the His tag is attached to the C-terminus or N-terminus, preferably the C-terminus, of amino acid sequence I, and in sequence I, X 1~6 at least three of X are, independently of one another, lysine or arginine; X7 is selected from arginine, lysine, or cysteine; X8 is selected from the group consisting of glycine, alanine, leucine, and valine; and X9 and X10 are each independently selected from the group consisting of glycine, alanine, leucine, and valine. 12 are, independently of each other, glutamine or asparagine, and X 10 is glutamate or aspartate, and X 11is selected from the group consisting of serine, threonine, and homoserine. In another preferred embodiment, the polypeptide of the present invention comprises a histidine tag (His tag) consisting of 3 to 9 consecutive histidines, wherein the His tag is attached to the C-terminus or N-terminus, preferably the C-terminus, of amino acid sequence I, and in sequence I, X 1~6 at least three of X are, independently of one another, lysine or arginine; X7 is selected from arginine, lysine, or cysteine; X8 is selected from the group consisting of glycine, alanine, leucine, and valine; and X9 and X10 are each independently selected from the group consisting of glycine, alanine, leucine, and valine. 12 are, independently of each other, glutamine or asparagine, and X 10 is glutamate or aspartate, and X 11 is selected from the group consisting of serine, threonine, and homoserine.

[0083] In another preferred embodiment, the polypeptide of the present invention comprises a histidine tag (His tag) consisting of three or more consecutive histidines, wherein the His tag is attached to the C-terminus or N-terminus, preferably the C-terminus, of amino acid sequence I, and in sequence I, X 1~6 is independently lysine or arginine; X7 is selected from arginine, lysine, or cysteine; X8 is selected from the group consisting of glycine, alanine, leucine, and valine; X9 and X 12 are, independently of each other, glutamine or asparagine, and X 10 is glutamate or aspartate, and X 11 is selected from the group consisting of serine, threonine, and homoserine. In another preferred embodiment, the polypeptide of the present invention comprises a histidine tag (His tag) consisting of 3 to 9 consecutive histidines, wherein the His tag is attached to the C-terminus or N-terminus, preferably the C-terminus, of amino acid sequence I, and in sequence I, X 1~6 is independently lysine or arginine; X7 is selected from arginine, lysine, or cysteine; X8 is selected from the group consisting of glycine, alanine, leucine, and valine; X9 and X12 are, independently of each other, glutamine or asparagine, and X 10 is glutamate or aspartate, and X 11 is selected from the group consisting of serine, threonine, and homoserine. 1~6 At least three of X are, independently of each other, lysine or arginine, X8 is glycine, and X9 and X 12 are, independently of each other, glutamine, and X 10 is glutamate and X 11 In another preferred embodiment, X is serine. 1~6 is lysine or arginine, X7 is selected from arginine, lysine or cysteine, X8 is glycine, X9 and X 12 are independently glutamines, and X 10 is glutamate and X 11 In another preferred embodiment, X is serine. 1~6 is lysine or arginine, X7 is selected from arginine, lysine or cysteine, X8 is glycine, X9 and X 12 are independently glutamines, and X 10 is glutamate and X 11 is serine.

[0084] In one embodiment, the X 1~6 At least three of X7 are, independently of each other, lysine or arginine, X8 is glycine, and X9 and X10 are selected from arginine, lysine, or cysteine. 12 are, independently of each other, glutamine, and X 10 is glutamate and X 11is serine, and the polypeptide comprises a polyhistidine, which is an amino acid sequence containing two or more consecutively linked histidines, preferably the polyhistidine is a histidine (His) tag, more preferably a His6 tag. A histidine tag is defined herein as an amino acid sequence consisting of two or more consecutively linked histidines (His tag). A His6 tag (His6) is defined herein as an amino acid sequence consisting of six consecutively linked histidines.

[0085] In another preferred embodiment, X1 to X6 are each independently lysine or arginine, X7 is selected from arginine, lysine or cysteine, X8 is glycine, and X9 and X 12 are, independently of each other, glutamine, and X 10 is glutamate and X 11 is serine, and the polypeptide comprises polyhistidine, which is an amino acid sequence containing two or more consecutively linked histidines, preferably, the polyhistidine is a histidine (His) tag, more preferably a His6 tag.

[0086] In another preferred embodiment, the polypeptide of the present invention comprises a histidine tag (His tag) consisting of three or more consecutive histidines, wherein the His tag is attached to the C-terminus or N-terminus, preferably the C-terminus, of amino acid sequence I, and in sequence I, X 1~6 is lysine or arginine, X7 is selected from arginine, lysine, or cysteine, X8 is glycine, and X9 and X 12 are, independently of each other, glutamine, and X 10 is glutamate and X 11is serine. In a preferred embodiment, the nanoparticle or the complex comprising the polypeptide of the present invention is capable of endosomal escape. In a preferred embodiment, the polypeptide of the present invention comprises a histidine tag (His tag) consisting of three or more consecutive histidines, and the nanoparticle or the complex comprising the polypeptide of the present invention is capable of endosomal escape. In a preferred embodiment, the polypeptide of the present invention comprises a histidine tag (His tag) consisting of three or more consecutive histidines, and the His tag is attached to the C-terminus or N-terminus, and the nanoparticle or the complex comprising the polypeptide of the present invention is capable of endosomal escape. In another preferred embodiment, the polypeptide of the present invention comprises a histidine tag (His tag) consisting of three or more consecutive histidines, where the His tag is attached to the C-terminus or N-terminus, preferably the C-terminus, of amino acid sequence I, and in sequence I, X 1~6 is lysine or arginine, X7 is selected from arginine, lysine, or cysteine, X8 is glycine, and X9 and X 12 are, independently of each other, glutamine, and X 10 is glutamate and X 11 is serine, and said nanoparticles or said complexes comprising said polypeptides of the invention are capable of endosomal escape.

[0087] When the polypeptide of the present invention forms a nanoparticle by self-assembly, X 13 ~X 29 These amino acids are exposed on the outer surface of the nanoparticle and are therefore the most amenable to mutation while still retaining the ability to self-assemble into caged nanoparticles.

[0088] Thus, in a preferred embodiment, the amino acid X is exposed on the outer surface of the nanoparticle. 13 ~X 29 is any amino acid.

[0089] In a preferred embodiment, X 13、 X 17 and X 19are each independently serine or a conservative substitution thereof.Preferably, the conservative substitution of serine is selected from the group consisting of cysteine, methionine, homocysteine, selenocysteine, hydroxynorvaline, 2-amino-5-hydroxypentanoic acid, allo-threonine, 3,3-dihydroxy-alanine, 4-hydroxy-L-isoleucine, (2s,3r)-2-amino-3-hydroxy-4-methylpentanoic acid, beta-hydroxyleucine, homoserine, 3-hydroxy-l-valine, 4,5-dihydroxy-isoleucine, 6-hydroxy-l-norleucine, s-(2-hydroxyethyl)-l-cysteine, phosphoserine, 4-hydroxy-l-threonine, threonine, and phosphothreonine. More preferably, the conservative substitution for serine is selected from the group consisting of cysteine, homocysteine, selenocysteine, hydroxynorvaline, 2-amino-5-hydroxypentanoic acid, allo-threonine, 3,3-dihydroxy-alanine, 4-hydroxy-L-isoleucine, (2s,3r)-2-amino-3-hydroxy-4-methylpentanoic acid, beta-hydroxyleucine, homoserine, 3-hydroxy-l-valine, 4,5-dihydroxy-isoleucine, 6-hydroxy-l-norleucine, s-(2-hydroxyethyl)-l-cysteine, phosphoserine, 4-hydroxy-l-threonine, threonine, and phosphothreonine. Even more preferably, said conservative substitution for serine is selected from the group consisting of hydroxynorvaline, 2-amino-5-hydroxypentanoic acid, allo-threonine, 3,3-dihydroxy-alanine, 4-hydroxy-L-isoleucine, (2s,3r)-2-amino-3-hydroxy-4-methylpentanoic acid, beta-hydroxyleucine, homoserine, 3-hydroxy-l-valine, 4,5-dihydroxy-isoleucine, 6-hydroxy-l-norleucine, s-(2-hydroxyethyl)-l-cysteine, phosphoserine, 4-hydroxy-l-threonine, threonine, and phosphothreonine.Even more preferably, said conservative substitution for serine is selected from the group consisting of homoserine, threonine, 4-hydroxy-l-threonine, 6-hydroxy-l-norleucine, 4,5-dihydroxy-isoleucine, 3-hydroxy-l-valine, hydroxynorvaline, 2-amino-5-hydroxypentanoic acid, allothreonine, 3,3-dihydroxy-alanine, 4-hydroxy-L-isoleucine, (2s,3r)-2-amino-3-hydroxy-4-methylpentanoic acid, beta-hydroxyleucine, and allo-threonine.

[0090] In another preferred embodiment, X 13、 X 17 and X 19 are each independently selected from the group consisting of serine, homoserine, and threonine. 13、 X 17 and X 19 are, independently of each other, serine.

[0091] In another preferred embodiment, X 14 , X 16 , and X 24 are, independently of each other, asparagine or a conservative substitution thereof. Preferably, the conservative substitution for asparagine is selected from the group consisting of glutamine, beta-hydroxyasparagine, 3-methyl-l-glutamine, (2s,4s)-2,5-diamino-4-hydroxy-5-oxopentanoic acid, and n-methylasparagine.

[0092] In another preferred embodiment, X 14 , X 16 , and X 24 are, independently of each other, asparagine. 14、 X 16 and X 24 are, independently of each other, asparagine or glutamine.

[0093] In another preferred embodiment, X 15 , X 20, X 26 and X 28 are, independently of each other, aspartate, glutamate or a conservative substitution thereof. Preferably, the conservative substitution of aspartate or glutamate is selected from the group consisting of 2s, 4r-4-methylglutamate, (3s)-3-methyl-l-glutamic acid, (3r)-3-methyl-l-glutamic acid, 5-o-methyl-glutamic acid, 4-hydroxy-glutamic acid, 6-carboxylysine, beta-hydroxyaspartic acid, 2-amino-propanedioic acid, 3,3-dimethylaspartic acid, 2-aminoadipic acid and 3-methylaspartic acid.

[0094] In another preferred embodiment, X 15 and X 20 are, independently of each other, aspartate. In another preferred embodiment, X 26 and X 28 are each independently glutamate. In another preferred embodiment, X 15 , X 20、 X 26 and X 28 are, independently of each other, aspartate or glutamate. 15 , X 20、 X 26 and X 28 are independently selected from the group consisting of glutamate, aspartate, 2s,4r-4-methylglutamate, (3s)-3-methyl-l-glutamic acid, (3r)-3-methyl-l-glutamic acid, 5-o-methyl-glutamic acid, 4-hydroxy-glutamic acid, 6-carboxylysine, beta-hydroxyaspartic acid, 2-amino-propanedioic acid, 3,3-dimethylaspartic acid, 2-aminoadipic acid and 3-methylaspartic acid.

[0095] In another preferred embodiment, X 18 and X 29are, independently of each other, leucine or a conservative substitution thereof. Preferably, the conservative substitution for leucine is selected from the group consisting of glycine, alanine, valine, tert-leucine, homoleucine, isoleucine, alloisoleucine 2-aminobutyric acid, diethylalanine, norleucine, and norvaline.

[0096] In another preferred embodiment, X 18 and X 29 are each independently leucine. In a preferred embodiment, the X 18 and X 29 are each independently selected from the group consisting of glycine, alanine, leucine, and valine. 18 and X 29 are independently selected from the group consisting of glycine, alanine, leucine, valine, tert-leucine, homoleucine, isoleucine, alloisoleucine 2-aminobutyric acid, diethylalanine, norleucine, and norvaline.

[0097] In another preferred embodiment, X 21、 X 22、 X 23、 X 25 and X 27 are, independently of each other, positively charged amino acids.

[0098] In another preferred embodiment, X 21、 X 22、 X 23、 X 25 and X 27are, independently of each other, arginine, lysine, or a conservative substitution thereof. Preferably, the conservative substitution for arginine or leucine is selected from the group consisting of histidine, 5-methyl-arginine, c-gamma-hydroxyarginine, 2-amino-4-guanidinobutyric acid, 2-amino-3-guanidinopropionic acid, canavanine, homoarginine, diaminobutyric acid, 2,3-diaminopropanoic acid, (2s)-2,8-diaminooctanoic acid, ornithine, and thialysine. More preferably, the conservative substitution for arginine or leucine is selected from the group consisting of 5-methyl-arginine, c-gamma-hydroxyarginine, 2-amino-4-guanidinobutyric acid, 2-amino-3-guanidinopropionic acid, canavanine, homoarginine, diaminobutyric acid, 2,3-diaminopropanoic acid, (2s)-2,8-diaminooctanoic acid, ornithine and thialysine.

[0099] In another preferred embodiment, X 21、 X 22、 X 23、 X 25 and X 27 are, independently of each other, histidine, arginine, or lysine. 21、 X 22、 X 23、 X 25 and X 27 are, independently of each other, arginine or lysine. 21、 X 22、 X 23、 X 25 and X 27 are, independently of each other, arginine. 21、 X 22、 X 23、 X 25 and X 27 are, independently of each other, lysine.

[0100] In another preferred embodiment, X 21、 X 22、 X 25 and X 27are each independently arginine. 23 is lysine. In another preferred embodiment, X 21、 X 22、 X 23、 X 25 and X 27 are independently selected from the group consisting of arginine, 5-methyl-arginine, c-gamma-hydroxyarginine, 2-amino-4-guanidinobutyric acid, 2-amino-3-guanidinopropionic acid, canavanine, homoarginine, lysine, diaminobutyric acid, 2,3-diaminopropanoic acid, (2s)-2,8-diaminooctanoic acid, ornithine and thialysine.

[0101] In another preferred embodiment, X 13、 X 17 and X 19 are, independently of each other, serine, and X 14、 X 16 and X 24 are, independently of each other, asparagine, and X 15 and X 20 are, independently of each other, aspartates, and X 18 and X 29 are, independently of each other, leucine, and X 26 and X 28 are, independently of each other, glutamate, and X 21、 X 22、 X 25 and X 27 are, independently of each other, arginine, and X 23 is lysine.

[0102] In another preferred embodiment, X 13、 X 17 and X 19 are each independently selected from the group consisting of serine, homoserine, and threonine; X 14、 X 16 and X 24 are, independently of each other, asparagine or glutamine, and X 15、 X 20、 X 26 and X28 are, independently of each other, aspartate or glutamate, 18 and X 29 are each independently selected from the group consisting of glycine, alanine, leucine, and valine; X 21、 X 22、 X 23 , X 25 and X 27 are, independently of each other, arginine or lysine.

[0103] In another preferred embodiment, X 13、 X 17、 and X 19 are independently selected from the group consisting of serine, homoserine, threonine, 4-hydroxy-l-threonine, 6-hydroxy-l-norleucine, 4,5-dihydroxy-isoleucine, 3-hydroxy-l-valine, hydroxynorvaline, 2-amino-5-hydroxypentanoic acid, allo-threonine, 3,3-dihydroxy-alanine, 4-hydroxy-L-isoleucine, (2s,3r)-2-amino-3-hydroxy-4-methylpentanoic acid, beta-hydroxyleucine, and allo-threonine; X 14 , X 16 , and X 24 are independently selected from the group consisting of glutamine, asparagine, beta-hydroxyasparagine, 3-methyl-l-glutamine, (2s,4s)-2,5-diamino-4-hydroxy-5-oxopentanoic acid, and n-methyl-asparagine; X 15 , X 20、 X 26 and X 28are independently selected from the group consisting of glutamate, aspartate, 2s,4r-4-methylglutamate, (3s)-3-methyl-l-glutamic acid, (3r)-3-methyl-ll-glutamic acid, 5-o-methyl-glutamic acid, 4-hydroxy-glutamic acid, 6-carboxylysine, beta-hydroxyaspartic acid, 2-amino-propanedioic acid, 3,3-dimethylaspartic acid, 2-aminoadipic acid and 3-methylaspartic acid; X 18 and X 29 are independently selected from the group consisting of glycine, alanine, leucine, valine, tert-leucine, homoleucine, isoleucine, alloisoleucine 2-aminobutyric acid, diethylalanine, norleucine, and norvaline; X 21、 X 22、 X 23、 X 25 and X 27 are independently selected from the group consisting of arginine, 5-methyl-arginine, c-gamma-hydroxyarginine, 2-amino-4-guanidinobutyric acid, 2-amino-3-guanidinopropionic acid, canavanine, homoarginine, lysine, diaminobutyric acid, 2,3-diaminopropanoic acid, (2s)-2,8-diaminooctanoic acid, ornithine and thialysine.

[0104] In another preferred embodiment, X8 is glycine or a conservative substitution thereof, preferably said conservative substitution for glycine is selected from the group consisting of alanine, leucine, valine, tert-leucine, homoleucine, isoleucine, alloisoleucine 2-aminobutyric acid, diethylalanine, norleucine, and norvaline; X9 and X 12 are, independently of each other, glutamine or a conservative substitution thereof, preferably the conservative substitution for glutamine is selected from the group consisting of asparagine, beta-hydroxyasparagine, 3-methyl-l-glutamine, (2s,4s)-2,5-diamino-4-hydroxy-5-oxopentanoic acid, and n-methylasparagine; X 10is glutamate or a conservative substitution thereof, preferably said conservative substitution of glutamate is selected from the group consisting of glutamate, aspartate, 2s,4r-4-methylglutamate, (3s)-3-methyl-l-glutamic acid, (3r)-3-methyl-l-glutamic acid, 5-o-methyl-glutamic acid, 4-hydroxy-glutamic acid, 6-carboxylysine, beta-hydroxyaspartic acid, 2-amino-propanedioic acid, 3,3-dimethylaspartic acid, 2-aminoadipic acid and 3-methylaspartic acid; X 11 is serine or a conservative substitution thereof, preferably said conservative substitution of serine is selected from the group consisting of homoserine, threonine, 4-hydroxy-l-threonine, 6-hydroxy-l-norleucine, 4,5-dihydroxy-isoleucine, 3-hydroxy-l-valine, hydroxynorvaline, 2-amino-5-hydroxypentanoic acid, allothreonine, 3,3-dihydroxy-alanine, 4-hydroxy-L-isoleucine, (2s,3r)-2-amino-3-hydroxy-4-methylpentanoic acid, beta-hydroxyleucine, and allo-threonine; More preferably, X8 is glycine, and X9 and X 12 are independently glutamine or asparagine, and X 10 is glutamate or aspartate, and X 11 is serine.

[0105] In another preferred embodiment, X 13 , X 17 , and X 19are, independently of each other, serine or a conservative substitution thereof, preferably the conservative substitution of serine is selected from the group consisting of homoserine, threonine, 4-hydroxy-l-threonine, 6-hydroxy-l-norleucine, 4,5-dihydroxy-isoleucine, 3-hydroxy-l-valine, hydroxynorvaline, 2-amino-5-hydroxypentanoic acid, allothreonine, 3,3-dihydroxy-alanine, 4-hydroxy-L-isoleucine, (2s,3r)-2-amino-3-hydroxy-4-methylpentanoic acid, beta-hydroxyleucine, and allo-threonine; X 14 , X 16 , and X 24 are, independently of each other, asparagine, glutamine, or a conservative substitution thereof, preferably, the conservative substitution for asparagine or glutamine is selected from the group consisting of beta-hydroxyasparagine, 3-methyl-l-glutamine, (2s,4s)-2,5-diamino-4-hydroxy-5-oxopentanoic acid, and n-methyl-asparagine; X 15 , X 20 , X 26 and X 28 are, independently of one another, aspartate or glutamate or a conservative substitution thereof, preferably said conservative substitution of aspartate or glutamate is selected from the group consisting of 2s,4r-4-methylglutamate, (3s)-3-methyl-l-glutamic acid, (3r)-3-methyl-l-glutamic acid, 5-o-methyl-glutamic acid, 4-hydroxy-glutamic acid, 6-carboxylysine, beta-hydroxyaspartic acid, 2-amino-propanedioic acid, 3,3-dimethylaspartic acid, 2-aminoadipic acid and 3-methyl-aspartic acid; X 18 and X 29 are, independently of each other, leucine or a conservative substitution thereof, preferably the conservative substitution for leucine is selected from the group consisting of glycine, alanine, valine, tert-leucine, homoleucine, isoleucine, alloisoleucine 2-aminobutyric acid, diethylalanine, norleucine, and norvaline; X 21 , X 22 , X 23 , X 25 and X 27 are, independently of each other, arginine, lysine or a conservative substitution thereof, preferably the conservative substitution for arginine or leucine is selected from the group consisting of histidine, 5-methyl-arginine, c-gamma-hydroxyarginine, 2-amino-4-guanidinobutyric acid, 2-amino-3-guanidinopropionic acid, canavanine, homoarginine, diaminobutyric acid, 2,3-diaminopropanoic acid, (2s)-2,8-diaminooctanoic acid, ornithine, and thialysine.

[0106] In another preferred embodiment, the at least three positively charged amino acids of X1 to X6 are independently selected from the group consisting of arginine, 5-methyl-arginine, c-gamma-hydroxyarginine, 2-amino-4-guanidinobutyric acid, 2-amino-3-guanidinopropionic acid, canavanine, homoarginine, lysine, diaminobutyric acid, 2,3-diaminopropanoic acid, (2s)-2,8-diaminooctanoic acid, ornithine, and thialysine; X7 is cysteine, a conservative substitution thereof, or a positively charged amino acid, preferably X7 is selected from the group consisting of homocysteine, cysteine, selenocysteine, arginine, 5-methyl-arginine, c-gamma-hydroxyarginine, 2-amino-4-guanidinobutyric acid, 2-amino-3-guanidinopropionic acid, canavanine, homoarginine, lysine, diaminobutyric acid, 2,3-diaminopropanoic acid, (2s)-2,8-diaminooctanoic acid, ornithine, thialysine, and serine; X8 is glycine or a conservative substitution for glycine selected from the group consisting of alanine, leucine, valine, tert-leucine, homoleucine, isoleucine, alloisoleucine 2-aminobutyric acid, diethylalanine, norleucine, and norvaline; X9 and X 12are, independently of each other, glutamine or a conservative substitution for glutamine selected from the group consisting of asparagine, beta-hydroxyasparagine, 3-methyl-l-glutamine, (2s,4s)-2,5-diamino-4-hydroxy-5-oxopentanoic acid, and n-methyl-asparagine; X 10 is a conservative substitution for glutamate selected from the group consisting of glutamate or aspartate, 2s,4r-4-methylglutamate, (3s)-3-methyl-l-glutamic acid, (3r)-3-methyl-l-glutamic acid, 5-o-methyl-glutamic acid, 4-hydroxy-glutamic acid, 6-carboxylysine, beta-hydroxyaspartic acid, 2-amino-propanedioic acid, 3,3-dimethylaspartic acid, 2-aminoadipic acid and 3-methylaspartic acid; X 11 is a serine or a conservative substitution for a serine selected from the group consisting of homoserine, threonine, 4-hydroxy-l-threonine, 6-hydroxy-l-norleucine, 4,5-dihydroxy-isoleucine, 3-hydroxy-l-valine, hydroxynorvaline, 2-amino-5-hydroxypentanoic acid, allothreonine, 3,3-dihydroxy-alanine, 4-hydroxy-l-isoleucine, (2s,3r)-2-amino-3-hydroxy-4-methylpentanoic acid, beta-hydroxyleucine, and allo-threonine; X 13、 X 17、 and X 19 are independently selected from the group consisting of serine, homoserine, threonine, 4-hydroxy-l-threonine, 6-hydroxy-l-norleucine, 4,5-dihydroxy-isoleucine, 3-hydroxy-l-valine, hydroxynorvaline, 2-amino-5-hydroxypentanoic acid, allo-threonine, 3,3-dihydroxy-alanine, 4-hydroxy-L-isoleucine, (2s,3r)-2-amino-3-hydroxy-4-methylpentanoic acid, beta-hydroxyleucine, and allo-threonine; X 14 , X 16 , and X 24are independently selected from the group consisting of glutamine, asparagine, beta-hydroxyasparagine, 3-methyl-1-glutamine, (2s,4s)-2,5-diamino-4-hydroxy-5-oxopentanoic acid, and n-methyl-asparagine; X 15 , X 20、 X 26 and X 28 are independently selected from the group consisting of glutamate, aspartate, 2s,4r-4-methylglutamate, (3s)-3-methyl-l-glutamic acid, (3r)-3-methyl-l-glutamic acid, 5-o-methyl-glutamic acid, 4-hydroxy-glutamic acid, 6-carboxylysine, beta-hydroxyaspartic acid, 2-amino-propanedioic acid, 3,3-dimethylaspartic acid, 2-aminoadipic acid and 3-methylaspartic acid; X 18 and X 29 are independently selected from the group consisting of glycine, alanine, leucine, valine, tert-leucine, homoleucine, isoleucine, alloisoleucine 2-aminobutyric acid, diethylalanine, norleucine, and norvaline; X 21、 X 22、 X 23、 X 25 and X 27 are independently selected from the group consisting of arginine, 5-methyl-arginine, c-gamma-hydroxyarginine, 2-amino-4-guanidinobutyric acid, 2-amino-3-guanidinopropionic acid, canavanine, homoarginine, lysine, diaminobutyric acid, 2,3-diaminopropanoic acid, (2s)-2,8-diaminooctanoic acid, ornithine and thialysine.

[0107] In another preferred embodiment, the at least three positively charged amino acids of X1 to X6 are, independently of one another, arginine or lysine; X7 is selected from the group consisting of homocysteine, cysteine, arginine, and lysine; X8 is selected from the group consisting of glycine, alanine, leucine, and valine; and X9 and X10 are each independently selected from the group consisting of glycine, alanine, leucine, and valine. 12are, independently of each other, glutamine or asparagine, and X 10 is glutamate or aspartate, and X 11 , X 13 , X 17 , and X 19 are each independently selected from the group consisting of serine, threonine, and homoserine; X 14 , X 16 , and X 24 are, independently of each other, asparagine or glutamine, and X 15 , X 20 , X 26 , and X 28 are, independently of each other, aspartate or glutamate, and X 18 and X 29 are each independently selected from the group consisting of leucine, glycine, alanine, and valine; X 21 , X 22 , X 23 , X 25 and X 27 are independently arginine or lysine.

[0108] In another preferred embodiment, the at least three positively charged amino acids X1 to X6 are, independently of one another, arginine or lysine, X7 is selected from the group consisting of homocysteine, cysteine, arginine, and lysine, X8 is glycine, and X9 and X 12 are, independently of each other, glutamine or asparagine, and X 10 is glutamate or aspartate, and X 11 is serine, and X 13 , X 17 , and X 19 are, independently of each other, serine, and X 14 , X 16 , and X 24 are, independently of each other, asparagine, and X 15 , X 20 , X 26 , and X 28 are, independently of each other, aspartate or glutamate, and X18 and X 29 are, independently of each other, leucine, and X 21 , X 22 , X 23 , X 25 and X 27 are independently arginine or lysine.

[0109] In another preferred embodiment, X 1~6 at least three of X are, independently of each other, lysine or arginine; X7 is selected from arginine, lysine or cysteine; X8 is selected from the group consisting of glycine, alanine, leucine, and valine; and X9 and X 12 are, independently of each other, glutamine or asparagine, and X 10 is glutamate or aspartate, and X 11 is selected from the group consisting of serine, threonine, and homoserine; 18 and X 29 are, independently of each other, leucine, and X 15 and X 20 are, independently of each other, aspartates, and X 26 and X 28 are, independently of each other, glutamate, and X 14 , X 16 and X 24は、 Independently of each other, asparagine, X 13 , X 17 and X 19 are, independently of each other, serine, and X 21 , X 22 , X 25 and X 27 are, independently of each other, arginine, and X 23 is lysine.

[0110] In another preferred embodiment, X 1~6 at least three of X are, independently of each other, lysine or arginine; X7 is selected from arginine, lysine or cysteine; X8 is selected from the group consisting of glycine, alanine, leucine, and valine; and X9 and X12 are, independently of each other, glutamine or asparagine, and X 10 is glutamate or aspartate, and X 11 is selected from the group consisting of serine, threonine, and homoserine; 13 , X 17 and X 19 are each independently selected from the group consisting of serine, homoserine, and threonine; X 14 , X 16 and X 24 are, independently of each other, asparagine or glutamine, and X 15 , X 20 , X 26 and X 28 are, independently of each other, aspartate or glutamate, 18 and X 29 are each independently selected from the group consisting of glycine, alanine, leucine, and valine; X 21 , X 22 , X 23 , X 25 , and X 27 are, independently of each other, arginine or lysine.

[0111] In another preferred embodiment, X 1~6 are each independently lysine or arginine, X7 is selected from arginine, lysine or cysteine, X8 is selected from the group consisting of glycine, alanine, leucine, and valine, X9 and X 12 are, independently of each other, glutamine or asparagine, and X 10 is glutamate or aspartate, and X 11 is selected from the group consisting of serine, threonine, and homoserine; 13 , X 17 and X 19 are each independently selected from the group consisting of serine, homoserine, and threonine; X 14 , X 16 and X 24 are, independently of each other, asparagine or glutamine, and X15 , X 20 , X 26 and X 28 are, independently of each other, aspartate or glutamate, 18 and X 29 are each independently selected from the group consisting of glycine, alanine, leucine, and valine; X 21 , X 22 , X 23 , X 25 , and X 27 are, independently of each other, arginine or lysine.

[0112] In another preferred embodiment, X 1~6 are each independently lysine or arginine, X7 is selected from arginine, lysine or cysteine, X8 is selected from the group consisting of glycine, alanine, leucine, and valine, X9 and X 12 are, independently of each other, glutamine or asparagine, and X 10 is glutamate or aspartate, and X 11 is selected from the group consisting of serine, threonine, and homoserine; 13 , X 17 and X 19 are, independently of each other, serine, and X 14 , X 16 and X 24 are, independently of each other, asparagine, and X 15 and X 20 are, independently of each other, aspartates, and X 18 and X 29 are, independently of each other, leucine, and X 26 and X 28 are, independently of each other, glutamate, and X 21 , X 22 , X 25 and X 27 are, independently of each other, arginine, and X 23 is lysine.

[0113] In another preferred embodiment, X 1~6at least three or at least four of, independently of one another, are lysine or arginine; X7 is selected from arginine, lysine or cysteine; X8 is selected from the group consisting of glycine, alanine, leucine, and valine; and X9 and X 12 are, independently of each other, glutamine or asparagine, and X 10 is glutamate or aspartate, and X 11 is selected from the group consisting of serine, threonine, and homoserine; 13 , X 17 and X 19 are each independently selected from the group consisting of serine, homoserine, and threonine; X 14 , X 16 and X 24 are, independently of each other, asparagine or glutamine, and X 15 , X 20 , X 26 and X 28 are, independently of each other, aspartate or glutamate, 18 and X 29 are each independently selected from the group consisting of glycine, alanine, leucine, and valine; X 21 , X 22 , X 23 , X 25 , and X 27 are, independently of each other, arginine or lysine, and the polypeptide contains polyhistidine, which is an amino acid sequence containing two or more consecutively linked histidines, and preferably, the polyhistidine is a histidine (His) tag, more preferably a His6 tag.

[0114] In another preferred embodiment, X 1~6 are each independently lysine or arginine, X7 is selected from arginine, lysine or cysteine, X8 is selected from the group consisting of glycine, alanine, leucine, and valine, X9 and X 12 are, independently of each other, glutamine or asparagine, and X 10is glutamate or aspartate, and X 11 is selected from the group consisting of serine, threonine, and homoserine; 13 , X 17 and X 19 are each independently selected from the group consisting of serine, homoserine, and threonine; X 14 , X 16 and X 24 are, independently of each other, asparagine or glutamine, and X 15 , X 20 , X 26 and X 28 are, independently of each other, aspartate or glutamate, 18 and X 29 are each independently selected from the group consisting of glycine, alanine, leucine, and valine; X 21 , X 22 , X 23 , X 25 , and X 27 are, independently of each other, arginine or lysine, and the polypeptide contains polyhistidine, which is an amino acid sequence containing two or more consecutively linked histidines, and preferably, the polyhistidine is a histidine (His) tag, more preferably a His6 tag.

[0115] In a preferred embodiment, the amino acid sequence I is a sequence selected from the group consisting of SEQ ID NOs: 2 to 5 and SEQ ID NOs: 10 to 16. In a preferred embodiment, the polypeptide of the present invention consists of a sequence selected from the group consisting of SEQ ID NOs: 2 to 5 and SEQ ID NOs: 10 to 16.

[0116] In a preferred embodiment, the amino acid sequence I is a sequence selected from the group consisting of SEQ ID NOs: 2 to 5, and SEQ ID NOs: 10 to 16, 37, and 38. In a preferred embodiment, the polypeptide of the present invention consists of a sequence selected from the group consisting of SEQ ID NOs: 2 to 5, and SEQ ID NOs: 10 to 16, 37, and 38.

[0117] In a preferred embodiment, the amino acid sequence I is SEQ ID NO:2. In a preferred embodiment, the amino acid sequence I is SEQ ID NO:3. In another preferred embodiment, the amino acid sequence I is SEQ ID NO:4. In another preferred embodiment, the amino acid sequence I is SEQ ID NO:5. In another preferred embodiment, the amino acid sequence I is SEQ ID NO:10. In another preferred embodiment, the amino acid sequence I is SEQ ID NO:11. In another preferred embodiment, the amino acid sequence I is SEQ ID NO:12. In another preferred embodiment, the amino acid sequence I is SEQ ID NO:13. In a preferred embodiment, the amino acid sequence I is SEQ ID NO:14. In another preferred embodiment, the amino acid sequence I is SEQ ID NO:15. In another preferred embodiment, the amino acid sequence I is SEQ ID NO:16. In another preferred embodiment, the amino acid sequence I is SEQ ID NO:37. In another preferred embodiment, the amino acid sequence I is SEQ ID NO:38.

[0118] In a preferred embodiment, the polypeptide of the invention consists of a sequence selected from the group consisting of SEQ ID NO:2. In another preferred embodiment, the polypeptide of the invention consists of a sequence selected from the group consisting of SEQ ID NO:3. In another preferred embodiment, the polypeptide of the invention consists of a sequence selected from the group consisting of SEQ ID NO:4. In another preferred embodiment, the polypeptide of the invention consists of a sequence selected from the group consisting of SEQ ID NO:5. In another preferred embodiment, the polypeptide of the invention consists of a sequence selected from the group consisting of SEQ ID NO:10. In another preferred embodiment, the polypeptide of the invention consists of a sequence selected from the group consisting of SEQ ID NO:11. In another preferred embodiment, the polypeptide of the invention consists of a sequence selected from the group consisting of SEQ ID NO:12. In another preferred embodiment, the polypeptide of the invention consists of a sequence selected from the group consisting of SEQ ID NO:13. In another preferred embodiment, the polypeptide of the invention consists of a sequence selected from the group consisting of SEQ ID NO:14. In another preferred embodiment, the polypeptide of the invention consists of a sequence selected from the group consisting of SEQ ID NO:15. In another preferred embodiment, the polypeptide of the invention consists of a sequence selected from the group consisting of SEQ ID NO:16. In another preferred embodiment, the polypeptide of the invention consists of a sequence selected from the group consisting of SEQ ID NO:37. In another preferred embodiment, the polypeptide of the invention consists of a sequence selected from the group consisting of SEQ ID NO:38. In a preferred embodiment, the polypeptide of the present invention consists of a sequence selected from the group consisting of SEQ ID NO: 3, and the polypeptide of the present invention comprises a histidine tag (His tag) consisting of three or more consecutive histidines, and the His tag is attached to the C-terminus or N-terminus, preferably the C-terminus, of amino acid sequence I. In another preferred embodiment, the polypeptide of the present invention consists of a sequence selected from the group consisting of SEQ ID NO: 3, and the polypeptide of the present invention comprises a histidine tag (His tag) consisting of 3 to 9 consecutive histidines, and the His tag is attached to the C-terminus or N-terminus, preferably the C-terminus, of amino acid sequence I.In a preferred embodiment, the polypeptide of the present invention comprises an additional tag, i.e. a peptide or non-peptide tag, preferably a peptide tag (i.e. a functional amino acid sequence). In a preferred embodiment, the tag is located at the C-terminus or N-terminus of the polypeptide of the present invention.

[0119] In a preferred embodiment, the tag is a non-peptide tag, preferably polyethylene glycol (PEG). Preferably, the PEG is attached to the amino acid sequence 1 via the amino acid serine or cysteine. PEG attached to the polypeptide of the invention increases stability and immunogenicity.

[0120] In another preferred embodiment, the tag is selected from the group consisting of polyhistidine, a His tag (i.e., an amino acid sequence consisting of two or more consecutively linked histidines), a degradation tag, a targeting tag, a cell permeation tag, and an endosomal escape tag.

[0121] In a preferred embodiment, the polypeptide of the present invention comprises polyhistidine. In a preferred embodiment, the polyhistidine is an amino acid sequence comprising two or more histidines. In another preferred embodiment, the polyhistidine is an amino acid sequence comprising two or more consecutively linked histidines. In another preferred embodiment, the polyhistidine is an amino acid sequence comprising three or more consecutively linked histidines. In another preferred embodiment, the polyhistidine is an amino acid sequence comprising 3 to 9 consecutively linked histidines. In another preferred embodiment, the polyhistidine is an amino acid sequence comprising 3, 6, or 9 consecutively linked histidines.

[0122] In a preferred embodiment, the polypeptide of the present invention comprises a histidine tag (His tag) consisting of consecutively linked histidines (His tag). Preferably, the His tag consists of three or more consecutive histidines. Preferably, the His tag consists of 3 to 9 consecutive histidines. Preferably, the His tag consists of 3, 6, or 9 consecutive histidines. Preferably, the His tag consists of 3 consecutive histidines. Preferably, the His tag consists of 9 consecutive histidines. Preferably, the His tag consists of 6 consecutive histidines (i.e., His6 tag). In a preferred embodiment, the His tag is attached to the C-terminus or N-terminus, preferably the C-terminus, of the amino acid sequence I. In a preferred embodiment, the His6 tag is attached to the C-terminus or N-terminus, preferably the C-terminus, of the amino acid sequence I. Preferably, the His tag consists of three or more consecutive histidines and is attached to the C-terminus or N-terminus, preferably the C-terminus, of amino acid sequence I. Preferably, the His tag consists of 3 to 9 consecutive histidines and is attached to the C-terminus or N-terminus of amino acid sequence I. Preferably, the His tag consists of 3 to 9 consecutive histidines and is attached to the C-terminus of amino acid sequence I. Preferably, the His tag consists of 3, 6 or 9 consecutive histidines and is attached to the C-terminus or N-terminus, preferably the C-terminus, of amino acid sequence I. Preferably, the His tag consists of three consecutive histidines (i.e., a His3 tag) and is attached to the C-terminus or N-terminus, preferably the C-terminus, of amino acid sequence I. Preferably, the His tag consists of nine consecutive histidines (ie, a His9 tag), and the His tag is attached to the C-terminus or C-terminus of amino acid sequence I, preferably the C-terminus.

[0123] In a preferred embodiment, the His tag, preferably the His6 tag, comprises a halogenated, preferably fluorinated histidine. In a preferred embodiment, the His tag comprises a fluorophore. In a preferred embodiment, the polypeptide of the invention comprises a fluorophore.

[0124] In a preferred embodiment, the polypeptide of the present invention comprises a degradation tag. Preferably, the degradation tag is functional in mammalian cells. In a preferred embodiment, the degradation tag is a C-terminal sequence of ornithine decarboxylase (cODC), preferably the C-terminal sequence of SEQ ID NO: 17, or a (poly)ubiquitin comprising or consisting of at least two consecutively linked ubiquitins. In another preferred embodiment, the degradation tag consists of the cODC of SEQ ID NO: 17 (EFPPEVEEQDDGTLPMSCAQESGMDRHPAACASARINV). In another preferred embodiment, the degradation tag comprises at least two consecutively linked ubiquitins. More preferably, the degradation tag consists of at least two consecutively linked ubiquitins.

[0125] In a preferred embodiment, the polypeptide of the present invention comprises a targeting tag, which is a peptide targeting tag or a non-peptide targeting tag. A preferred peptide targeting tag is mentioned in Zhao et al. (Tumor-targeting Peptides: Ligands for Molecular Imaging and Therapy, Anticancer Agents Med Chem. 2018, 18(1):74-86). The targeting tag is preferably bound to a cancer target, and is therefore referred to herein as a cancer targeting tag. The cancer target comprises a receptor with increased expression levels in certain tumor cells and tumor antigens. In a preferred embodiment, the cancer targeting tag is a peptide ligand, peptidomimetic, or antibody that binds to a cancer target. Preferably, the cancer targeting tag is folic acid. For example, folic acid can be bound to the polypeptide of the present invention via a peptide bond.

[0126] In further embodiments, the polypeptide of the present invention comprises an endosomal escape peptide or a cell-penetrating peptide (CPP). An endosomal escape peptide is, for example, dimerized and disulfide-linked TAT or a thiol group. The term "cell-penetrating peptide" or CPP as used herein refers to a group of peptides that have the ability to penetrate the plasma membrane to deliver cargo to cells. Preferably, the CPP used in the polypeptide of the present invention is a hydrophilic or cationic peptide. In another embodiment, the CPP is selected from amphipathic, anionic or hydrophobic peptides. A database of over 1,600 CPPs is described by Agrawal et al. (Agrawal P, Bhalla S, Usmani SS, Singh S, CHaudhary K, Raghava GPS, et al. CPPsite 2.0: a repository of experimentally validated cell-penetrating peptides. Nucl Acids Res. 2016, 44: D1098-D103).

[0127] In a preferred embodiment, said additional tags comprised in the polypeptides of the invention are attached via a releasable bond, such as a photocleavable bond, or via a reversible bond.

[0128] The polypeptides of the present invention can self-assemble into nanoparticles, preferably into caged nanoparticles.Furthermore, the mutant proteins of SEQ ID NO: 1 can also self-assemble into nanoparticles, preferably into caged nanoparticles.

[0129] In a further aspect, the present invention relates to a nucleic acid encoding a polypeptide according to the invention.

[0130] In a further aspect, the present invention relates to nanoparticles comprising at least one polypeptide according to the invention.

[0131] In a preferred embodiment, the at least one polypeptide of the nanoparticles of the present invention each comprises a histidine tag consisting of at least three consecutively linked histidines, each of the histidine tags being attached to the C-terminus or N-terminus, preferably the C-terminus, of the at least one polypeptide.

[0132] In a preferred embodiment, the at least one polypeptide of the nanoparticle of the present invention each comprises a histidine tag consisting of at least three consecutively linked histidines, each of the histidine tags being attached to the C-terminus or N-terminus, preferably the C-terminus, of the at least one polypeptide, and the nanoparticles can be unloaded with cargo without nanoparticle degradation.In a preferred embodiment, the at least one polypeptide of the present invention each comprises a histidine tag consisting of at least three consecutively linked histidines, each of the histidine tags being attached to the C-terminus or N-terminus, preferably the C-terminus, of the at least one polypeptide, and the nanoparticles can be unloaded with cargo without nanoparticle degradation in vivo and in vitro. In a preferred embodiment, the at least one polypeptide of the nanoparticle of the invention each comprises a histidine tag consisting of at least three consecutively linked histidines, each of the histidine tags being attached to the C-terminus or N-terminus, preferably the C-terminus, of the at least one polypeptide, and the nanoparticles are capable of loading with a cargo in vitro and unloading with a cargo in vivo without the nanoparticles degrading.In a preferred embodiment, the at least one polypeptide of the invention each comprises a histidine tag consisting of at least three consecutively linked histidines, each of the histidine tags being attached to the C-terminus or N-terminus, preferably the C-terminus, of the at least one polypeptide, and the nanoparticles are capable of endosomal escape and unloading with a cargo without the nanoparticles degrading. Preferably, the cargo is a negatively charged macromolecule, more preferably an RNA, even more preferably an RNA selected from the group consisting of antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), small hairpin RNAs (shRNAs), microRNAs (miRNAs) and anti-miRNAs, most preferably siRNAs.

[0133] In a preferred embodiment, the polypeptide of the present invention contained in the nanoparticle of the present invention consists of a sequence selected from the group consisting of SEQ ID NO: 3, the polypeptide of the present invention comprises a histidine tag (His tag) consisting of three or more consecutive histidines, the His tag is attached to the C-terminus or N-terminus, preferably the C-terminus, of the amino acid sequence I, and the nanoparticle can be loaded with a cargo without the nanoparticle being degraded. In a preferred embodiment, the polypeptide of the present invention contained in the nanoparticle of the present invention consists of a sequence selected from the group consisting of SEQ ID NO: 3, the polypeptide of the present invention comprises a histidine tag (His tag) consisting of three or more consecutive histidines, the His tag is attached to the C-terminus or N-terminus, preferably the C-terminus, of the amino acid sequence I, and the nanoparticle can be loaded with a cargo in vitro and can be unloaded with a cargo in vivo without the nanoparticle being degraded. In a preferred embodiment, the nanoparticle of the present invention is contained in a composition, preferably a pharmaceutical composition, including a pharma- ceutically acceptable carrier.

[0134] The term "nanoparticle" as used herein refers to a particle in the nanometer size range (i.e., from about 1 nm to about 1000 nanometers) that can encapsulate molecules and has a surface with a regularly arranged array of linked molecules that self-assemble to form the nanoparticle.

[0135] The nanoparticles of the present invention have a positively charged cavity.Therefore, they can encapsulate cargo such as oligonucleotides (ONs).Furthermore, they can enter cells and conditionally release cargo into cells, preferably into cytoplasm.Therefore, they can be used to deliver ONs into cells to control gene expression via antisense ONs, for example, for vaccination or immune system stimulation.

[0136] In a preferred embodiment, the nanoparticles of the present invention can encapsulate a cargo, preferably the cargo is a negatively charged polymer, more preferably RNA, even more preferably RNA selected from the group consisting of antisense oligonucleotides (ASO), small interfering RNA (siRNA), small hairpin RNA (shRNA), microRNA (miRNA) and anti-miRNA, most preferably siRNA, and can deliver the encapsulated cargo to cells. Preferably, the cargo is delivered intracellularly. In a preferred embodiment, the nanoparticles of the present invention can encapsulate a cargo, preferably the cargo is a negatively charged polymer, more preferably RNA, even more preferably RNA selected from the group consisting of antisense oligonucleotides (ASO), small interfering RNA (siRNA), small hairpin RNA (shRNA), microRNA (miRNA) and anti-miRNA, most preferably siRNA, and can release the encapsulated cargo intracellularly. In a preferred embodiment, the nanoparticles of the present invention can encapsulate a cargo extracellularly, can enter a cell with the encapsulated cargo, and can release the cargo intracellularly. In a preferred embodiment, the nanoparticles of the present invention can encapsulate a cargo extracellularly, enter a cell with the encapsulated cargo, and release the cargo into the cytoplasm of the cell. In a preferred embodiment, the nanoparticles of the present invention can encapsulate a cargo in vitro and release the cargo in vivo, preferably into a cell, more preferably into the cytoplasm of the cell. In a preferred embodiment, the nanoparticles of the present invention can encapsulate a cargo in vitro, enter a cell with the encapsulated cargo, and release the cargo in vivo, preferably into a cell, more preferably into the cytoplasm of the cell.Preferably, the cargo is a negatively charged macromolecule, more preferably an RNA, even more preferably an RNA selected from the group consisting of antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), small hairpin RNAs (shRNAs), microRNAs (miRNAs) and anti-miRNAs, most preferably siRNAs.

[0137] In a preferred embodiment, the nanoparticle of the present invention can be loaded with cargo without the nanoparticle being degraded. In a preferred embodiment, the nanoparticle of the present invention can be loaded with cargo outside the cell and can be unloaded inside the cell without the nanoparticle being degraded. In a preferred embodiment, the nanoparticle of the present invention can be loaded with cargo outside the cell and can be unloaded inside the cell without the nanoparticle being degraded. In a preferred embodiment, the nanoparticle of the present invention can be loaded with cargo outside the cell and can be unloaded inside the cell without the nanoparticle being degraded. Preferably, the cargo is a negatively charged macromolecule, more preferably RNA, even more preferably RNA selected from the group consisting of antisense oligonucleotide (ASO), small interfering RNA (siRNA), small hairpin RNA (shRNA), microRNA (miRNA) and anti-miRNA, most preferably siRNA.

[0138] In a preferred embodiment, the nanoparticles of the invention can be loaded with cargo in vivo and in vitro and can be unloaded in vivo and in vitro without the nanoparticles degrading.In a preferred embodiment, the nanoparticles of the invention can be loaded in vitro and can be unloaded in vivo without the nanoparticles degrading.

[0139] In a further embodiment, the nanoparticle comprises at least one subunit, the subunit comprising at least one polypeptide according to the invention. The term "subunit" as used herein refers to a building block that assembles and forms the nanoparticle of the invention. The subunit comprises at least one polypeptide of the invention. Preferably, the subunit comprises three polypeptides of the invention, preferably exactly three peptides of the invention. More preferably, the subunit consists of three polypeptides of the invention. In another preferred embodiment, the subunit comprises three identical peptides of the invention, preferably exactly three identical peptides of the invention. More preferably, the subunit consists of three identical polypeptides of the invention. In another more preferred embodiment, the subunit comprises or more preferably consists of three polypeptides of the invention, the subunit having C3 symmetry.

[0140] In a preferred embodiment, the nanoparticle comprises exactly 24 polypeptides of the invention. In a preferred embodiment, the nanoparticle comprises exactly 8 subunits. In another preferred embodiment, the nanoparticle has an octahedral structure (octahedral point group symmetry). In a preferred embodiment of the invention, the nanoparticle has a quaternary structure of multiple subunits, preferably 8 subunits, each of which comprises 3 polypeptides of the invention.

[0141] In a preferred embodiment, the nanoparticle of the present invention comprises a central cavity (also referred to herein as a cavity, an internal cavity or a lumen). The nanoparticle comprising a central cavity is also referred to herein as a "caged nanoparticle" or a "cage". In a preferred embodiment, the caged nanoparticle comprises (i) an external scaffold and (ii) a central cavity. Preferably, the external scaffold surrounds, i.e., is assembled around, the central cavity. The cavity can be empty or can contain cargo.

[0142] The nanoparticles of the present invention have a positively charged interior. The caged nanoparticles of the present invention are positively charged on the cavity surface. The positive charge is due to multiple positively charged amino acids such as arginine or lysine. Therefore, the nanoparticles of the present invention have a very strong affinity for encapsulating negatively charged macromolecules.

[0143] In a preferred embodiment, the cavity has a diameter of about 6.5 nm to about 8 nm. In a preferred embodiment, the caged nanoparticle has a porous structure, i.e., the nanoparticle comprises pores. Preferably, the external scaffold of the caged nanoparticle comprises pores connected to the cavity of the nanoparticle. Pores are defined herein as openings or gaps in the nanoparticle and the external scaffold of the nanoparticle, respectively.

[0144] The loading (i.e. encapsulation) and unloading (i.e. release) of cargo into nanoparticles works through pores. The term loading or encapsulation refers to the incorporation of cargo into nanoparticles, including the cavities, scaffolding and porous structure of the nanoparticles. The term unloading (or release) refers to the partial or complete, preferably complete, liberation or displacement / exchange of cargo by another cargo. Preferably, unloading is performed under competitive conditions, i.e. under conditions where the cargo to be unloaded and the other cargo to be loaded compete with each other.

[0145] In a preferred embodiment, the caged nanoparticle comprises six pores. Preferably, the caged nanoparticle comprises six pores connected to the cavity. Preferably, the external scaffold comprises six pores connected to the cavity of the nanoparticle.

[0146] In another preferred embodiment, the pores have a diameter of about 3 nm to about 4 nm.In another preferred embodiment, the nanoparticle comprises 6 pores having a diameter of 3 to 4 nm.

[0147] In another preferred embodiment, the nanoparticles have an outer diameter of up to about 50 nm. In a highly preferred embodiment, the nanoparticles have an outer diameter of about 13 nm.

[0148] In another more preferred embodiment, the nanoparticle comprises six pores having a diameter of about 3-4 nm, the internal cavity has a diameter of about 8 nm, and the outer diameter of the nanoparticle is about 13 nm.

[0149] In a preferred embodiment, the nanoparticles of the present invention are capable of encapsulating and releasing a cargo without nanoparticle degradation, preferably the cargo is a negatively charged macromolecule, more preferably an RNA, even more preferably an RNA selected from the group consisting of an antisense oligonucleotide (ASO), a small interfering RNA (siRNA), a small hairpin RNA (shRNA), a microRNA (miRNA) and an anti-miRNA.

[0150] Due to the multimeric nature of nanoparticles, modification of the polypeptides of the invention with a functional moiety, for example a peptide tag or a chemical group such as PEG, provides for multivalent presentation of this functional moiety on the nanoparticle surface.

[0151] In a preferred embodiment, the nanoparticles, in particular the caged nanoparticles, comprise a functional moiety (also referred to herein as moiety). Preferably, the moiety is located on the outer surface of the nanoparticle. More preferably, the additional moiety is attached to the nanoparticle, preferably to the outer surface of the nanoparticle.

[0152] In a preferred embodiment, the moiety is attached to the nanoparticle or its outer surface by a covalent or non-covalent bond, preferably a covalent bond, including, and preferably a peptide or disulfide bond.

[0153] In another preferred embodiment, the moiety attached to the nanoparticle is a peptide or non-peptide tag of a polypeptide of the invention.

[0154] In another preferred embodiment, the moiety is selected from the group consisting of polyhistidine, a His tag (i.e., an amino acid sequence consisting of two or more consecutively linked histidines), a degradation tag, a targeting tag, a cell permeation tag, and an endosomal escape tag.

[0155] The targeting tag is preferably bound to a cancer target, i.e., the targeting tag is a cancer targeting tag. The cancer target comprises a receptor that has an increased expression level in / on a specific tumor cell and a tumor antigen. In a preferred embodiment, the cancer targeting tag is a peptide ligand, a peptidomimetic, or an antibody that binds to a cancer target. The cancer targeting tag is preferably folic acid.

[0156] In a preferred embodiment, the nanoparticles of the invention exhibit at least 72 histidyl residues on the outer surface of the nanoparticle, and in a more preferred embodiment, the nanoparticles of the invention exhibit at least 72-216 histidyl residues on the outer surface of the nanoparticle.

[0157] In a preferred embodiment, the nanoparticles of the present invention exhibit at least 72 histidyl residues on the outer surface of the nanoparticle, which are attached to the C-terminus or N-terminus, preferably the C-terminus, of amino acid sequence I, and the nanoparticles can be unloaded with cargo in vivo and in vitro without degradation. In a preferred embodiment, the nanoparticles of the present invention exhibit at least 72 histidyl residues on the outer surface of the nanoparticle, which are attached to the C-terminus or N-terminus, preferably the C-terminus, of amino acid sequence I. In a further preferred embodiment, the nanoparticles of the present invention exhibit at least 72-216 histidyl residues on the outer surface of the nanoparticle, which are attached to the C-terminus or N-terminus, preferably the C-terminus, of amino acid sequence I.

[0158] In a preferred embodiment, the nanoparticles of the invention exhibit at least 96 histidyl residues, preferably 144 histidyl residues, on the outer surface of the nanoparticle. In a further preferred embodiment, the nanoparticles of the invention exhibit 3-50, preferably 24 histidine-rich amino acid sequences on their outer surface, each of which is independently linked to the N-terminus or C-terminus of the polypeptide of the invention, and each of which comprises at least 5, preferably 6 histidine residues. Preferably, the histidine-rich amino acid sequences have a length of 30 amino acids or less, preferably 25 amino acids or less, more preferably 20 amino acids or less, even more preferably 15 amino acids or less, even more preferably 10 amino acids or less, even more preferably 5 or 6 amino acids.

[0159] In a further preferred embodiment, the nanoparticles of the invention exhibit at least 72, preferably at least 96, more preferably at least 120, even more preferably at least 144 histidyl residues on their outer surface. In a further preferred embodiment, the nanoparticles of the invention exhibit about 144 histidyl residues on their outer surface.

[0160] In a more preferred embodiment, the nanoparticles of the present invention exhibit 24 His tags on their outer surface, each of which consists of three or more consecutively linked histidines. In a further preferred embodiment, the nanoparticles of the present invention exhibit 24 His tags on their outer surface, each of which consists of three to nine consecutively linked histidines. In a more preferred embodiment, the nanoparticles of the present invention exhibit 24 His tags on their outer surface, each of which consists of three or more consecutively linked histidines, and the His tags are attached to the C-terminus or N-terminus, preferably the C-terminus, of the amino acid sequence I. In a further preferred embodiment, the nanoparticles of the present invention exhibit 24 His tags on their outer surface, each of which consists of three to nine consecutively linked histidines, and the His tags are attached to the C-terminus or N-terminus, preferably the C-terminus, of the amino acid sequence I.

[0161] In another preferred embodiment, the nanoparticles of the invention exhibit 3-50, preferably 24 His6 tags on their outer surface, each of which consists of 6 consecutively linked histidines. In a preferred embodiment, the nanoparticles of the invention exhibit 3-50, preferably 24 amino acid sequences comprising a His6 tag (defined herein as a sequence consisting of 6 consecutively linked histidines, i.e. homo-hexa-histidine), on their outer surface, each of which is independently attached to the N-terminus or C-terminus of the polypeptide of the invention. Preferably, the His6 tag comprising a sequence has a length of 30 amino acids or less, preferably 25 or less, more preferably 20 or less, even more preferably 15 or less, even more preferably 10 or less. In a preferred embodiment, the nanoparticles of the invention exhibit 3-50, preferably 24 His6 tags on their outer surface, each of which is independently attached to the N-terminus or C-terminus of the polypeptide of the invention.

[0162] These histidine-rich peptides are important for delivery to the cytoplasm of target cells, likely due to their endosomal escape properties. It has been reported that histidine residues can play an important role in the endosomal escape of synthetic peptides and some viruses. However, the use of multimeric protein assemblies to present multiple copies of histidine-rich functional peptides has not been demonstrated and represents a novel approach to the cytoplasmic delivery of protein nanoparticles.

[0163] In a preferred embodiment, the nanoparticles of the invention are modified after production, either genetically (for direct fusion of peptides) or chemically.

[0164] The nanoparticles of the invention show only negligible cytotoxicity. To quantify dehydrogenase activity, in vitro cytotoxicity was measured in HeLa cells over 24 hours using WST-8 (see Materials and Methods, Cytotoxicity below). The nanoparticles of the invention reduced viability to a maximum of about 95%. The reduction in viability was between about 0% and about 5% at concentrations between 12 μg / mL and 193 μg / mL protein (400 nM cage). In comparison, Lipofectamine 2000 reduced cell viability to about 35-45% at a 19-fold lower mass concentration (10 μg / mL) under the same assay conditions.

[0165] In a further aspect, the present invention relates to a complex comprising a nanoparticle of the invention and one or more cargo molecules.

[0166] In a preferred embodiment, the complex comprises a caged nanoparticle of the invention and one or more cargo molecules encapsulated in the cavity of the caged nanoparticle.

[0167] In a preferred embodiment, the complex of the present invention is capable of inducing an immune response in an organism, preferably said organism is an animal, more preferably a mammal, even more preferably a mouse or a human, most preferably a human.

[0168] The cargo molecule of the complex of the invention is preferably a macromolecule. In a further preferred embodiment, the macromolecule is negatively charged.

[0169] As used herein, the term "negatively charged" includes and preferably refers to molecules that have negatively charged groups. More preferably, the negatively charged molecules have negatively charged groups at neutral or physiological pH.

[0170] Due to the highly positively charged interior of the nanoparticles of the present invention due to arginine residues, the nanoparticles have a strong affinity for encapsulating negatively charged macromolecules such as ONs. Treatment of cells with the complexes of the present invention results in intracellular delivery of the complexes and release of the negatively charged functional macromolecules. Thus, the complexes of the present invention are capable of entering cells, endosomal escape, and intracellular release of negatively charged macromolecules. For example, the complexes containing ONs provided selective knockdown of desired genes through cytoplasmic delivery and release of ONs.

[0171] The complex of the present invention can also enter cells and release negatively charged macromolecules such as ONs into cells, preferably into the cytoplasm.Therefore, the complex of the present invention is conditionally stable against negatively charged macromolecules such as ONs.The highly positively charged interior of the cage provides a strong driving force for encapsulating negatively charged macromolecules such as ONs, providing a complex that is stable for several weeks in standard buffer at room temperature.

[0172] The complexes of the present invention are stable outside the cell, although the encapsulation is reversible in the presence of high concentrations of competing guest molecules. In the presence of high concentrations of negatively charged competitors, such as nucleic acids, such as those found in the cytoplasm of cells, the negatively charged macromolecules, such as ONs, are gradually released and can perform their biological functions. This concept of competitor-induced site-specific release of negatively charged macromolecules, such as ONs, is unique and can be modified by changing the number and location of arginine residues inside the protein cage. Thus, in a preferred embodiment, the nanoparticles of the present invention are capable of reversibly encapsulating and releasing cargo. In a further preferred embodiment, the nanoparticles of the present invention are capable of reversibly encapsulating and releasing cargo without the nanoparticles degrading. In a further preferred embodiment, the nanoparticles of the present invention are capable of encapsulating and releasing cargo without the nanoparticles degrading. The cargo is preferably a negatively charged macromolecule, more preferably an RNA, even more preferably an RNA selected from the group consisting of antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), small hairpin RNAs (shRNAs), microRNAs (miRNAs) and anti-miRNAs.

[0173] In a further embodiment, the nanoparticles of the present invention are capable of encapsulating a cargo outside a cell, preferably the cargo is a negatively charged macromolecule, more preferably RNA, even more preferably RNA selected from the group consisting of antisense oligonucleotides (ASO), small interfering RNA (siRNA), small hairpin RNA (shRNA), microRNA (miRNA) and anti-miRNA, and the nanoparticles encapsulating the cargo are capable of releasing the cargo inside a cell.

[0174] In a preferred embodiment, each of the one or more negatively charged macromolecules has a diameter of about 3.5 nm or less.In a more preferred embodiment, each of the one or more negatively charged macromolecules has a diameter of about 2 nm or less.In a preferred embodiment, each of the one or more negatively charged macromolecules has a diameter of about 2 nm and a length of about 8 nm.Preferably, the macromolecules are linear monomer chains, preferably having a diameter of about 2 nm and a length of about 8 nm.

[0175] In a preferred embodiment, the negatively charged macromolecule is a nucleic acid or a polypeptide.

[0176] In another preferred embodiment, the cargo molecule is an oligonucleotide (ON).

[0177] The term "oligonucleotide" as used herein refers to a compound comprising two or more nucleotides linked together by nucleoside bonds. The oligonucleotide is a polyribonucleotide or polydeoxyribonucleotide or a mixture thereof, preferably selected from single-stranded or double-stranded (a) unmodified, i.e. naturally occurring, RNA or DNA, (b) modified RNA or DNA, or (c) RNA or DNA mimics such as locked nucleic acid (LNA) or peptide nucleic acid (PNA). The oligonucleotide is preferably selected from the group consisting of (a) single-stranded and double-stranded DNA, (b) DNA that is a mixture of single-stranded and double-stranded regions, (c) single-stranded and double-stranded RNA, (d) RNA that is a mixture of single-stranded and double-stranded regions, and (e) hybrid molecules comprising DNA and RNA that are single-stranded or double-stranded or a mixture of single-stranded and double-stranded regions. In a further preferred embodiment, the oligonucleotide is a triple-stranded region and higher order structure comprising RNA or DNA, or both RNA and DNA. In a further embodiment, the oligonucleotide is synthetic, genomic or recombinant. In one embodiment, oligonucleotide refers to (a) DNA or RNA that contains at least one modified nucleotide or at least one nucleotide analog, or (b) DNA or RNA with a backbone modified for stability or other reasons.

[0178] The term "modified RNA" or "modified DNA" as used herein refers to an oligonucleotide as defined above that has at least one modified internucleoside bond and / or at least one sugar modification and / or at least one base modification compared to naturally occurring ribonucleotide or deoxyribonucleotide based oligonucleotides. Modified internucleoside bond refers to the presence of modified forms of phosphodiester that do not naturally occur in RNA and DNA. Examples of internucleoside bond modifications known to those skilled in the art and compatible with the present invention include, among others, phosphoramidates, phosphorodiamidates, phosphorothioates, phosphorodithioates, H-phosphonates, methylphosphonates and methylphosphonothioates. Sugar modifications refer to the presence of modified forms of ribosyl moieties (i.e., furanosyl moieties) that naturally occur in RNA and DNA, such as bicyclic sugars, tetrahydropyrans, morpholinos, 2'-modified sugars, 3'-modified sugars, 4'-modified sugars, 5'-modified sugars, and 4'-substituted sugars. Examples of suitable sugar modifications will be known to those skilled in the art and include 2'-O-alkyl or 2'-O-(substituted)alkyl, such as 2'-O-methyl, 2'-O-(2-cyanoethyl), 2'-O-(2-methoxy)ethyl (2'-MOE), 2'-O-(2-thiomethyl)ethyl, 2'-O-(haloalkoxy)methyl, such as 2'-O-(2-chloroethoxy)methyl (MCEM), 2'-O-(2,2-dichloroethoxy)methyl (DCEM). These include, but are not limited to, 2'-O-alkoxycarbonyl, e.g., 2'-O-modified RNA nucleotide residues such as 2'-O-[2-(methoxycarbonyl)ethyl] (MOCE), 2'-O-[2-(N-methylcarbamoyl)ethyl] (MCE), 2'-O-[2-(N,N-dimethylcarbamoyl)ethyl] (DMCE), particularly 2'-O-methyl modified or 2'-O-(2-methoxy)ethyl (2'-MOE).Other important modifications include, for example, locked nucleic acids (LNA), xylo-LNA, alpha-L-LNA, beta-D-LNA, cEt (2'-O,4'-C constrained ethyl) LNA, cMOEt (2'-O,4'-C constrained methoxyethyl) LNA, ethylene-bridged nucleic acids (ENA), hexitol nucleic acids (HNA), fluorinated HNA (F-HNA), pyranosyl-RNA (p-RNA), bridged or bicyclic nucleic acids (BNA) as found in 3'-deoxypyranosyl-DNA (p-DNA), or other modified sugar moieties such as morpholino (PMO), cationic morpholino (PMOPlus) or PMO-X, all known to those skilled in the art. As used herein, the term "base modification" refers to a modification of a base (i.e., a pyrimidine or purine base) naturally occurring in RNA and / or DNA. Base modifications are known to those skilled in the art and include, but are not limited to, modified forms of natural purine and pyrimidine bases (e.g., adenine, uracil, guanine, cytosine, and thymine), such as hypoxanthine, pseudouracil, pseudothymine, 2-thiopyrimidine (e.g., 2-thiouracil, 2-thiothymine), 2,6-diaminopurine, 5-substituted pyrimidine (e.g., 5-halouracil, 5-methyluracil, 5-methylcytosine), 7-deazaguanine, 7-deazaadenine, 7-aza-2,6-diaminopurine, 8-aza-7-deazaguanine, 8-aza-7-deazaadenine, or 8-aza-7-deaza-2,6-diaminopurine.It is also encompassed by the present invention that the oligonucleotide comprises two or more, the same or different, internucleoside bond modifications, sugar modifications, and / or base modifications. Thus, the oligonucleotides referred to in the present invention may consist of any combination of nucleotides and their modifications as described above.

[0179] More preferably, the one or more negatively charged macromolecules are one or more oligoribonucleotides selected from the group consisting of antisense oligonucleotides (ASO), small interfering RNA (siRNA), small hairpin RNA (shRNA), microRNA (miRNA) and anti-miRNA.More preferably, the oligonucleotide can stimulate IFN-alpha production in cells, preferably dendritic cells.

[0180] In a preferred embodiment, the one or more negatively charged polymers are one or more ONs, and the total number of nucleotides in the one or more ONs is not more than about 300. In another preferred embodiment, the total number of nucleotides in the one or more ONs is about 10 to about 300, preferably about 20 to about 300, more preferably about 40 to about 300, even more preferably about 50 to about 300, even more preferably about 100 to about 300, and even more preferably about 200 to about 300.

[0181] In another preferred embodiment, the total number of nucleotides of the one or more ONs is about 10 to about 300, preferably about 10 to about 200, more preferably about 10 to about 50, even more preferably about 10 to about 40, and even more preferably about 10 to about 30.

[0182] In another preferred embodiment, the total number of nucleotides of the one or more ONs is about 10 to about 300, preferably about 20 to about 200, and more preferably about 40 to about 100.

[0183] In a preferred embodiment, the total number of nucleotides of said one or more ONs is about 300 or less, and said ONs are RNA, preferably ssRNA.

[0184] In a further preferred embodiment, the one or more ONs are single-stranded ONs (ssONs), preferably ssRNA or ssDNA, and the ssONs have a combined length of about 40 nt or more, preferably about 40 to about 300 nt, more preferably about 40 to about 200 nt, even more preferably about 40 to about 100 nt, and even more preferably about 40 nt. In another preferred embodiment, the one or more ONs are double-stranded ONs (dsONs), preferably dsRNA or dsDNA, and the dsONs have a combined length of about 40 bp or more, preferably about 40 to about 300 bp, more preferably about 40 to about 200 bp, even more preferably about 40 to about 100 bp, and even more preferably about 40 bp.

[0185] In a preferred embodiment, the one or more macromolecules are one or more oligonucleotides, and the one or more oligonucleotides are encapsulated in the nanoparticle and are not susceptible to DNAse hydrolysis.Therefore, in a preferred sense, the term "encapsulated" indicates that the one or more oligonucleotides in the encapsulated state are not susceptible to DNAse hydrolysis.More preferably, the term "encapsulated" indicates that the one or more oligonucleotides in the encapsulated state are not susceptible to DNAse hydrolysis, and the DNAse is DNAseI or Benzonase.Even more preferably, the term "encapsulated" indicates that the one or more oligonucleotides in the encapsulated state are not susceptible to Benzonase hydrolysis.

[0186] The negatively charged macromolecules are preferably encapsulated within the nanoparticles by non-covalent bonds, which are preferably electrostatic bonds.

[0187] Any other reagents, such as adjuvants, can be included within the nanoparticles.

[0188] In a further preferred embodiment, the negatively charged macromolecule has an association rate constant k on is (6.6±0.6)×10 5 M -1 s-1 ONs bind to the nanoparticles (Figure 2c). The binding kinetics are determined by measuring fluorescence quenching and fluorimetry. The data were fitted to a single exponential decay with a rate constant (k) plotted against the ON concentration. obs ), linear fit).

[0189] In a further preferred embodiment, the negatively charged macromolecule is an ON that dissociates from the nanoparticle and has a dissociation constant K d (2.4±0.3)x10 -10 M is the dissociation rate constant, K off (1.6±0.1)x10 -4 seconds -1 To determine the off-rate, a 100-fold excess of unlabeled DNA was used to induce a slow release of the encapsulated Atto488-ssDNA cargo (Fig. 2d). The data were fitted to a single exponential decay, yielding a dissociation rate constant, koff, of (1.6 ± 0.1) x 10 -4 s -1 Using the association and dissociation rate constants, it was found to be (2.4±0.3)x10 -10 Equilibrium dissociation constant K of M d was calculated.

[0190] In a preferred embodiment, the negatively charged macromolecule contained in the complex is a nucleic acid, preferably an ON, and the nanoparticle of the complex of the present invention can protect the nucleic acid, preferably the ON, from degradation by nuclease.In a preferred embodiment, the nuclease has a molecular weight of more than 14 kD, preferably more than 20 kD, more preferably more than 30 kD, even more preferably more than 40 kD, even more preferably more than 50 kD, even more preferably more than 60 kD.In a preferred embodiment, the nuclease has a molecular weight of more than 14 kD.In a preferred embodiment, the nuclease has a molecular weight of more than 60 kD.

[0191] In a preferred embodiment, the complexes or nanoparticles of the invention exhibit approximately 30-fold increased cellular uptake compared to controls using naked, ie, free, Atto488-ssDNA.

[0192] In a further aspect, the present invention provides a method for producing a nanoparticle of the invention comprising the step of self-assembling a polypeptide of the invention into said nanoparticle.

[0193] In a preferred embodiment, the method for producing the nanoparticles of the present invention comprises the steps of (i) producing the polypeptides of the present invention, and (ii) allowing the polypeptides of the present invention to self-assemble into said nanoparticles. The polypeptides for producing the nanoparticles of the present invention are preferably produced by recombinant expression. In a preferred embodiment, the polypeptides are recombinantly expressed in bacterial cells, preferably Escherichia coli cells. Upon expression, the polypeptides of the present invention self-assemble into well-defined nanoparticles that can be isolated.

[0194] In a preferred embodiment, the method for producing nanoparticles further comprises a step of isolating nanoparticles.The isolation step is preferably affinity chromatography, more preferably immobilized metal affinity chromatography.In a preferred embodiment, the isolation step is affinity chromatography using a support containing nickel, cobalt, or copper.Most preferably, the isolation step is Ni-NTA affinity chromatography.

[0195] The positively charged interior of the nanoparticles of the invention allows for the incorporation of contaminating nucleic acids from host cells expressing the polypeptides of the invention. These unwanted cargoes can be removed by high ionic strength to weaken electrostatic interactions and digest the contaminating RNA with RNase A.

[0196] Thus, in a preferred embodiment, the method for producing nanoparticles further comprises treating the nanoparticles with a high ionic strength buffer and / or RNase. In a preferred embodiment, the high ionic strength buffer has an ionic strength of 0-2M. In a further preferred embodiment, the method for producing nanoparticles of the invention comprises (i) producing a polypeptide of the invention via recombinant expression, (ii) treating the expressed polypeptide in a buffer having an ionic strength of 0-2M and comprising RNase and / or DNase, to allow the polypeptide of the invention to self-assemble into the nanoparticles. Preferably, the high ionic strength of the buffer, 0-2M, is adjusted by the addition of NaCl. Preferably, the high ionic strength buffer comprises, in addition to RNase and / or DNase, sodium phosphate buffer, NaCl, imidazole, and optionally lysozyme. The buffer comprises, for example, about 50 mM sodium phosphate buffer (pH 7.4), about 1000 mM NaCl, and imidazole, supplemented with lysozyme, DNaseI, and RNaseA. The high ionic strength buffer contains at least 20 mM imidazole.

[0197] In a further aspect, the present invention provides a method for producing a complex of the present invention, comprising mixing the nanoparticles of the present invention with one or more negatively charged macromolecules. In a preferred embodiment, the mixing step is carried out in an aqueous buffer, preferably at room temperature.

[0198] In a further aspect, the present invention provides a method for transfecting a cell comprising the step of contacting said cell with a complex of the present invention.

[0199] As used herein, the term "transfection" refers to the process of introducing a negatively charged macromolecule, preferably a nucleic acid, more preferably an ON, into a cell. Preferably, the method for transfecting a cell is an in vitro process.

[0200] In a preferred embodiment, the cell is a eukaryotic cell. More preferably, the cell is an animal cell, even more preferably a mammalian cell.

[0201] In a further aspect, the present invention relates to the use of the complex of the invention for transfecting a cell. EXAMPLES

[0202] Example 1 - Materials and Methods Materials and Instrumentation All enzymes used for molecular cloning were purchased from New England BioLabs (USA). All synthetic oligonucleotides were purchased from MicrosynthAG (Switzerland). Plasmid miniprep and DNA purification kits were purchased from ZymoResearch (USA). Isopropyl-beta-D-thiogalactopyranoside (IPTG) was purchased from Fluorochem (UK). Lysozyme was purchased from PanReacAxon Lab AG (Switzerland). Ni-NTA agarose from Qiagen (Germany) was used for isolation of His-tagged proteins. DNaseI was from Roche (Switzerland) and RNase A was from Merck (Germany). Benzonase was purchased from Merck-Millipore (USA). GelRed was purchased from Biotium, Inc. (USA). Plasmid pET29b(+)-O3-332 was kindly provided by Professor David Baker.

[0203] DNA and protein quantification was performed using a NanoDrop 2000c spectrophotometer from ThermoFisher Scientific Inc. (USA). All size-exclusion chromatography was performed on an NGC™ medium pressure chromatography system from Bio-Rad Laboratories, Inc. (USA). Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed and developed on a PhastGel system from GE Healthcare (USA). Agarose gel electrophoresis (AGE) and denaturing polyacrylamide gel electrophoresis (PAGE) were performed on a Mini-Sub® Cell GT and Mini-PROTEAN system, respectively, both from Bio-Rad Laboratories, Inc. (USA). Gel images were taken using an EOS1100D from Canon (Japan). Transmission electron microscope (TEM) images were obtained on a Morgagni 268 from FEI (USA). Fluorescence microscope images were acquired on an Eclipse-Ti inverted microscope from Nikon (Japan). Confocal fluorescence microscopy images were acquired on a SP8-AOBS from Leica (Germany).Flow cytometry was performed on an LSRFortessa from BD Biosciences (USA).

[0204] Molecular modeling X-ray diffraction data from the original O3-33 assembly (PDB:3VCD) (King, NP et al., Science 2012, 336, 1171-1174) was used to pick sequence locations for mutations to arginines, which were modeled with UCSF Chimera (Pettersen, EF et al., J. Comput. Chem. 2004, 25, 1605-1612) using the Dynameomics backbone-independent rotamer library (Scouras, AD et al., Protein Sci. 2011, 20, 341-352).

[0205] Molecular cloning The OP gene was purchased from ATG:biosynthetics (Germany) and obtained as plasmid pGH-OP. The OP gene insert was excised from pGH-OP and cloned into vector pET29b(+)-O3-33 vector (King et al., 2012, supra) using XhoI and NdeI restriction sites, replacing the O3-33 gene, resulting in plasmid pET29b(+)-OP. The OP gene without the His6 tag was prepared by cloning into a DNA cassette encoding GS** at the XhoI site immediately upstream of the His6 tag. The plasmid sequence was confirmed by Sanger DNA sequencing performed by Microsynth AG (Switzerland).

[0206] Protein expression Proteins were expressed in E. coli strain BL21-Gold(DE3) transformed with either pET29b(+)-O3-33, pET29b(+)-OP, or without pET29b(+)-OP_His6. Cells were grown at OD 600 The strains were grown at 37 °C in LB medium containing kanamycin sulfate (86 µM) until the Aβ reached 0.6–0.8, and protein overexpression was induced with IPTG (0.1 mM). After approximately 18 h of incubation at 25 °C, cells were harvested by centrifugation (5,000 × g) at 4 °C for 15 min. Cell pellets were stored at -20 °C until purification.

[0207] Cell lysis, Ni-NTA and RNA removal of OPs Because OPs can be loaded with small RNA molecules during expression in E. coli, optimized protocols were developed to isolate empty cages with high purity. These included the use of high ionic strength buffers to weaken interactions with nucleic acids and prolonged incubation with RNase A. Each cell pellet from an 800 mL culture was resuspended in 10 mL of lysis buffer (50 mM sodium phosphate buffer (pH 7.4), 1000 mM NaCl, 20 mM imidazole) supplemented with lysozyme (0.1 mg / mL), DNase I (10 U / mL), RNase A (5 U / mL), and protease inhibitor cocktail (Sigma) and incubated at 37 °C for 1.5 h.

[0208] After lysis, sonication, and centrifugation (10,000 × g) for 25 min at 25 °C, the supernatant was loaded onto 5 mL of Ni-NTA resin in a gravity-flow column and incubated for 15 min. After multiple washes with lysis buffer containing 20 mM and 40 mM imidazole, the target protein was eluted with elution buffer (50 mM sodium phosphate buffer (pH 7.4), 300 mM NaCl, 500 mM imidazole). Typically, 10–20 mL was collected and supplemented with 2 U / mL RNase A, 5 mM EDTA, and protease inhibitor cocktail and incubated overnight at 37 °C to digest contaminating E. coli RNA that was not removed during Ni-NTA purification. The protein was then ready for SEC. From this point onwards, protein storage and all experiments were performed at room temperature unless otherwise stated.

[0209] Dissolution of O3-33 and Ni-NTA Isolation of O3-33 followed the same steps as OP, but conditions were less stringent because nucleic acid contamination is not an issue. For lysis, sonication, and Ni-NTA, the buffers used were of low ionic strength (50 mM sodium phosphate buffer (pH 7.4), 300 mM NaCl, and 20 mM imidazole). After isolation from Ni-NTA in elution buffer (50 mM sodium phosphate buffer (pH 7.4), 300 mM NaCl, 500 mM imidazole), the protein was ready for SEC.

[0210] Size Exclusion Chromatography (SEC) Prior to SEC, protein samples were buffer exchanged into 20 mM sodium phosphate buffer (pH 7.4) containing 200 mM NaCl and 5 mM EDTA using Amicon Ultra-15 centrifugal filter units (30k MWCO) (Merck Millipore, USA). This process also removes RNaseA and some of the digested nucleic acid fragments from the OPs. The fully assembled 24-mer cages were then isolated by SEC at room temperature using a Superose 6Increase 10 / 300 GL column from GE Healthcare (USA) at a flow rate of 1.0 mL / min. Both O3-33 and OP cages are eluted in 15–16 mL of eluent of 20 mM sodium phosphate buffer (pH 7.4) containing 200 mM NaCl and 5 mM EDTA. The purified proteins were stored at room temperature in the SEC eluent buffer. Proteins were quantified by absorbance at 280 nm. In addition, removal of all RNA was confirmed by A 260 / A 280 The purity of the protein was confirmed by SDS-PAGE staining with Coomassie blue and by staining with a non-denaturing agarose gel stained with GelRed, a highly sensitive nucleic acid stain.

[0211] General properties of protein cages All native gel electrophoresis was performed using 2% or 3% (w / v) agarose gels in Tris-acetate-EDTA buffer (40 mM Tris-HCl, 19 mM acetic acid, 1 mM EDTA, pH 8.3). When necessary, gels were cast with GelRed to detect unlabeled nucleic acids and stained with Coomassie blue for protein visualization. In a typical experiment for protein analysis, approximately 100 or 200 pmol of capsid (with respect to monomer) per lane was loaded in 10 μL of buffer containing an additional 2 μL of 70% (v / v) aqueous glycerol. Gels were run at 100 V for 30 min, stained with Coomassie blue to visualize proteins, and ONs were detected by Atto488 fluorescence.

[0212] SEC analysis was performed under the same conditions used for cage isolation. Negative staining transmission electron microscopy (TEM) was performed as previously reported (Beck, T. et al., Angew. Chem. Int. Ed. 2015, 54, 937-940). For all TEM experiments, storage buffer (20 mM sodium phosphate buffer (pH 7.4), 200 mM NaCl, and 5 mM EDTA) containing 3–5 μM (monomer) protein sample was used. DLS measurements were performed at 25 °C on a Zetasizer Nano (Malvern Instruments, UK) using storage buffer containing 150–250 μM (monomer) of 0.22 μm filtered sample.

[0213] Melting Temperature Melting temperatures were obtained with a StepOnePlus Real-Time PCR system (Applied Biosystems, USA) using the Protein ThermalShift™ Dye Kit (Thermo Fisher Scientific, USA). Proteins were measured in triplicate at 5, 10, and 20 μM in a buffer consisting of 25 mM Tris-HCl (pH 8.0), 200 mM NaCl. Values ​​were calculated by averaging all data. [Table 1]

[0214] Table 4 shows the melting temperatures, Tm, of O3-33 and OP proteins in the presence and absence of two equivalents of siRNA duplex.

[0215] Protein Crystallography Sitting-drop vapor diffusion experiments were set up on an Intelli-Plate R96-3LV using a Phoenix crystallization robot (Art Robbins Instruments). Initial crystallization attempts were performed at 20 °C. Well-diffracting OP crystals were obtained using the sitting-drop vapor diffusion method in 2 M (NH4)2SO4 and 5% 2-propanol with 3 mg / mL enzyme solution at 20 °C. Crystals were transferred to a reservoir solution containing 20% ​​(v / v) glycerol as cryoprotectant and then flash-cooled at -173 °C in a stream of nitrogen gas. X-ray diffraction data sets were collected on an X06SA at the Swiss Light Source (Paul Scherrer Institute, Villigen, Switzerland) using an EIGER X16M detector. A wavelength of 1.0000 Å was used for data collection.

[0216] Diffraction data of OP were processed and scaled using the XDS program package (Kabsch W., Acta Crystallogr. D Biol. Crystallogr. 2010, 66, 125-132). The initial phase was determined by molecular replacement using the structure of O3-33 (PDB code: 3VCD) as a search model. Molecular replacement was carried out with Phaser (McCoy, AJ et al., J. Appl. Crystallogr. 2007, 40, 658-674). The structure was manually modified with Coot (Emsley, P. et al., Acta Crystallogr. D Biol. Crystallogr. 2004, 60, 2126-2132) and refined with PHENIX (Adams, PD et al., Acta Crystallogr. D Biol. Crystallogr. 2010, 66, 213-221). The final crystallographic data and intensity statistics are summarized in Table 5.

[0217] Electrophoretic mobility shift assay (EMSA) All EMSAs were performed on 3% (w / v) agarose gels as described above. For Atto488-labeled ssDNA, 10 pmol of DNA was used per sample (=one gel lane) and incubated at room temperature with a total volume of 10 μL of PBS containing various molar equivalents of protein. For unlabeled dsDNA and dsRNA, 40 pmol of duplex was used per sample under the same incubation conditions and gels were cast with GelRed for visualization.

[0218] Cargo capacity Pure OP protein (1 nmol) was incubated overnight at room temperature with a total volume of 200 μL of SEC buffer (20 mM sodium phosphate buffer (pH 7.4), 200 mM NaCl, and 5 mM EDTA) containing 5 equivalents of either ssDNA, dsDNA, or dsRNA. The mixtures were purified by SEC and absorbance spectra were obtained. All absorbance spectra were corrected for light scattering using a|e UV-Vis-IR software. Protein and nucleic acid concentrations were determined from absorbance values ​​at 280 and 260 nm using the formula described by Porterfield and Zlotnick (Porterfield, JZ et al., Virology 2010, 407, 281-288).

[0219] Encapsulation kinetics All kinetic measurements were performed in PBS at room temperature. on For each experiment to determine k, the fluorescence emission of 800 μL of Atto488-labeled DNA (10 nM) solution was measured at 515 nm (excitation, 488 nm) and this value was taken as t = 0 s. Small volumes of concentrated OP solution were then added to give final concentrations ranging from 5 to 125 nM, and the decrease in emission over time was monitored at 10 s intervals. Each measurement of emission versus time was fitted to a single exponential function, and k was calculated for each concentration of OP. obs Next, these k obs The values ​​are plotted against [OP] and k on was obtained from the slope of the linear fit. k at low concentrations (<25 nM) of OP obs The value of k is unreliable as it shifts from one to two guest DNA molecules per cage (Figure 17). Thus, k in the range of 25–125 nM obs Only k on is used to determine the y-intercept for the linear fit k of 1.6 x 10-4s off The measured value was fixed.

[0220] k offTo measure K, 800 μL of Atto488-labeled DNA (10 nM) and OP (5 nM) solution was incubated until no further change in fluorescence was observed. This provided an OP cage containing two ssDNA molecules, as would be the case if encapsulation of a second DNA molecule into a 1:1 complex were excluded. off The measurements are reduced to a single rate constant. Due to the high stability of the OP:DNA complex, an excess of unlabeled ssDNA was used to displace the encapsulated Atto488-DNA and restore fluorescence when it is released from the protein cage. After addition of 1 μM unlabeled ssDNA, the change in fluorescence emission at 515 nm was monitored at 60 s intervals for 16 h. The data were fitted to a single exponential function, k off was generated.

[0221] Nuclease digestion assay Complexes of OPs with either ssDNA, dsDNA, or dsRNA (1:1 molar ratio) were prepared by incubation in PBS for 1 h at room temperature. Equivalent stocks containing only nucleic acid were also prepared. The stocks were then divided into aliquots to provide samples for each gel lane. Each sample contained 24 pmol of OPs / nucleic acid in a total volume of 10 μL of PBS supplemented with MgCl2 (2.5 mM), CaCl2 (0.5 mM). Control samples were kept as is, and nuclease samples received 0.2 U of RNaseA, DNaseI, or Benzonase. All samples were then incubated at 37 °C for 18 h before being analyzed on a native agarose gel stained with GelRed and then Coomassie blue (Figure 14).

[0222] cell culture HeLa and A431 cells were maintained in Dulbecco's modified Eagle's medium (high glucose), MCF-7 and Vero cells were maintained in Iscove's modified Dulbecco's medium, HepG2 and HT29 in RPMI-1640 medium, and CHO in Ham's F-12K medium. In all cases, the medium was supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 2 mM GlutaMAX, and 1 μg / mL gentamicin. Cells were cultured at 37 °C with 5% CO2 and were typically split at a 1:4 ratio every 3 days. HeLa-GFP cells were maintained in the same manner as HeLa cells, with the addition of 0.1 mM non-essential amino acids (NEAA) and 10 μg / mL blasticidin (selective antibiotic) to the medium. Neither NEAA nor blasticidin were found to be effective within these time frames and were therefore not added to the medium for experiments.

[0223] cytotoxicity The cytotoxicity of OPs and Lipofectamine2000 (Thermo Fisher Scientific, USA) was assessed using Sigma's WST-8-based Cell Counting Kit-8 according to the manufacturer's instructions. HeLa cells were seeded at a density of 5,000 cells per well in 96-well plates in 100 μL of medium and allowed to recover for 24 h at 37°C and 5% CO2. Samples of OPs (pre-sterilized by filtration through a 0.22 μm membrane) and Lipofectamine2000 were prepared by serial dilution in sterile PBS. A total volume of 10 μL of sample was added to each well to provide the final concentrations shown in Figure 15. As a negative control, 10 μL of PBS containing 10% TritonX-100 was used per well. The positive control was just PBS. Cells were incubated at 37°C with 5% CO2 for 24 or 48 h before adding 10 μL of CKK-8 reagent to each well. Plates were then incubated at 37° C. and 5% CO2 for 4 hours, after which the absorbance at 450 nm was measured. The absorbance of CKK-8 in medium without cells was used for background subtraction, and samples were normalized to untreated cells to provide the values ​​shown in FIG 15. Samples were measured in triplicate.

[0224] Cellular uptake by flow cytometry HeLa cells were seeded in 500 μL of medium at a density of 30,000 cells per well in 24-well plates and allowed to recover for 24 h at 37 °C and 5% CO2, reaching a confluency of 70–90%. Both OP proteins and Atto488-DNA were filter-sterilized through a 0.22 μm membrane and stocks were prepared in sterile PBS. For each well, 20 μL of sample in PBS was added to 200 μL of medium, resulting in a final Atto488-DNA concentration of 200 nM. Cells were incubated for 24 h at 37 °C with 5% CO2, then washed with PBS and trypsinized (0.05% trypsin-EDTA (Thermo Fisher Scientific, USA), 4 min at 37 °C). Cells were collected in cold medium and washed twice with cold PBS before being resuspended in flow cytometry buffer (PBS containing 5% FBS and 10 μg / mL propidium iodide).

[0225] Cellular uptake by confocal fluorescence microscopy HeLa cells were seeded at a density of 15,000 cells per well on μ-slide 8-well chambered coverslips with ibiTreat surface from ibidi GmbH (Germany). Cells were incubated in 200 μL of medium at 37 °C and 5% CO2 for 24 h before sample addition. Both OP proteins and Atto488-DNA were filter-sterilized through a 0.22 μm membrane and stocks were prepared in sterile PBS. For each well, 10 μL of sample in PBS was added to 100 μL of medium, resulting in a final Atto488-DNA concentration of 200 nM. After incubation of cells at 37 °C with 5% CO2O2 for 24 h, they were washed with PBS and nuclear stained with 100 μL of Hoechst 33342 solution (5 μg / mL in PBS) for 10 min at 37 °C. Cells were then washed twice with PBS and examined by microscopy in PBS with 5% FBS at 37 °C.

[0226] GFP knockdown HeLa-GFP cells were seeded in 24-well plates at a density of 30,000 cells per well in 500 μL of medium and allowed to recover for 24 h at 37 °C and 5% CO2 to reach approximately 70% confluency. Sterile protein, RNA, and Lipofectamine 2000 samples were prepared in PBS. Except for the Lipofectamine 2000 control, all samples (20 μL in PBS) were added to the cells in 200 μL OptiMEM and incubated for 4 h at 37 °C and 5% CO2, after which 300 μL of complete medium was added. The cells were then further incubated at 37 °C and 5% CO2, giving a total of 48 h between sample addition and flow cytometry analysis. Although there was only a small change in knockdown efficiency of Lipofectamine 2000 under the conditions used for all other samples, toxicity was an issue. Therefore, the minimum amount of Lipofectamine 2000 required was used to minimize toxicity without compromising knockdown efficiency. This was determined to be 1 μL of Lipofectamine 2000 per 40 pmol of siRNA, which is also the minimum amount recommended by the manufacturer. We then used the manufacturer's recommended protocol and incubated cells in medium containing siRNA lipoplexes (pre-prepared in PBS) for 48 h at 37 °C, 5% CO2 prior to flow cytometry analysis.

[0227] Prior to flow cytometry analysis, fluorescence microscopy was performed directly in the 24-well plates to obtain a qualitative measurement of GFP expression levels and to assess cell health (Figure 16). Cells were then washed with PBS and trypsinized. Cells were collected in cold medium and washed twice with cold PBS before being resuspended in flow cytometry buffer (PBS containing 5% FBS and 10 μg / mL propidium iodide). Untreated HeLa-GFP cells with matched medium and incubation conditions were used as a positive control, and HeLa cells not expressing GFP were used as a negative control for GFP fluorescence to optimize the cytometer settings. Samples were measured at least three times with different batches of protein and siRNA.

[0228] Purification of OPs without His6 tag Ammonium sulfate precipitation was used as previously reported (Beck, T. et al., Angew._Chem. Int. Ed. Engl., 2015, 54, 937-940), with modifications to optimize removal of small RNA molecules. Each cell pellet from 800 mL of culture was resuspended in 10 mL of buffer (25 mM Tris-HCl buffer (pH 8.0), 1000 mM NaCl) supplemented with lysozyme (0.1 mg / mL), DNaseI (10 U / mL), RNase A (5 U / mL), and protease inhibitor cocktail (Sigma) and incubated at 37 °C for 1.5 h. After lysis, the suspension was sonicated and centrifuged (10,000 × g, 25 °C, 25 min). The supernatant was then heated at 65°C for 30 min and centrifuged (10,000×g, 4°C, 25 min) to pellet the denatured E. coli proteins. Ammonium sulfate was added to the supernatant to 70% of its saturation concentration and the suspension was centrifuged (10,000×g, 4°C, 20 min). The protein pellet was resuspended in 20 mL of buffer (25 mM Tris-HCl buffer, pH 8.0, 1000 mM NaCl) and ammonium sulfate precipitation was performed two more times. Finally, the precipitated proteins were resuspended in low salt buffer (25 mM Tris-HCl buffer, pH 8.0, 200 mM NaCl) and incubated overnight at 37°C to digest contaminating E. coli RNA after the addition of 2 U / mL RNase A, 5 mM EDTA, and protease inhibitor cocktail. The protein was then purified by SEC in a buffer consisting of 25 mM 2-(N-morpholino)ethanesulfonic acid (pH 5.5), 1000 mM NaCl, and 250 mM MgSO4 to weaken the interactions between the remaining guest molecules and the protein cage. From this point on, the protein was stored in PBS buffer at room temperature.

[0229] Displacement of cargo by tRNA First, the ability of OPs to encapsulate tRNA was assayed by EMSA (Figure 17). Samples were prepared with 20 pmol tRNA (transfer RNA from wheat germ, Fluka, Germany) in 10 μL PBS with or without OPs (1.2 molar equivalents) and analyzed by native agarose gel stained with GelRed. The intracellular concentration of tRNA was calculated based on the average volume of HeLa cells, the mass of RNA isolated from a single cell, and the percentage of total RNA that is tRNA (Luby-Phelps, K. In International Review of Cytology, Eds. Walter, H., Brooks, DE, Srere, PA, Academic Press: 1999; Vol. 192, p189-221; Lodish H, BA, Zipursky SL In Molecular Cell Biology, 4th ed.; WH Freeman: New York, 2000). This estimate does not take into account the effects of molecular crowding in the cytoplasm, the relative proportion of free tRNA, or other molecules that may also be encapsulated by OPs. For the displacement assay, complexes of OPs with Atto488-DNA duplexes (1:1 molar ratio) were prepared by incubation in PBS for 1 h at room temperature. The stock was then divided into aliquots to provide samples for each gel lane. Each sample contained 10 pmol OP / nucleic acid in a total volume of 10 μL PBS. 2 μL of concentrated tRNA stock was then added to the samples at various time points to obtain a final [tRNA] of 26 μM, and the samples were incubated at 37 °C. Samples were then analyzed on a native agarose gel and visualized by Atto488 fluorescence (Figure 4b).

[0230] Serum stability Complexes of OPs and siRNA (1:1 molar ratio) were prepared by incubation in PBS for 1 h at room temperature. The stock was then divided into aliquots to provide samples for each gel lane. Each sample contained 10 pmol of OPs / nucleic acid in a total volume of 5 μL of PBS. At various time points, 5 μL of PBS containing 20% ​​fetal bovine serum was added to the samples and incubated at 37°C. Samples were then analyzed on a native agarose gel and visualized with GelRed and Coomassie blue (Figure 22).

[0231] Small angle X-ray scattering SAXS data were obtained at beamline P12 of the PETRA-III synchrotron (DESY, Hamburg, Germany) with an X-ray wavelength of 1.24 Å. A Pilatus 1M detector was placed 2 m from the sample to collect a scattering vector range of 0.028–6.7 nm-1. Samples were measured in SAXS buffer (25 mM Tris-HCl buffer (pH 8.0), 200 mM NaCl, 5 mM EDTA, and 10% glycerol) of various concentrations (0.5–5 mg / mL protein), and data from samples showing minimal aggregation and noise were used for further analysis. All samples were dialyzed in SAXS buffer to provide a well-matched buffer blank. For OP:dsDNA and OP:dsRNA, protein cages were incubated overnight with two equivalents of duplex prior to dialysis in SAXS buffer. Scattering curves were analyzed using PRIMUS16, and pair distance distributions were calculated using AUTOGNOM.

[0232] Dissociation of double-stranded DNA To ensure that the hpDNA did not dissociate, the fluorescence spectrum of 800 µL of PBS solution containing 10 nM Atto488-hpDNA was measured from 450 nm to 600 nm. Subsequently, 50 nM OTR501 was added to each sample and the fluorescence decay was followed over 600 s before another spectrum was recorded. The same procedure was applied to a 10 nM dsDNA solution (Atto-488 ssDNA and Luc-g), a 10 nM dsDNA solution with 8 M urea, and a 10 nM solution of Atto-488ssDNA and GFP-g.

[0233] Example 2 - Protein and Nucleic Acid Sequences The molecular weight (MW), isoelectric point (pI), and extinction coefficient at 280 nm (ε 280 , M -1 cm -1 ) were calculated using the SIB Bioinformatics Resource Portal tools (http: / / web.expasy.org / protparam / ). [Table 2-1] [Table 2-2] [Table 2-3]

[0234] SDS-PAGE and Coomassie blue visualization showed different mobilities resulting from different migration of proteins OP and OTR101 to OTR503, proving that all proteins have the same mass of approximately 20 kDa and that all variants are of adequate purity. [Table 3]

[0235] Uppercase letters indicate deoxyribonucleotides and lowercase letters indicate ribonucleotides. A488 refers to the fluorophore Atto488 phosphoramidite attached during solid phase synthesis.

[0236] Example 3 - Structural characterization of nanoparticles As a starting scaffold, we chose O3-33, a computationally designed self-assembling protein cage by Baker and colleagues (King, NP et al., Computational Design of Self-Assembling Protein Nanomaterials with Atomic Level Accuracy. Science 2012, 336, 1171-1174), which is a non-functional protein cage, a computationally designed native scaffold with no ability to encapsulate or deliver macromolecules into cells.

[0237] To enable cargo loading, we introduced binding interactions into O3-33. Amino acids Thr11, Pro39, Glu66, Trp103, Phe130, and Leu163 were replaced with arginines to create an O3-33 mutant (herein referred to as OP), which has a strongly positively charged internal cavity (Fig. 1b, 5). OP proteins can be overexpressed in E. coli cells and isolated by Ni-NTA affinity chromatography via the C-terminal His6 tag (Fig. 6). Due to the strongly positively charged internal cavity, there was significant contamination from endogenous E. coli RNA. However, these RNA contaminations were easily removed using high ionic strength buffers to weaken electrostatic interactions and RNase A to digest the contaminating RNA (see Materials and Methods, Cell Lysis, Ni-NTA, and RNA Removal for OPs).

[0238] The ability of OPs to form the desired cage-like quaternary structures (Fig. 1a) was assessed by size-exclusion chromatography (SEC), dynamic light scattering (DLS), and native agarose gel electrophoresis (AGE) (Figs. 7, 8). All data were consistent with the formation of assemblies of the same size as the O3-33 cage. Furthermore, OPs and O3-33 were indistinguishable by TEM (Figs. 1c, 9), and X-ray diffraction confirmed that the addition of 144 arginines to a cavity of approximately 8 nm in diameter had little effect on the folding and cage structure of the monomers (Fig. 1d). The mean square deviations were between 0.5 and 0.7 Å for all Cα atoms of each monomer.

[0239] Furthermore, characterization of the OP mutants OTR101–OTR503 by SEC, AGE, and TEM showed that the structures of all OP mutants were identical to OP.

[0240] Example 4 - Loading of nucleic acid cargo With the structural integrity of the empty protein cages established, loading of nucleic acid cargo was investigated in vitro. DNA and RNA duplexes with a diameter of 2 nm can pass through pores with a diameter of approximately 3.5 nm, allowing encapsulation. Electrophoretic mobility shift assays (EMSA) revealed that the parent O3-33 cage does not affect the electrophoretic mobility of a 21-nt Atto488-labeled single-stranded (ss) DNA, Atto488-ssDNA (Figure 10). In contrast, colocalization of protein and DNA bands was observed with OPs (Figure 2a). Binding of OPs with double-stranded (ds)DNA and dsRNA was also evaluated (Figure 11), with results similar to ssDNA. In all cases, nearly complete binding of oligonucleotides was observed upon addition of 0.5 equivalents of OP, suggesting two guests per cage. This stoichiometry was consistent with the A of SEC-purified complexes of OPs with ssDNA, dsDNA, or dsRNA. 260 / A 280 This was confirmed by the ratio (Figs. 2b and 12, Table 3). [Table 4]

[0241] Example 5 - Binding Kinetics Binding kinetics were determined by fluorescence measurements using encapsulation-induced fluorescence quenching of the DNA-binding fluorophore Atto488 (Figure 13). The binding rate constant k on =(6.6±0.6)x10 5 M -1 s -1 (Figure 2c) and the dissociation rate constant k off =(1.6±0.1)x10 -4 s -1 (Figure 2d) shows that the dissociation constant of this protein-DNA complex, Kd=(2.4±0.3)x10 -10 This Kd value was used to calculate M, which is consistent with the reported value for RNA-protein interactions in viruses (10 -8 -10 -7 M), two orders of magnitude lower than the range of most tightly binding transcription factors (10 -15 -10 -10 It must be noted that the crucial difference of this artificial system is the lack of sequence specificity, which is an advantage for the delivery device, since it allows the packaging of any desired nucleotide sequence, as well as the chemical modification of the oligonucleotides to carry a negative charge.

[0242] A key role of a nucleic acid delivery system is to protect its cargo from nuclease degradation. Therefore, we performed digestion assays using three nucleases: DNaseI (30 kDa), RNase A (14 kDa), and benzonase50 (60 kDa). AGE (Figure 14) showed protection from larger enzymes. Only RNase A was able to enter the cage and digest the cargo. These nuclease assay data support the kinetic studies suggesting that the guest tightly binds to the interior cavity with a negligible dissociation rate.

[0243] For many nucleic acid delivery vectors, such as cationic lipids and polymers, a compromise must be made between transfection efficiency and cytotoxicity. In vitro cytotoxicity was measured over 24 h in HeLa cells using WST-8 to quantify dehydrogenase activity (Figure 15, Table 6). OPs showed negligible toxicity up to 400 nM cage (193 μg / mL protein). These results compare favorably with a commonly used transfection reagent, the cationic lipid Lipofectamine 2000, which reduced cell viability by 35%–45% at a 19-fold lower mass concentration (10 μg / mL) under the assay conditions described above. [Table 5]

[0244] Example 6 - Cellular uptake and cargo release Furthermore, the ability of the nanoparticles of the present invention to enter cells and deliver their nucleic acid cargo was investigated using flow cytometry and confocal fluorescence microscopy (CFM) with Atto488-ssDNA cargo as a probe. Seven different cell lines, including HeLa cells, were treated with either 200 nM free Atto488-ssDNA or Atto488-ssDNA packaged in OP cages, and the fluorescence of the cells was measured by flow cytometry. Plots of median fluorescence intensity show efficient cellular uptake of the OP cages in six of the seven cell lines tested (Figure 3a-c). In HeLa cells, there was a nearly 30-fold increase in cellular uptake of ssDNA in these cells compared to background, indicating delivery to more than 90% of HeLa cells. An even greater effect was seen in Vero and HepG2 cells. To confirm this finding, CFM was performed on cells treated with either free Atto488-ssDNA or OP cages loaded with Atto488-ssDNA (Figure 16). While cells treated with free Atto488-DNA showed no appreciable fluorescence, in cells treated with OP:Atto488-DNA, intracellular fluorescence was localized to many intense foci, confirming high uptake efficiency (Figure 3b). These punctate structures, suggestive of endocytosis, are commonly observed for nanoparticles in this size range.

[0245] Example 7 - Regulation of Gene Expression Reports of non-viral delivery systems that can deliver functional nucleic acid cargo without the need for additional transfection agents are rare. As the high cellular uptake of the OP cage was confirmed, we tested the cage's ability to deliver siRNA and modulate gene expression using HeLa cells stably expressing green fluorescent protein (GFP) as a model to measure protein expression. Using Lipofectamine2000 as a positive control, GFP-expressing HeLa cells were treated with naked siRNA, OP-encapsulated siRNA, empty OP cage, and OP cage loaded with scrambled sequence siRNA. To determine gene knockdown efficiency, GFP fluorescence was qualitatively measured by fluorescence microscopy (Figure 16) and quantitatively measured by flow cytometry (Figure 4a). After treatment with 20 pmol of OP-packaged siRNA and incubation for 48 h, an approximately 70% decrease in GFP fluorescence was observed, which is within the range of efficacy of Lipofectamine2000. Furthermore, the significantly lower toxicity of the OPs improved cell viability relative to the commercial reagent (Figure 16), which was at a concentration of 2.5 μg / mL in these assays. The lack of effect of the OP cage loaded with scrambled sequence siRNA confirmed that expression levels were target mRNA specific and not due to induction of antiviral interferon pathway mechanisms.

[0246] Example 8 - His6 tag and high cytoplasmic concentration of RNA contribute to ON delivery efficiency Successful induction of RNAi requires delivery of siRNA to the cytoplasm. Thus, the above data suggest that OP cages can achieve endosomal escape and release their cargo. Without being bound by any theory, we propose two explanations. First, the ability of histidine-rich peptides to promote endosomal escape is well documented, both by the proton sponge effect and by the ability of protonated histidine to permeabilize the endosomal membrane. Each OP monomer has a His6 tag, so that the complete 24-mer cage displays a total of 144 histidyl residues on its exterior. To test whether this affects siRNA delivery, we created mutant versions of OPs without the His6 tag and assayed for RNAi activity (Materials and Methods, Purification of OPs without His6 tag). Under the same experimental conditions, only about 40% reduction in GFP fluorescence was observed (Figure 4a), indicating that the His6 tag indeed contributes to delivery efficiency.

[0247] Second, the release of cargo molecules in the cytoplasm can be explained in terms of the kinetic parameters shown in Figure 2d. Although the OP-nucleic acid complex is stable, the encapsulation is reversible in the presence of high concentrations of competing guest molecules. Therefore, we predicted that high cytoplasmic concentrations of tRNA would provide a site-specific release mechanism for the siRNA cargo, liberating it for RNAi-induced gene knockdown. This hypothesis was tested in vitro, where OP cages containing A488-dsDNA were treated with PBS containing an intracellular concentration of tRNA (26 μM) at 37 °C and a time-dependent release of the cargo was observed over a period of 6 h (Figures 4b and 19). For oligonucleotides acting on mRNA in the cytoplasm, exploiting the physicochemical properties of the cytoplasm provides a simple solution for cargo release.

[0248] Conversely, the same experiment performed using 10% fetal bovine serum did not result in any release or degradation of the cargo (Figure 22).

[0249] Example 9 - Protein crystallography of nanoparticles [Table 6]

[0250] Example 10-OP and its mutants OTR101 to OTR503 In vitro studies of single-stranded DNA loading To test whether the various mutants of OP, OTR101-OTR503, can carry ssDNA, we investigated their interaction with ssDNA by electrophoretic mobility shift assay (EMSA). This predicts that colocalization of DNA and protein bands will be observed in the bound mutants, while the mobility of the ssDNA band will be unaffected in the unbound mutants. As shown in Figure 26, this colocalization is observed in all investigated mutants containing a minimum of three arginine mutations per monomer, whereas in all investigated mutants containing one or two arginines per monomer, as well as in O3-33, there was no migration of the Atto488-ssDNA band.

[0251] Binding kinetics of mutants compared to OP We investigated whether the results obtained from EMSA could be verified in the framework of a fluorescence assay. As shown in Figure 27, we can indeed conclude that mutants with two or fewer arginines do not bind ssDNA. Furthermore, we can see that the relative decrease in fluorescence, which corresponds to the quenching effect of the capsid, increases with increasing electrostatic contribution.

[0252] The kinetic parameters for ssDNA binding by all variants with three or more arginine mutations per monomer are shown in Table 7 below. [Table 7]

[0253] In vitro studies of double-stranded DNA loading We show that OP protein variants with three, four, or five arginines can load ssDNA, and their loading ability for dsDNA will be of interest, especially since double-stranded siRNAs are more relevant for biomedical applications. For all dsDNA measurements, we used hairpin DNA (hpDNA), which contains a loop region of four nucleobases between the two complementary strands. hpDNA was chosen to avoid dissociation of the two complementary strands of dsDNA.

[0254] Prior to developing the fluorescence-based assay, cargo loading was investigated by EMSA for all mutants that bind to ssDNA (Figure 28). Mutants OTR402, OTR501, OTR502, OTR503, and OP were found to bind to hpDNA, but this was not the case for OTR301, OTR302, and OTR401. Thus, the 10 -10 M -1 Only the capsid variant with the highest binding affinity can also bind dsDNA / hpDNA.

[0255] The kinetic parameters for hpDNA binding by all variants with 5 or more arginine mutations per monomer are shown in Table 8 below. [Table 8]

[0256] Example 11 - Mutation of externally displayed histidine-rich peptides OP cages tagged with one hexa-histidine tag per monomeric protein at the C-terminus have been shown to efficiently escape endosomal traps, thereby successfully releasing their siRNA cargo into the cell cytoplasm for gene knockdown. Histidine-tagged OP cage mutants containing 3, 6, or 9 histidines fused to the C-terminus were created and assayed for gene knockdown activity with reference to the OP cage containing 6 histidine tags. As shown in Figure 29, all three mutants show the same ability to deliver siRNA to mammalian cells and reduce the expression level of the target protein, in this case GFP. In addition, the importance of the location of the hexa-histidine tag was investigated by testing mutant OP-cODC for gene silencing activity. OP-cODC contains a 38 amino acid C-terminal appendage after the hexa-histidine tag. As shown in Figure 29, this abolishes the gene knockdown ability of OP cage-containing siRNA, likely due to interference with the endosomal escape mechanism of the hexa-histidine tag.

[0257] Example 12 - Immunogenicity of OP cages in mice Two groups of four BALB / c mice received PBS containing 1 or 10 μg of OP particles by tail vein injection on days 0, 16, and 38, and were bled on days 0, 14, 29, 52, and 73. Evaluation of OP-specific IgG1, IgG2a, and IgG2b in serum was performed by enzyme-linked immunosorbent assay (ELISA). Briefly, two-fold dilution series of mouse serum samples were applied to OP-coated multiwell immunoplates (Sigma M9410) and then detected with biotinylated anti-mouse antibodies against various IgG isotypes (Abcam ab97238 / ab97243 / ab97248). Colorimetric development was performed using streptavidin-HRP (Biolegend 405210) and 3,3',5,5'-tetramethylbenzidine (TMB, Biolegend 77247 / 77248) as the chromogenic substrate. The optical density of the chromogenic substrate was measured at 450 nm and plotted against serum sample dilution (Figure 30). A 1 / 2000 dilution was chosen to compare immune responses at each time point (Figure 31). After every injection, an increase in anti-OP IgG titers was measured with a dose-dependent response (Figure 31). By day 72, one month after the second booster, IgG titers showed a slight decline. This study indicates that OP particles induce a specific immune response.

Claims

1. A polypeptide comprising an amino acid sequence I consisting of: MX 13 QAIGILELX 1 SIAAGMELGDAMLKSAX 14 VX 15 LLVSKTISX 2 GKFLMLGGDIX 8 AIX 9 X 12 AIX 10 TGTX 11 QAGX 3 LLVDLVLAX 16 IHPSVLPAIX 17 GX 18 NX 19 VX 20 X 7 X 21 QAVGIVETX 4 SVAACISAADX 22 AVX 23 GSX 24 VTLVRVHMAX 5 GIGGKCYMVVAGDVSDAVALAVTASSAGAYGX 6 LVYASLIPX 25 PHX 26 AMWX 27 QMVX 28 GX 29 E (SEQ ID NO: 1) X 1 ~X 29 are each independently an amino acid, provided that 1 ~X 6 and optionally, X of SEQ ID NO: 1, provided that at least three of the X are, independently of one another, positively charged amino acids. 1 ~X 29 A polypeptide in which up to five amino acids at positions other than those indicated by are replaced by any amino acid.

2. The X 1 ~X 6 2. The polypeptide of claim 1, wherein at least three of the positively charged amino acids are independently selected from the group consisting of arginine, 5-methylarginine, C-gamma-hydroxyarginine, 2-amino-4-guanidinobutyric acid, 2-amino-3-guanidinopropionic acid, canavanine, homoarginine, lysine, diaminobutyric acid, 2,3-diaminopropanoic acid, (2s)-2,8-diaminooctanoic acid, ornithine, and thialysine.

3. The X 1 ~X 6 3. The polypeptide of claim 1 or 2, wherein at least three of the positively charged amino acids are, independently of each other, arginine or lysine.

4. The X 1 ~X 6 At least four of X are positively charged amino acids, preferably 1 ~X 6 At least five of X are positively charged amino acids, more preferably 1 ~X 6 The polypeptide of any one of claims 1 to 3, wherein each of is a positively charged amino acid.

5. X 7 is cysteine, a conservative substitution thereof, or a positively charged amino acid, preferably X 7 is selected from the group consisting of homocysteine, cysteine, selenocysteine, arginine, 5-methyl-arginine, c-gamma-hydroxyarginine, 2-amino-4-guanidinobutyric acid, 2-amino-3-guanidinopropionic acid, canavanine, homoarginine, lysine, diaminobutyric acid, 2,3-diaminopropanoic acid, (2s)-2,8-diaminooctanoic acid, ornithine, thialysine, and serine, more preferably X is 7 The polypeptide according to any one of claims 1 to 4, wherein is selected from the group consisting of homocysteine, cysteine, arginine, and lysine.

6. X 8 is glycine or a conservative substitution thereof; X 9 and X 12 are, independently of each other, glutamine, asparagine, or a conservative substitution thereof; X 10 is glutamate, aspartate, or a conservative substitution thereof; X 11 The polypeptide according to any one of claims 1 to 5, wherein is serine or a conservative substitution thereof.

7. X 13 , X 17 , and X 19 are, independently of each other, serine or a conservative substitution thereof; X 14 , X 16 , and X 24 are, independently of each other, asparagine, glutamine, or a conservative substitution thereof; X 15 , X 20 , X 26 , and X 28 are, independently of each other, aspartate, glutamate, or a conservative substitution thereof; X 18 and X 29 are, independently of each other, leucine or a conservative substitution thereof; X 21 , X 22 , X 23 , X 25 , and X 27 The polypeptide according to any one of claims 1 to 6, wherein each of the is independently arginine, lysine, or a conservative substitution thereof.

8. The polypeptide according to any one of claims 1 to 7, wherein the amino acid sequence I is an amino acid sequence selected from the group consisting of SEQ ID NOs: 2 to 5, and SEQ ID NOs: 10 to 16, 37, and 38.

9. The polypeptide according to any one of claims 1 to 8, further comprising a histidine tag, the histidine tag consisting of at least two consecutively linked histidines (His tag), preferably the His tag consisting of six consecutively linked histidines (His6 tag).

10. A nucleic acid sequence encoding a polypeptide according to any one of claims 1 to 9.

11. Nanoparticles comprising at least one polypeptide according to any one of claims 1 to 10.

12. A complex comprising the nanoparticle of claim 11 and one or more cargo molecules, wherein the one or more cargo molecules are encapsulated in the nanoparticle.

13. 13. The complex of claim 12, wherein the one or more cargo molecules are one or more oligonucleotides, preferably the one or more oligonucleotides are RNA selected from the group consisting of antisense oligonucleotides (ASO), small interfering RNA (siRNA), small hairpin RNA (shRNA), microRNA (miRNA), and anti-miRNA.

14. 14. The complex of claim 12 or 13, wherein the one or more oligonucleotides encapsulated in the nanoparticles are not susceptible to DNAse hydrolysis.

15. A method for transfecting a cell, comprising the step of contacting said cell with a complex according to claims 12-14.